WO1998022457A1 - Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents - Google Patents

Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents Download PDF

Info

Publication number
WO1998022457A1
WO1998022457A1 PCT/US1997/021344 US9721344W WO9822457A1 WO 1998022457 A1 WO1998022457 A1 WO 1998022457A1 US 9721344 W US9721344 W US 9721344W WO 9822457 A1 WO9822457 A1 WO 9822457A1
Authority
WO
WIPO (PCT)
Prior art keywords
radicals
alkyl
amino
alkoxy
radical
Prior art date
Application number
PCT/US1997/021344
Other languages
French (fr)
Other versions
WO1998022457A9 (en
Inventor
Jeffery A. Zablocki
Eugene Tarlton, Jr.
James P. Rizzi
Nathan B. Mantlo
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to CA002271767A priority Critical patent/CA2271767A1/en
Priority to IL12992897A priority patent/IL129928A0/en
Priority to DE69728688T priority patent/DE69728688T2/en
Priority to IL15525897A priority patent/IL155258A0/en
Priority to AU52659/98A priority patent/AU734841B2/en
Priority to AT97947617T priority patent/ATE264318T1/en
Priority to JP52391498A priority patent/JP2001506980A/en
Priority to EP97947617A priority patent/EP0948495B1/en
Priority to DK97947617T priority patent/DK0948495T3/en
Priority to SI9730639T priority patent/SI0948495T1/en
Priority to US09/269,600 priority patent/US6180643B1/en
Priority to HU9903330A priority patent/HUP9903330A2/en
Publication of WO1998022457A1 publication Critical patent/WO1998022457A1/en
Publication of WO1998022457A9 publication Critical patent/WO1998022457A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention comprises a new class of compounds useful in treating diseases, such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • diseases such as TNF- ⁇ , IL-l ⁇ , IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes.
  • the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation.
  • This invention in particular, relates to novel aryl and heteroaryl substituted fused pyrrole compounds, compositions containing such compounds and methods of use of such compounds.
  • the subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
  • Interleukin- 1 (IL-1) and Tumor Necrosis Factor alpha (TNF-a) are proinflammatory cytokines secreted by a variety of cells including monocytes and macrophages in response to many inflammatory stimuli (e.g. lipopolysaccharide - LPS) or external cellular stress (e.g. osmotic shock, peroxide) .
  • inflammatory stimuli e.g. lipopolysaccharide - LPS
  • external cellular stress e.g. osmotic shock, peroxide
  • Elevated levels of TNF- ⁇ and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs.
  • rheumatoid arthritis Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous le
  • HIV-1, HIV- 2, HIV- 3, cyto effetovirus (CMV) , influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF- ⁇ .
  • Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome.
  • Viruses sensitive to TNF- ⁇ inhibition e.g., HIV-1, HIV- 2, HIV- 3, are also affected by IL-1.
  • TNF- ⁇ and IL-1 appear to play a role in pancreatic ⁇ cell destruction and diabetes.
  • Pancreatic ⁇ cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic ⁇ cells often accompanies type I diabetes.
  • Pancreatic ⁇ cell functional abnormalities may occur in patients with type II diabetes.
  • Type II diabetes is characterized by a functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production.
  • Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin.
  • Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.
  • TNF-a soluble receptors for TNF-a (e.g., TNFR-55 or TNFR-75) which have demonstrated efficacy in animal models of TNF-a mediated disease states (for a PEG dimer of TNFR- 55 see Edwards CHI Meeting Nov. 13-15 (1995) and rhu sTNFR:Fc p-75 see Moreland) .
  • soluble receptors for TNF-a e.g., TNFR-55 or TNFR-75
  • the above approaches block the effects of TNF-a and IL-1 by either protein sequesterazation or receptor antagonism, but an additional approach to blockade is to intervene in the cellular production and secretion of IL-1 and/or TNF.
  • CQ and HCQ Chloroquine (CQ) and hydroxychloroquine (HCQ) accumulate in lysosomes of monocytes (Borne Handbook of Cardiovascular and Antiinflammatory Agents p27-104 (1986)). CQ and HCQ inhibit cartilage cathepsin B and cartilage chondromucoprotease, and they may have membrane stabilizing effects on the lysozomes .
  • TNF-a is upstream in the cytokine cascade of inflammation wherein elevated levels of TNF-a lead to elevated levels of other cytokines including IL-1, IL-6 and IL-8
  • inhibiting the production of TNF-a may also reduce levels of other cytokines including but not limited to IL-1, IL-6 or IL-8.
  • IL-8 is implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8 including but not limited to the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis .
  • IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels would lead to diminished neutrophil infiltration.
  • TNF-a plays a role in head trauma, stroke, and ischemia.
  • TNF-a levels increased in the contused hemisphere (Shohami et al J. Cereb. Blood Flow Metab. 14:615-619 (1994)).
  • the levels of mRNA of TNF-a increased (Feurstein et al Neurosci . Lett. 164: 125-128 (1993)).
  • Administration of TNF-a into the rat cortex resulted in significant PMN accumulation in capillaries and adherance in small blood vessels.
  • the TNF-a promotes the infiltration of other cytokines (IL-lb, IL-6), and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein Stroke 25:1481-1488 (1994) ) .
  • TNF-a may play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF-a secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al, J. Immunol. 142: 431 (1989)). The role of TNF-a in the HIV associated states of cachexia and muscle degradation has been discussed (Lahdevirta et al The American J. Med. 85:289 (1988) ) .
  • Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; antiviral therapy including those viruses sensitive to TNF-a inhibition - HIV-1, HIV- 2, HIV- 3; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome.
  • IL-1 is a more potent inducer of stromelysin than is TNF-a (Firestein Am. J. Pathol . 140:1309-1314, (1992)).
  • TNF-a Firestein Am. J. Pathol . 140:1309-1314, (1992)
  • neutrophil, lymphocyte, and monocyte emigration occurs. The emigration is attributed to the induction of chemokines (i.e. IL-8), and the up regulation of adhesion molecules (Dinarello Eur. Cytokine Netw. 5:517-531 (1994)).
  • IL-1 does play a role in promoting certain viral life cycles. Cytokine- induced increase of HIV expression in a chronically infected macrophage line has been associated with the concomittant and selective increase of IL-1 production (Folks et al J. Immunol. 136:40-49, (1986)). The role of IL-1 in cachexia has been discussed (Beutler et al J. Immunol. 135:3969-3971 (1985)). The role of IL-1 in muscle degeneration has been discussed (Baracos et al N. Eng. J. Med. 308:553- 558 (1983) ) .
  • IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (eg ischemia) is mediated by the chemotactic nature of IL-8 including but not limited to the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis .
  • IL-8 apparently also has the ability to activate neutrophils. Thus, reduction in IL-8 levels could lead to diminished neutrophil infiltration.
  • Substituted imidazole and fused imidazole compounds have been described for use in the treatment of cytokine mediated diseases by inhibition of proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF.
  • Substituted imidazoles for use in the treatment of cytokine mediated diseases have been described in WO 93/14081; WO 96/21452; and WO 96/21654 (each of which is incorporated herein by reference in its entirety) .
  • Substituted imidazoles for use in the treatment of inflammation has been described in US Pat. 3,929,807 (which is incorporated herein by reference in its entirety) .
  • the present invention relates to selected antiinflamatory compounds, analogs and pharmaceutically acceptable salts and prodrugs thereof.
  • the subject compounds are characterized as aryl and heteroaryl substituted fused pyrrole compounds.
  • the invention compounds advantageously treat inflammation related diseases. Therefore, this invention also encompasses pharmaceutical compositions and methods for prophylaxis and treatment of inflamation.
  • the subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
  • Xi is N, CH or CRi
  • X 2 is N, CH or CR 2
  • X 3 is N, CH or CR 3
  • X 4 is N, CH or CR 4 ; provided that at least one of Xi, X 2 , X 3 and X 4 is N or CH, and that not more than two of Xi, X 2 , X 3 and X 4 are N; wherein Ri , R 2 , R 3 and R 4 are each independently -Z-Y;
  • Xi is N;
  • X 2 is CH or CR 2 ;
  • X 3 is CH or CR 3 ; and
  • X 4 is CH or CR 4 ; and more preferably, Xi is N;
  • X 2 is CR 2 ;
  • X 3 is CH or CR ; and
  • X 4 is CH;
  • R 2 is independently -Z-Y; and preferably, R 2 is independently Y; and R 3 is independently -Z-Y; preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R 20 / -C(0)-OR 2 ⁇ , -C (0) -NR5R21 , - S(O) 2 "R 20 or -S (0) 2-NR 5 R 21 radicals; more preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N,N- dimethylamido, methylsulfonyl or aminosulfonyl radicals; even more preferably,
  • Xi is N; X 2 is CH or CR 2 ; X 3 is CH or CR 3 ; and X 4 is N; and more preferably, Xi is N; X 2 is CR 2 ; X 3 is CH or CR 3 ; and X 4 is N; wherein R 2 is independently -Z-Y; and preferably, R 2 is independently -Z-Y; and R 3 is independently -Z-Y; preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20# -C(0)-OR2i, -C (0) -NR 5 R 2 ⁇ , -S(O) 2 "R 20 or "S (0) 2-NR5R21 radicals; and most preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, acety
  • Xi is N;
  • X 2 is CH or CR 2 ;
  • X 3 is N; and
  • X 4 is CH or CR 4 ; and more preferably, X ! is N;
  • X 2 is CR 2 ;
  • X 3 is N; and
  • X 4 is CH or CR ;
  • R 2 is independently -Z-Y; and preferably, R 2 is independently Y; and R 4 is independently -Z-Y; preferably, R 4 is halo, trifluoromethyl, phenyl, methyl, hydroxyethyl, hydroxymethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R 2 o, -C(0)-OR2i, -C (0) -NR5R21 , -S(O)2" 20 or - S (O) 2-NR5R21 radicals; more preferably, R4 is halo, phenyl, trifluoromethyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, N,N- dimethylamido, amido, methylsulfonyl or aminosulfonyl radicals; or
  • Xi is N; X 2 is N; X 3 is CH or CR 3 ; and X 4 is CH or CR 4 ; and more preferably, Xi is N; X 2 is N; X 3 is CR 3 ; and X is CH or CR ;
  • R 3 is independently -Z-Y; and preferably, R 3 is independently Y; and R 4 is independently -Z-Y; preferably, R 4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20/ -C(0)-0R2i, -C (0) -NR5R21 , - S(0) 2 -R 2 o or -S (0) 2 - R 5 R 21 radicals; and more preferably, R 4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals; or
  • Xi is CH or CRi ;
  • X 2 is CH or CR 2 ;
  • X 3 is N; and
  • X 4 is N; and more preferably, X is CH or CRi;
  • X 2 is CR ;
  • X 3 is N; and
  • X 4 is N;
  • Ri is independently -Z-Y; preferably, Ri is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R 20 - -C(0)-0R 2 ⁇ , -C(0) -NR5R21, -S(O) 2 -R20 or -S(0) 2 - NR 5 R 21 radicals; and more preferably, Ri is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N,N- dimethylamido, methylsulfonyl or aminosulfonyl radicals; and R 2 is independently -Z-Y; and preferably, R 2 is independently Y; or
  • Xi is CH or CRi;
  • X 2 is CH or CR 2 ;
  • X 3 is CH or CR 3 ; and
  • X is CH or CR 4 , provided that at least one of Xi, X , X 3 and X 4 is CH; more preferably, Xi is CH; X is CH; X 3 is CH or CR 3 ; and X is CH or CR 4 ; and even more preferably, Xi is CH; X 2 is CH; X 3 is CR 3 ; and X 4 is CH or CR 4 ;
  • Ri is independently -Z-Y; and preferably, Ri is independently Y; and R 2 is independently -Z-Y; and preferably, R 2 is independently Y; and R 3 is independently -Z-Y; and preferably, R 3 is independently Y; and R 4 is independently -Z-Y; preferably, R 4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R 20 , -C(0)-OR 2 ⁇ , -C(0) -NR5R21, -S(0) 2 -R 2 o or -S(0) 2 - NR 5 R 21 radicals; and more preferably, R 4 is halo, phenyl, trifluoromethyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl,
  • Xi is CH? X 2 is CH or CR 2 ; X 3 is CH or CR 3 ; and X 4 is CH; and even more preferably, Xi is CH; X 2 is CR 2 ; X 3 is CH or CR 3 ; and X is CH;
  • R 2 is independently -Z-Y; and preferably, R 2 is independently Y; and R 3 is independently -Z-Y; preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R 2 o, -C(0)-0R 2 ⁇ , -C (0) -NR 5 R 21 , - S(0) 2 -R 2 o or - S (0) 2 -NR 5 R 21 radicals; and more preferably, R 3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
  • R 2 and R 4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri , R 2 , R 3 and R 4 is 0-4, preferably 0-3; each Z is independently a (1) bond; (2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dial, and
  • each Z is independently a (1) bond; (2) C]_- C 8 alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 3.
  • each Z is independently a (1) bond; (2) C 1 -C 8 alkyl, C2-C8 alkenyl or C 2 -C 8 alkynyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonyl amino, C 1 -C 4 alkylsulfon
  • each Z is independently a (1) bond; (2) C 1 -C 4 alkyl or C 2 -C 5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonyl amino, hydroxy, C 1 -C 2 alkoxy, C ⁇ -C 2 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 3.
  • each Z is independently a (1) bond; (2) C 1 -C 4 alkyl or C 2 -C 5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ - C 2 alkyl) amino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C 1 -C 2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C ⁇ -C 2 alkoxy, C 1 -C 2 alkylthio, cyano, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, ace
  • each Z is independently a (1) bond; or (2) C 1 -C 4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(C ⁇ -C 2 alkyl)amino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 2 alkoxy, C 1 -C 2 alkyl thio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C 1 -C 2 alkoxy, C ⁇ -C alkylthio, cyano, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; still even more preferably, each Z is independently a (1) bond; or (2) C 1 -C 4 alkyl radical optionally substituted by 1 - 2 radicals of amino, t- butoxy carbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals; and most preferably, each Z is a bond
  • each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -C(0)-R 2 o, -C(0)-0R 2 ⁇ , -C(0) -NR5R21, -C(NR 5 ) -NR5R2 1 , -OR21, -0-C(0)-
  • R 2 ⁇ , -0-C(0) -NR5R21, -SR21, -S(O ) -R 20 , -S(O ) 2 -R 20 , -S(0) 2 - NR 5 R 21 , -NR 5 R 21 , -NR 22 "C (0) - R 21 , -NR 22 -C (0) -OR 20 , "NR 22 -
  • each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -
  • each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, - C(O)-R 20 , -C(0)-0R 2 ⁇ , -C(0) -NR5R21, -OR21, -SR21, -S(0)- R 20 , -S(O) 2 -R 2 0. -S(0) 2 -NR 5 R 2 ⁇ , -NR 5 R 2i , -NR 22 -C (0) -R 2i , - NR 2 2-S(0) -R 2 o or -NR 2-S(0) 2 -NR 5 R2i radical;
  • each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -C(0)-R 2 o, -C(0) -NR5R21, -0R 2 ⁇ , -SR 2 ⁇ , -S(O)-R 20 , -NR5R21, -NR 22 -C(0) -R 2 i, -NR 22 -S(O) 2 -R20 or -NR 22 -S(0) 2 - NR 5 R 21 radical; and most preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -NR 5 R 21 , -NR 22 -C (0) -R 21 or -NR 22 - S(O) -R20 radical;
  • each R 5 is independently (1) hydrogen radicals; (2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano or halo; or (3) aryl, heteroaryl, aralkyl, heteroaralkyl , heterocyclyl, heterocyclylalkyl , cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
  • each R 5 is independently (1) hydrogen radicals; (2) C ⁇ -C 8 alkyl, C 2 -C 8 alkenyl or C 2 -Cs alkynyl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di - (Ci -C 4 -alkyl) amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano or halo; or (3) aryl, heteroaryl, aryl -Ci -C 4 -alkyl , heteroaryl -Ci -C 4 - alkyl, heterocyclyl, heterocyclyl -Ci -C 4 -alkyl , C3-C 8 cycloalkyl or C 3 -Cs - cycloalkyl -Ci -C 4 -alkyl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino
  • each R 5 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di - (C 1 -C 4 -alkyl) amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio or halo; or (3) aryl, heteroaryl, aryl -C 1 -C 4 -alkyl , heteroaryl -Ci -C 4 -alkyl , heterocyclyl, heterocyclyl -Ci -C 4 -alkyl , C 3 -C 8 cycloalkyl or C 3 -Cs -cycloalkyl-C ⁇ -C 4 -alkyl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di - (C
  • each R 5 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl or C 2 -Cs alkenyl radicals optionally substituted by 1-3 radicals of amino, di - (Ci -C 4 -alkyl) amino, hydroxy, C 1 -C 4 alkoxy, Ci- C 4 alkylthio or halo; or (3) phenyl -Ci -C -alkyl , heteroaryl -Ci -C 2 -alkyl , heterocyclyl -Ci -C 2 -alkyl or C 3 - C ⁇ -cycloalkyl -Ci -C 2 -alkyl radicals optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 4 - alkyl) amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C 4 alkyl or C 1 -C 2 halo
  • each R 5 is independently (1) hydrogen radical; (2) C 1 -C 4 alkyl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 - alkyl) amino, hydroxy, C 1 -C 2 alkoxy, C 1 -C 2 alkylthio or halo; or (3) phenyl -Ci -C 2 -alkyl , heteroaryl -Ci -C 2 - alkyl , heterocyclyl -C 1 -C 2 - alkyl or C 3 -C 6 -cycloalkyl -Ci -C 2 - alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Ci -C 2 -alkyl) amino, hydroxy, C 1 -C 2 alkoxy, Ci- C 2 alkylthio, methoxy, methylthio, cyano, C 1 -C 4 alkyl or trifluoromethyl radicals;
  • each R 5 is independently (1) hydrogen radical; (2) C 1 -C 4 alkyl radical optionally substituted by 1-3 halo radicals; or (3) phenyl -Ci -C 2 - alkyl or heteroaryl -C ⁇ -C 2 -alkyl , radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals; still even more preferably, each R 5 is independently hydrogen or C 1 -C 4 alkyl radical; and most preferably, each R 5 is a hydrogen radical;
  • each R 20 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1 - 3 radicals of -CO 2 R 23/ amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N- (alkoxycarbonyl ) - N- (alkyl) amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl , cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonyl amino, alkylsulfonyla
  • each R 20 is independently (1) Ci-C ⁇ alkyl, C 2 -C 8 alkenyl or C 2 -C 8 alkynyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, N-((C ⁇ -C 4 alkoxy) carbonyl ) - N-(Ci-C 4 alkyl) amino, aminocarbonylamino, C 1 -C 4 alkyl sulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio,
  • each R 20 is independently (1) Ci-Cs alkyl, C 2 -C 5 alkenyl or C 2 -C 5 alkynyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 amino, C 1 -C 4 alkyl amino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, N-UC 1 -C 4 alkoxy) carbonyl) -N- (C 1 -C 4 alkyl) amino, aminocarbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkyl sulfinyl, Ci- C 4 alkylsulfonyl , halo or aryl -Ci -C 4 -alkoxy, aryl
  • each R 20 s independently (1) Ci- C ⁇ alkyl or C 2 -C 5 alkenyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) mino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, N-((C ⁇ -C 4 alkoxy) carbonyl) -N- (C 1 -C 4 alkyl) amino, aminocarbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C 1 -C 4 alkylsulfonyl , halo or aryl -C 1 -C 4 -alkoxy, aryl -Ci -C 4 -alkylthio, aryl-Ci
  • each R 20 is independently (1) Ci-Cs alkyl or C 2 -C 5 alkenyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 amino, C 1 -C 4 alkylamino, di - (C 1 -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, N-((C ⁇ -C 4 alkoxy) carbonyl) -N- (Ci -C 4 alkyl) amino, aminocarbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C 1 -C 4 alkylsulfonyl , halo or aryl -C 1 -C 4 -alkoxy, aryl-C -C 4 -alkoxy, aryl-C -C 4 -alkoxy,
  • each R 20 is independently (1) Ci- C 8 alkyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 amino, C 1 -C 4 alkylamino, di-(C ⁇ -C4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, -((C ⁇ -C 4 alkoxy) carbonyl) -N- (Ci- C 4 alkyl) amino, aminocarbonyl amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C 1 -C 4 alkylsulfonyl , halo or C 3 -C 6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(C ⁇ -C 4 alkyl)amino, C 1 -C 5 al
  • each R 20 s independently (1) Ci-C ⁇ alkyl radicals optionally substituted by 1-3 radicals of -CO 2 R 23 , amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or C 5 -C 6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl , hydroxy, or C 1 -C 4
  • each R 2 o is independently (1) Ci-Cg alkyl radicals optionally substituted by 1-3 radicals of -C0 2 R 23 , amino, methylamino, dimethylamino, t-butoxy carbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or C 5 - C ⁇ cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by t- butoxycarbonyl ; or (3) aryl or heteroaryl radicals optionally substituted
  • each R 2 ⁇ is independently hydrogen radical or R 20 ;
  • each R 22 is independently (1) hydrogen radical; (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, al
  • each R 22 is independently (1) hydrogen radical; (2) C 1 -C 4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C 1 -C 4 alkyl sulfonyl, cyano, halo, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of 1-3
  • each R 3 is independently hydrogen or C 1 -C 4 alkyl, or aryl, heteroaryl, aryl -Ci -C 4 -alkyl or heteroaryl -C 1 -C 4 -alkyl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C 1 -C 4 alkylsulfonyl , cyano, halo, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals;
  • each R 23 is independently hydrogen or C 1 -C 4 alkyl, or phenyl, heteroaryl, phenyl -Ci -C 2 -alkyl or heteroaryl -C 1 -C 2 -alkyl optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, Ci- C 4 alkoxy, C 1 -C 4 alkylthio, cyano, halo, C 1 -C 4 alkyl or C 1 -C 2 haloalkyl of 1-3 halo radicals;
  • each R 23 is independently hydrogen or C 1 -C 4 alkyl, or phenyl, heteroaryl, phenyl -Ci -C 2 - alkyl or heteroaryl -Ci -C 2 -alkyl optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, Ci- C 2 alkoxy, C 1 -C 2 alkylthio, cyano, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; yet more preferably, each R 23 is independently hydrogen or C 1 -C 4 alkyl, or phenyl -Ci -C - alkyl or heteroaryl -Ci - C 2 -alkyl optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) mino,
  • Rio is a hydrogen, R 30 , -C(0)-R 2 9/ -C(O)-OR 30 , -C(O)- NR3 R 32 , -S(O) 2 "R 30 or -S (0) 2-NR31R32 radical; preferably, Rio is a hydrogen, R 30 , -C(0)-R 2 g, -C (0) -NR31R32 , -S(0) - R 30 or -S (0) 2 -NR 31 R 32 radical; more preferably, Rio is a hydrogen, R 30 , -C(0)-R 29 or -C (0) -NR31R32 radical; and most preferably, Rio is a hydrogen or methyl radical;
  • R 11 and R 12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of R 30 , halo, cyano, -C(0)-R3o, -C(0)-OR29, -C (0) -NR 3 ⁇ R 32 , -C(NR 3 ⁇ ) -NR 31 R 32 , -OR 29 , -0-C(0)-R 29 , -0-C(0) -NR31R32, -0- C ( 0 ) -NR 33 -S(O) 2 -R30, -SR29, -S ( O ) -R 30 , -S ( O ) 2 -R 30 , -S ( 0 ) 2 - NR 31 R 32 , -S(0) 2 -NR 33 -C(0) -R 30 , - S (0) 2 -NR33 -C(0) -OR 30 , -S(0) 2 -NR 33 -C(0) -NR 3 1R32, -NR
  • Rn and R ⁇ 2 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R 30 , halo, cyano radicals, -C(0)-R 3 o, -C(0) 0R 29 , -C(0) -NR31R32, -C(NR 3i ) -NR31R32, -OR29, -SR 29 , " S(O)-R 30 , -S(O) 2 -R 30 , -S(0)2-NR 31 R 3 2, -NR 3 ⁇ R 32 , -NR 33 - C(0)-R 29 or -NR 33 -C (0) -OR 3 o radicals;
  • Ru and R 12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R 3 0, halo, cyano, -C(0)-R 3 o, -C(0)-0R 2 g, -C(0) -NR 3i R 32 , -C(NR 3 ⁇ ) -NR 3 ⁇ R 32 , -OR 29 , -SR 29 , -S(O)-R 30 , -S(O) 2 -R 30 , -S(0)2-NR 3 ⁇ R 3 2, -NR 3 ⁇ R 32 or - R 33 -C ( 0 ) - R 29 radicals;
  • Ru and R 12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R 3 o, halo, cyano, -C (0) -NR 31 R 32 , -OR2 9 , -SR 29 , -S(O)-R 30 , -S(O) 2 -R 30 , -S(0) 2 -NR 3 ⁇ R 3 2, -NR 3 ⁇ R 32 or -NR 33 -C (0) -R 29 radicals;
  • Ru is a heteroaryl radical optionally substituted by 1-2 radicals of R 30 halo, cyano, -C (0) -NR31R32 , -OR29, -SR 2 g, -NR31R32 or -NR33- C(0)-R 29 radicals; and R ⁇ 2 is an aryl radical optionally substituted by 1-2 radicals of R 30 , halo, cyano, -C(0)- NR31R32, -OR 29 , -SR29, -S ( O ) -R 30 , -S(O ) 2 -R30, -S ( 0 ) 2 - NR 3 1R 3 2, -NR31R32 or -NR 33 -C (0) -R 29 radicals;
  • Rn is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R 12 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals;
  • Ru is a 4 -pyridyl, 4- quinolinyl, 4-imidazolyl or 4 -pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R 12 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals; and
  • Ru is a 4 -pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R 12 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl , methyl or trifluoromethyl radicals; and
  • R ⁇ is a substituted aryl radical and R12 is heteroaryl radical, or R ⁇ is a heteroaryl radical and R12 is a substituted aryl radical;
  • each R 30 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR 31 R 31 , -CO 2 R 23 hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo ' or aralkoxy, aralkylthio, aralkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1 - 3 radicals of amino, alkylamino, dialkylamino, alkanoyl amino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; (2) heterocyclyl radical optionally substituted by 1-3 radical
  • each R 30 is independently (1) C 1 -C 4 alkyl, C 2 -C 4 alkenyl or C 2 -C 4 alkynyl radicals optionally substituted by 1-3 radicals of -NR 31 R 31 , -CO 2 R 23 , hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, C 1 -C 4 alkylsulfinyl , C -C 4 alkylsulfonyl , cyano, halo or aryl - C 1 -C 4 -alkoxy, aryl -Ci -C 4 -alkylthio, aryl-C ⁇ -C 4 - alkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoyl radical
  • each R30 is independently (1) Ci* C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di - (Ci -C4 -alkyl) amino radicals; or
  • each R 30 is independently (1) C 1 -C 4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, hydroxy, C ⁇ -C 2 alkoxy, halo, C 1 -C 4 alkyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl) amino, acetamido, hydroxy, C ⁇ -C 2 alkoxy, halo, Ci- C 4 alkyl or trifluoromethyl radicals;
  • each R 30 is independently (1) Ci- C 4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and most preferably, R 30 is independently (1) C 1 -C 4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals
  • each R 29 is independently hydrogen radical or R 3 o; and preferably, R 29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
  • each R 3 ⁇ is independently (1) hydrogen radicals; (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
  • each R 3 ⁇ is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by an C 3 -Cs cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoyl amino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonyl amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, Ci- C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C 3 -C 8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-
  • each R 31 is independently (1) hydrogen radicals; or (2) C 1 -C 4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, C 1 -C 4 alkyl or trifluoromethyl radicals; even more preferably, each R 31 is independently hydrogen or C 1 -C 4 alkyl radicals; and most preferably, R 31 is independently hydrogen, methyl or ethyl radicals;
  • each R 32 is independently (1) hydrogen radicals; (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl ;
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by an C 3 -C 8 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoyl amino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonyl amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, Ci- C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C 3 -C 8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C 8
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by an C 3 -C 6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1 - 3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoyl amino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonyl amino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkylthio, cyano, Ci- C 4 alkyl or C 1 -C 4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C 3 -C 6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, hydroxy, C 1 -C 4 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl) amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamin , hydroxy, Ci- C 4 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals;
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical or C 1 -C 2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C 2 alkyl)amino, acetamido, hydroxy, C 1 -C 2 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(C ⁇ -C2 alkyl) amino, acetamido, hydroxy, C 1 -C 2 alkoxy, C 1 -C 4 alkyl or trifluoromethyl radicals;
  • each R 32 is independently (1) hydrogen radicals; (2) C 1 -C 4 alkyl radical or C -C 2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and
  • each R 32 is independently (1) hydrogen or C 1 -C 4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and
  • each R 33 is independently (1) hydrogen radical; or (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; preferably, each R 33 is independently (1) ' hydrogen radical; or (2) C 1 -C 4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C 1 -C 4 alkylamino, di-(C ⁇ -C 4 alkyl)amino, C 1 -C 5 alkanoylamino, (C 1 -C 4 alkoxy) carbonylamino, C 1 -C 4 alkylsulfonylamino,
  • Compounds of interest include the following:
  • 6- (3 ' -amino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole ;
  • Alkyl alone or in combination, means a straight - chain or branched- chain alkyl radical containing preferably 1- 15 carbon atoms (C 1 -C 15 ), more preferably 1-8 carbon atoms (C -C ⁇ ), even more preferably 1-6 carbon atoms (C - C ⁇ ) , yet more preferably 1-4 carbon atoms (C 1 -C 4 ), still more preferably 1-3 carbon atoms (C 1 -C 3 ), and most preferably 1-2 carbon atoms (C 1 -C 2 ).
  • radicals include methyl, ethyl, n -propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the like.
  • Hydroalkyl means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical.
  • examples of such radicals include hydroxymethyl, 1-, 2 -hydroxyethyl , 1-, 2-, 3 - hydroxypropyl , 1 , 3 -dihydroxy- 2 -propyl , 1,3- dihydroxybutyl , 1 , 2 , 3 , 4 , 5 , 6 -hexahydroxy- 2 -hexyl and the like.
  • Alkenyl alone or in combination, means a straight- chain or branched- chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C 2 -C 15 ), more preferably 2-8 carbon atoms (C 2 -C 8 ), even more preferably 2-6 carbon atoms (C 2 -C 6 ), yet more preferably 2-4 carbon atoms (C 2 -C 4 ), and still more preferably 2-3 carbon atoms (C 2 -C 3 ).
  • alkenyl radicals include ethenyl, propenyl, 2 -methylpropenyl , 1,4- butadienyl and the like.
  • Alkynyl alone or in combination, means a straight- chain or branched chain hydrocarbon radical having one or more triple bonds, preferably 1-2 triple bonds and more preferably one triple bond, and containing preferably 2-15 carbon atoms (C 2 -C 15 ), more preferably 2-8 carbon atoms (C 2 -C ⁇ ), even more preferably 2-6 carbon atoms (C 2 -Cg), yet more preferably 2-4 carbon atoms (C 2 -C 4 ), and still more preferably 2-3 carbon atoms (C 2 -C 3 ) .
  • alkynyl radicals include ethynyl , propynyl (propargyl), butynyl and the like.
  • Alkoxy alone or in combination, means a radical of the type "R-0-" wherein “R” is an alkyl radical as defined above and "0" is an oxygen atom.
  • alkoxy radicals include methoxy, ethoxy, n -propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert- butoxy and the like.
  • Alkoxycarbonyl alone or in combination ⁇ means a radical of the type "R-O-C(O)-" wherein "R-0-" is an alkoxy radical as defined above and “C (0) " is a carbonyl radical .
  • Alkoxycarbonylamino alone or in combination, means a radical of the type “R-O-C (0) -NH- " wherein "R-O-C(O)” is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
  • Alkylthio alone or in combination, means a radical of the type "R-S-" wherein "R” is an alkyl radical as defined above and “S” is a sulfur atom.
  • alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert -butylthio and the like.
  • Alkylsulfinyl means a radical of the type "R-S(O)-" wherein "R” is an alkyl radical as defined above and “S (0) " is a mono -oxygenated sulfur atom.
  • alkylsulfinyl radicals include methylsulfinyl , ethylsulfinyl , n-propylsulfinyl , isopropylsulfinyl , n-butylsulfinyl , iso-butylsulfinyl , sec-butylsulfinyl , tert-butylsulfinyl and the like.
  • Alkylsulfonyl means a radical of the type "R-S(0) 2 -" wherein "R” is an alkyl radical as defined above and “S (0) 2 " is a di -oxygenated sulfur atom.
  • alkylsulfonyl radicals include methylsulfonyl , ethylsulfonyl , n-propylsulfonyl , isopropylsulfonyl , n-butylsulfonyl , iso-butylsulfonyl , sec-butylsulfonyl, tert-butylsulfonyl and the like.
  • Alkylsulfonylamino means a radical of the type “R- S (0) 2 -NH- " wherein "R-S(0) 2 -” is an alkylsulfonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
  • Aryl alone or in combination, means a phenyl or naphthyl radical which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocyclo, alkanoylamino, amido, amidino, alkoxycarbonylamino, N- alkylamidino, alkylamino, dialkylamino, N-alkylamido, N,N- dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl , alkylsulfonyl and the like.
  • aryl radicals are phenyl, p-tolyl, 4-methoxyphenyl, 4- (tert -butoxy) phenyl , 3 -methyl - 4 -methoxyphenyl , 4-CF 3 - phenyl, 4 - fluorophenyl , 4-chlorophenyl, 3 -nitrophenyl , 3 -aminophenyl , 3 -acetamidophenyl , 4 -acetamidophenyl , 2- ethyl - 3 -acetamidophenyl , 2 -methyl - 3 -aminophenyl , 3- methyl -4 -aminophenyl , 2 -amino- 3 -methylphenyl , 2,4- dimethyl - 3 -aminophenyl , 4 -hydroxyphenyl , 3 -methyl -4- hydroxyphenyl, 1- naphthyl, 2 -n
  • Alkyl alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2 -phenylethyl , dibenzylmethyl , hydroxyphenylmethyl , methylphenylmethyl , diphenylmethyl , dichlorophenylmethyl , 4- methoxyphenylmethyl and the like.
  • Alkoxy alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2 -phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4- methoxyphenylmethoxy and the like.
  • Alkoxycarbonyl means a radical of the type "R-O-C(O)-" wherein “R-0-” is an aralkoxy radical as defined above and “-C(O) -” is a carbonyl radical .
  • Aryloxy alone or in combination, means a radical of the type "R-0-" wherein “R” is an aryl radical as defined above.
  • Alkanoyl alone or in combination, means a radical of the type "R-C(O)-" wherein "R” is an alkyl radical as defined above and "-C(O)-” is a carbonyl radical.
  • alkanoyl radicals include acetyl, trifluoroacetyl , hydroxyacetyl , propionyl, butyryl, valeryl, 4 -methylvaleryl , and the like.
  • Alkanoylamino alone or in combination, means a radical of the type "R-C(0)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
  • Aminocarbonyl alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di - substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
  • Aminocarbonylamino alone or in combination, means an amino substituted carbonyl substituted on a second amino (ureido) radical, wherein each amino radical may optionally be mono- or di- substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
  • Aminoalkanoyl means an alkanoyl radical as defined above derived in which at least one, preferably 1-2, hydrogen atom is replaced by an amino radical, wherein each amino radical may optionally be mono- or di - substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
  • Bicyclic as used herein is intended to include both fused ring systems, such as naphthyl and ⁇ - carbolinyl , and substituted ring systems, such as biphenyl, phenylpyridyl , naphthyl and diphenylpiperazinyl .
  • Cycloalkyl alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic or bicyclic alkyl radical, preferably monocyclic, containing preferably 3-10 carbon atoms (C 3 - C 10 ) more preferably 3-8 carbon atoms (C 3 -C 8 ), even more preferably 3-6 carbon atoms (C 3 -Cg) which is optionally be benzo fused and which is optionally substituted as defined herein with respect to the definition of aryl.
  • cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, dihydroxycyclohexyl , cycloheptyl, octahydronaphthyl , tetrahydronaphthyl, dimethoxytetrahydronaphthyl , 2 , 3 -dihydro- IH- indenyl and the like.
  • Cycloalkylalkyl alone or in combination, means an alkyl radical as defined above which is substituted by a cycloalkyl radical as defined above.
  • Examples of such cycloalkylalkyl radicals include cyclopropylmethyl , cyclobutylmethyl , cyclopentylmethyl , cyclohexylmethyl ,
  • cycloalkylcarbonyl means an acyl radical of the formula cycloalkyl -C (0) - in which the term “cycloalkyl” has the significance give above, such as cyclopropylcarbonyl , cyclohexylcarbonyl , adamantylcarbonyl , 1 , 2 , 3 , 4 - tetrahydro-2 -naphthoyl , 2- acetamido -1,2,3,4- tetrahydro - 2 - naphthoyl , 1 - hydroxy- 1, 2 , 3 , 4 - tetrahydro- 6 -naphthoyl and the like.
  • Heteroatoms means nitrogen, oxygen and sulfur heteroatoms .
  • Heterocyclyl alone or in combination, means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4 , more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring.
  • Heterocyclyl is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N- oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 carbon atoms and more preferably 5-6 carbon atoms, and benzo fused ring systems.
  • Heterocyclyl radicals may optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidi ⁇ o, N- alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals.
  • heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo- fused and optionally substituted by 1-2 oxo or thioxo radicals.
  • heterocyclyl radicals include pyrrolidinyl , piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl , 4 -benzyl -piperazin- 1 -yl , pyrimidinyl, tetrahydrofuryl , pyrazolidonyl, pyrazolinyl, pyridazinonyl , pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2 , 3 -dihydroindolyl , tetrahydroquinolinyl , 1,2,3,4- tetrahydroisoquinolinyl , 1,2,3,4- tetrahydro- 1 - oxo- isoquinolinyl , 2 , 3 -dihydrobenzofuryl , benzopyranyl , methylenedioxyphenyl , benzo
  • Heterocyclylalkyl means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heterocyclyl radical as defined above, such as pyrrolidinylmethyl , tetrahydrothienylmethyl , piperidinylethyl and the like.
  • Heteroaryl alone or in combination, means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 5-6 ring members in each ring, which is optionally benzo fused or saturated carbocyclic fused, preferably 3-4 carbon atoms (C 3 -C 4 ) and which is optionally substituted as defined above with respect to the definitions of aryl and heterocyclyl.
  • heteroaryl is a radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo- fused or saturated C 3 -C 4 - carbocyclic - fused.
  • heteroaryl groups include imidazolyl,
  • Heteroaralkyl alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3 - furylpropyl , 2- pyrrolyl propyl, chloroquinolinylmethyl , 2 - thienylethyl , pyridylmethyl , 1 - imidazolylethyl and the like.
  • Halogen and "halo”, alone or in combination, means fluoro, chloro, bromo or iodo radicals.
  • Haloalkyl alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals.
  • haloalkyl radicals include 1 , 1 , 1 - trifluoroethyl , chloromethyl , 1-bromoethyl , fluoromethyl , difluoromethyl , trifluoromethyl, bis (trifluoromethyl) methyl and the like.
  • leaving group generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
  • Protecting group generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like.
  • aralkyl examples include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts.
  • aryl groups include phenyl, naphthyl, indanyl, anthracenyl , 9 - (9 -phenylfluorenyl) , phenanthrenyl , durenyl and the like.
  • Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like.
  • Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl , t- butoxycarbonyl , iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri - fluoroacetyl , tri -chloro acetyl, phthaloyl and the like.
  • a mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group.
  • Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example,
  • heterocyclic groups can further include adjoining aryl and cycloalkyl rings.
  • the heterocyclic groups can be mono-, di - or tri - substituted, such as nitrophthalimidyl .
  • Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also sutiable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
  • Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl , triethylsilyl , tri - isopropylsilyl , tert- butyldimethylsilyl , dimethylphenylsilyl , 1,2- bis (dimethylsilyl) benzene, 1 , 2 -bis (dimethylsilyl) ethane and diphenylmethylsilyl . Silylation of an amino groups provide mono- or di - silylamino groups.
  • Silylation of aminoalcohol compounds can lead to a N, , 0- tri - silyl derivative.
  • Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group.
  • Suitable silylating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF.
  • Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
  • Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine.
  • a protecting group such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof.
  • a t-butoxycarbonyl protecting group can be removed utilizing an inorgan
  • Carboxy protecting group such as methyl, ethyl, benzyl, tert-butyl, 4- methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.
  • indole and azaindole synthesis can be used to prepare the compounds of this invention which are included by reference (for reviews of indole synthesis see G. Gribble Recent Developments in Indole Ring Synthesis -Methodology and Applications in Contemporary Organic Synthesis p- 145 -172; R. Sundberg and P. V. Nguyen Five Membered Ring Systems: Pyrroles and Benzo Derivatives, Chapter 5, Comprehensive Heterocyclic Chemistry) and the schemes shown below.
  • Ri , R 2 , R 3 and R 4 will not contain halogen substituted aryl or heteroaryl and other radicals well known to those skilled in the art which have the potential of interfering with, competing with or inhibiting the ring formation reaction.
  • Ri , R 2 , R 3 and R will not contain an amino substituted aryl or heteroaryl and other radicals well known to those skilled in the art which have the potential of interfering with, competing with or inhibiting the ring formation reaction.
  • Such substituted benzoyl chlorides can be prepared from the corresponding commercially available benzoic acids by treatment with oxalyl chloride or thionyl chloride (Tet. Lett. 1993, 3543-3546; and Julia et al J. Chem. Soc. Perkin Trans I 1991, Vol 5, 1101-1105, respectively) .
  • examples of commercially available aryl aldehydes include 3- phenoxybenzaldehyde, 6 -bromoveratraldehyde, 2 -bromo benzaldehyde, 2 - fluorobenzaldehyde, 4 -fluoro benzaldehyde, 2 -chlorobenzaldehyde, 2,4-dichloro benzaldehyde, 2 -chloro- 6 - fluorobenzaldehyde, o- anisaldehyde, 2 , 3 -dimethoxybenzaldehyde, 3 - cyano benzaldehyde, 3 - fluoro-p-anisaldehyde, 3- (3,4- dichlorophenoxy) benzaldehyde, 3- (3- (trifluoromethyl) phenoxy) benzaldehyde, 3- (4 -methoxyphenoxy) benzaldehyde, 3
  • heteroaryl aldehydes examples include 2 , 6 -diphenyl -4 -pyridinecarboxaldehyde, quinoline- 3 -carboxaldehyde, 2 -chloro- 3 - quinolinecarboxaldehyde, 2 -chloro- 6 -methoxy- 3 - quinolinecarboxaldehyde, 2 - imidazolecarboxaldehyde, N- 1 -benzyl -2 - imidazole carboxaldehyde, 2-methyl-3- imidazolecarboxaldehyde, 3- imidazolecarboxaldehyde,
  • heteroaryl carboxylic acids or derivatives thereof can be converted to heteroaryl aldehydes by standard synthetic transformations well known to those skilled in the art.
  • heteroarylester can be reduced to the aldehyde by treatment with diisobutylaluminum hydride.
  • heteroaryl - carboxylic acids or derivatives thereof that can be converted into heteroaryl aldehydes (XI) include methyl 2 - chloro- 6 -methyl - 4 -pyrimidinecarboxylate; 4- carboxypyrimidine; methyl 2 , 6 -dimethylamino- 4 - pyrimidine carboxylate; and methyl 4 , 6 -diphenyl - 2 - pyrimidine carboxylate.
  • heteroaryl - halides can be converted into heteroaryl aldehydes (XI) by lithium-halogen exchange and quenching of the anion with dimethylformamide .
  • heteroarylhalides that can be converted into heteroaryl aldehydes (XI) include 6 -chloro -2 , 4 -dimethoxypyrimidine; 4 -chloro- 2- methylthio pyrimidine; 2 -amino- 4 -chloro- 6 - methylpyrimidine; 4 - chloro- 2 -phenylquinazoline; 4- chloro- 2 -methylquinoline; 4 -chloro- 2 -methylquinoline;
  • N-methyl -N-methoxyamide (XVII) can be obtained through reaction of R ⁇ 2 -C(0)Cl (for example, 3 , 5 -bis (trifluoromethyl) benzoyl chloride; 2 -bromobenzoyl chloride; 2 - fluorobenzoyl chloride; pentafluorobenzoyl chloride; 2 , 4 -difluorobenzoyl chloride; 2,6-difluoro benzoyl chloride; 2 , 6 -dichlorobenzoyl chloride; o- toluoyl chloride; m-anisoyl chloride; 3 , 4 , 5 - trimethoxy benzoyl chloride; 4 -biphenylcarbonyl chloride; 4 -tertbutyl benzoyl chloride; 4 -n-butylbenzo
  • Such acid chlorides can be prepared from the corresponding Ri 2 "C(0)OH by treatment with oxalyl chloride or thionyl chloride (Tet. Lett. 1993, 3543-3546 and Julia et al J. Chem. Soc. Perkin Trans. I 1991, Vol 5, 1101-1105, respectively).
  • the dimethylketal XX prepared according to Scheme Vb, can be used in the process of Scheme II in place of the alphahydroxyketone (Via) and alphasilyloxyketone (Vlb) .
  • the dimethylketal XX can be prepared by reacting the anion of the dimethoxyacetal XIX with the aldehyde XV.
  • the dimethoxyacetal XIX can be readily prepared from the corresponding aldehyde XI (for example, 2 , 6 -diphenyl -4 -pyridinecarboxaldehyde; quinoline- 3 -carboxaldehyde; 2 -chloro- 3 -quinoline carboxaldehyde; 2 - chloro- 6 -methoxy- 3 - quinoline carboxaldehyde; 2 - imidazolecarboxaldehyde; N- 1 -benzyl - 2 - imidazolecarboxaldehyde; 2 -methyl - 3 - imidazole carboxaldehyde; 3- imidazolecarboxaldehyde; 2 -ethyl -4- methyl - 3 - imidazolecarboxaldehyde; 4 -methyl - 5 - imidazole carboxaldehyde; and 2 -phenyl - 4 - imi
  • indoles or azaindoles (III) can be prepared (Scheme VI) by reacting 2 - substituted indoles or azaindoles (XIX) (for example, 2 - (4 - fluorophenyl) indole; 2 - (2 -naphthyl) indole; and 2 - (4 -chlorophenyl ) indole, which are commercially available) with R n -L, where L is a leaving group such as chloro, bromo, iodo, and the like radicals (for example, 4- chloropyridine, 4 -chloroquinoline or 4- chloropyrimidine, which are commercially available) .
  • XIX 2 - substitutedoles or azaindoles
  • R n -L where L is a leaving group such as chloro, bromo, iodo, and the like radicals (for example, 4- chloropyridine, 4 -chloro
  • the 2 - substituted indole or azaindole (XIX) can be treated with methyl magnesium bromide in ether followed by the addition of R l ⁇ -L and heated in a metal bomb at 160°C for 20 hours to afford the indole or azaindole (III) (US Pat. 3,551,567).
  • substituted acetylenes and iodoanilines can be coupled via a palladium mediated process as described in Scheme I.
  • Substituted 2- iodoanilines can either be purchased or prepared by standard methods well known to those skilled in the art. For instance, monoiodination of a substituted aniline derivative would afford the 2 - iodoaniline derivative using a variety of iodination reagents, such as N-iodo succinimide.
  • Substituted acetylenes can be obtained as described in Scheme IV as illustrated in Scheme VIII for 1- (4 -pyridyl) -2 - (4 - fluorophenyl) ethyne (1).
  • the adduct (6) of diphenylphosphite and 4 -pyridinecarboxaldehyde (5) is treated with phosphorous oxychloride to afford the chloro derivative (7).
  • Condensation and elimination to the alkyne (1) is effected by treating the chloro derivative (7) and 4 - fluorobenzaldehyde (8) with 2.1 equivalents of potassium t-butoxide.
  • Scheme IX illustrates the preparation of substituted indoles according to the method of Scheme III, a titanium oxide mediated coupling.
  • the grignard of 4 -bromopyridine (10) is prepared by low temperature treatment (-78°C) with n-butyl lithium followed by treatment with magnesium bromide etherate.
  • a cooled solution of the grignard of (10) is added to anthranilonitrile (9) at low temperature ⁇ -50°C) followed by warming to room temperature.
  • the resultant imine (11) is hydrolyzed by treatment with sulfuric acid to the anilinoketone (12) .
  • Acylation of the anilinoketone (12) with 4 - fluorobenzoyl chloride (13) affords the ketoamide (14) .
  • the regiospecific synthesis of indole (3) is completed by treatment of the ketoamide (14) with titanium oxide.
  • Scheme X illustrates the preparation of indoles and azaindoles according to the method of Scheme II, acid mediated condensation of an aminoaryl or aminoheteroaryl and a substituted benzoin.
  • Condensation of 2,6- diaminopyridine (15) with 1- (4 -fluorophenyl) -2 - 1- butyldimethylsiloxy-2- (4-pyridyl) ethanone (16) is effected by treatment with an excess of p- toluenesulfonic acid in xylene at high temperatures to afford the azaindoles (17) and (18) which can be separated by flash chromatography.
  • N-4 - t-butoxycarbonylaminobutanoyl compound (21) which can be readily converted into the aminobutanoyl compound (22) by exposure to 90% trifluoroacetic acid and water for 1 hour.
  • aminoalkylsulfonyl compound (26) can be prepared according to the method shown in Scheme XII .
  • a fluoro radical can be introduced at the 5 -position of (17) through the use of N- fluorobenzenesulfonimide to afford the fluoro derivative (28) .
  • a bromo compound like (27), or an appropriately 6-amino and indole NH protected derivative thereof, can be converted into the fluoro derivative by lithium halogen exchange followed by quenching of the lithio anion with N- fluorobenzene sulfonimide (Synlett. 187 (1991) and Tetrahedron Lett. 1631 (1992)). These reactions exemplify in a specific fashion the further substitution of an azaindole system after the indole has been formed by electrophilic substitution.
  • aryl halide can be converted into an aryl stannane by lithium halogen exchange followed by quenching with a trialkylstannyl chloride (for example, tributylstannyl chloride or trimethylstannyl chloride) .
  • a trialkylstannyl chloride for example, tributylstannyl chloride or trimethylstannyl chloride
  • Schemes XVI -XXIII illustrate the use of palladium mediated couplings to prepare compounds of this invention.
  • bromo compound (31) can be coupled to aniline (other amines work as well, see Buchwald et al . , J. Am. Chem. Soc. 7901 (1994); Buchwald et al., Angew. Chem. Int. Ed. Engl . 1348 (1995); Hartwig et al., J. Am. Chem. Soc. 5969 (1994)) in. a palladium (0) mediated coupling to afford compound (33) as illustrated in Scheme XVI.
  • compound (31) can be coupled with an aryl boronic acid to afford a phenyl substituted derivative (43) as illustrated in Scheme XVII SCHEME XXI
  • Bromo compound (34) can be coupled to a heterocycle like imidazole as exemplified in Scheme XVIII which has been demonstrated in the literature for similar systems ((35) plus 2 -bromopyridine using tetrakistriphenylphosphine palladium (0), A. S. Bell et al., Tetrahedron Lett. 5013 (1988) and Synthesis 843 (1987)).
  • Compound (37) (Scheme IXX) can be prepared from 4 -amino-2 -mercapto-6 -methylpyrimidine by conversion to the corresponding 2 - iodo derivative (iodine and hydrogen iodide in analogy to the conditions of bromine and HBr found in Zh. Org. Khim. (1991) 2235-2236) then converted into (37) in the manner illustrated in Scheme X.
  • the Reformatsky reagent (38) can be coupled to the iodo derivative (37) using tetrakistriphenylphosphine SCHEME XXIV
  • the bromo derivative (31) can be converted to the carboxymethyl derivative (42) as illustrated in Scheme XXI utilizing the previously employed conditions for similar transformations (Pd2(dba)3, triphenylphosphine, methanol, carbon monoxide used with 2 , 6 -dichloropyrazine, see Synthesis 923 (1990)) .
  • the sulfide (51) can be oxidized to the sulfoxide (52) by treatment with t- butylhydroperoxide in the presence of the pyridine (Kagan et al . , Tetrahedron asymmetry (1990) 597-610) or further oxidized to the sulfone (53) (Trost et al . , Tetrahedron Lett (1981) 1287) .
  • a sulfonamide radical can be introduced prior to the indole forming process (Schemes I or II) and then further fuctionalized as illustrated in Scheme XXV.
  • Sulfonyl halides can be prepared by the reaction of a suitable alkyl, aryl, heteroaryl, heterocyclyl and the like Grignard or lithium reagents with sulfuryl chloride, or sulfur dioxide followed by oxidation with a halogen, preferably chlorine.
  • Alkyl, aryl, heteroaryl, heterocyclyl and the like Grignard or lithium reagents can be prepared from their corresponding halide (such as chloro or bromo) compounds which are commercially available or readily prepared from commercially available starting materials using known methods in the art.
  • mercaptans may be oxidized to sulfonyl chlorides using chlorine in the presence of water under carefully controlled conditions.
  • sulfonic acids may be converted into sulfonyl halides using reagents such as PCI5, S0C1 2 , C1C(0)C(0)C1 and the like, and also to anhydrides using suitable dehydrating reagents.
  • the sulfonic acids are either commercially available or may be prepared using procedures well known in the art from commercially available starting materials.
  • sulfinyl halides or sulfenyl halides can be utilized to prepare compounds wherein the sulfonyl moiety is replaced by an sulfinyl or thio moiety, respectively.
  • Arylsulfonic acids, benzo fused heterocyclyl sulfonic acids or heteroaryl sulfonic acids can be prepared by sulfonation of the aromatic ring by well known methods in the art, such as by reaction with sulfuric acid, S0 , S0 3 complexes, such as DMF(S0 3 ), pyridine (SO 3 ) , N, -dimethylacetamide (SO 3 ) , and the like.
  • sulfuric acid S0 , S0 3 complexes, such as DMF(S0 3 ), pyridine (SO 3 ) , N, -dimethylacetamide (SO 3 ) , and the like.
  • sulfonyl halides are prepared from such aromatic compounds by reaction with DMF(S0 3 ) and S0C1 2 or C1C (0) C (0)C1. The reactions may be performed stepwise or in a single pot.
  • Alkyl sulfonic acids, aryl sulfonic acids, heterocyclyl sulfonic acids, heteroaryl sulfonic acids, alkylmercaptans , arylmercaptans , heterocyclylmercaptans , heteroarylmercaptans, alkylhalides , arylhalides, heterocyclylhalides, heteroarylhalides, and the like are commercially available or can be readily prepared from starting materials commercially available using standard methods well known in the art.
  • Thioether derivatives can be converted into the corresponding sulfone or sulfoxide by oxidizing the thioether derivative with a suitable oxidation agent in a suitable solvent.
  • suitable oxidation agents include, for example, hydrogen peroxide, sodium meta- perborate, oxone (potassium peroxy monosulfate) , meta- chloroperoxybenzoic acid, periodic acid and the like, including mixtures thereof.
  • Suitable solvents include acetic acid (for sodium meta-perborate) and, for other peracids, ethers such as THF and dioxane, and acetonitrile, DMF and the like, including mixtures thereof.
  • Prodrugs of the compounds of this invention are also contemplated by this invention.
  • a prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of this invention following adminstration of the prodrug to a patient.
  • the suitability and techniques involved in making and using prodrugs are well known by those skilled in the art.
  • For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985).
  • Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) .
  • esters such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) .
  • Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med
  • reaction mixture was transfered to a jacketed addition funnel at -50°C, the solution was added to a cooled solution (-50°C) of anthranilonitrile (15.0 g, 0.127 mol) and benzene (400 mL) over 10 minutes. The reaction was allowed to warm to 23°C. After 16 h, the reaction was poured into 18% sulfuric acid (100 mL) , and was digested for 1 h. The resultant mixture was extracted with ethyl acetate ( (400 mL) , washed with water (3 x 400 mL) , and dried (MgS04) .
  • the top layer of xylene and p- toluenesulfonic acid was decanted from the bottom layer of gummy product residue.
  • the lower product layer was partitioned between saturated bicarbonate (100 mL) , and ethyl acetate (250 mL) .
  • the ethyl acetate layer was washed with brine (1 x 100 mL) , and dried (Na2S04) .
  • reaction was allowed to warm to 23°C. After 16 h at 23°C, the reaction was poured into saturated bicarbonate (80 mL) , extracted with ethyl acetate (2 x 100 mL) , washed with brine (1 x 100 mL) , and dried (Na2S04) .
  • the TFA salt of (21) was dissolved in 2 mL of water containing 3 equivalents of 1 N HCl and subsequently freeze-dried to afford the HCl salt of 6 - (4 ' -amino-2 ' -oxo-amino) - 3 - (4 - pyridyl) -2- (4 -fluorophenyl) -7 -aza- indole (21).
  • the HCl salt was used in biological testing or alternatively the free base can be used in biological testing which was obtained by partioning the hydrochloride salt between ethyl acetate and saturated bicarbonate.
  • 6-Amino-3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (17) 50 mg, 0.164 mmol
  • acetic anhydride 0.5 mL
  • the reaction was diluted with ethyl acetate (50 mL) , washed with NaOH (1 N, 50 mL) , and dried (Na2S ⁇ 4) .
  • Butoxycarbonyl-L-histidine was used in place of N-t-Boc g-aminobutyric acid which afforded 6 - (2 ' -N,N-Di- 1- Butoxycarbonyl-L-histidinyl) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (75) after preparative plate chromatography: Mass Spectrum (CI) 642 (MH+) .
  • 6-Amino-3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (17) (100 mg, 0.329 mmol), benzaldehyde (100 ml, 0.987 mmol), and 1 , 2 -dichloroethane (20 mL) were allowed to stir for 15 min followed by the addition of sodium triacetoxyborohydride (139 mg, 0.658 mmol) as a solid. After 16 h at 23°C, the reaction was partitioned between ethyl acetate (200 mL) and satd bicarbonate (80 mL) .
  • 6-Amino-3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (17) 250 mg, 0.822 mmol
  • N- fluorobenzenesulphonamide 259 mg, 0.822 mmol
  • DMF 4 mL
  • Compound (160) was obtained as a side product from example 104 wherein a small amount of unreacted ethyl chloroformate resulted in acylation of the 6 -amino function to afford 6 - (ethoxycarbonylamino) - 3 - (4 - pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole (160) after preparative plate chromatography: Mass Spectrum (CI) 377 (MH * ) .
  • Example 110 The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF- ⁇ and IL-l- ⁇ .
  • the second assay measured the inhibition of TNF- ⁇ and/or IL-l- ⁇ in mice after oral administration of the test compounds.
  • the third assay a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding.
  • the fourth assay a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.
  • COX-1 and COX-2 a Cyclooxygenase enzyme
  • Test compounds were evaluated in vi tro for the ability to inhibit the production of tumor necrosis factor (TNF) by monocytes activated with bacterial lipopolysaccharide (LPS) .
  • TNF tumor necrosis factor
  • LPS bacterial lipopolysaccharide
  • Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from the local blood bank and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol-Paque Plus (Pharmacia).
  • PBMCs peripheral blood mononuclear cells
  • FCS fetal calf serum
  • 0.3 mg/ml glutamate 100 U/ml penicillin G
  • 100 mg/ml streptomycin sulfate complete media
  • Cells were plated into Falcon flatbottom 96 well culture plates (200 ⁇ l/well) and cultured overnight at 37°C and 6% C ⁇ 2 • Nonadherent cells were removed by washing with 200 ⁇ l/well of fresh medium. Wells containing adherent cells ( ⁇ 70% monocytes) were replenished with 100 ⁇ l of fresh medium.
  • Test compounds were dissolved in DMZ .
  • Compound stock solutions were prepared to an initial concentration of 10 - 50 ⁇ M.
  • Stocks were diluted initially to 20 - 200 ⁇ M in complete media.
  • Nine twofold serial dilutions of each compound were then prepared in complete medium.
  • TNF ELISA Flat bottom 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 ⁇ L/well of 3 ⁇ g/ml murine anti -human TNFa MAb (R&D Systems #MAB210) . Plates were then blocked 1 h at room temperature with 200 ⁇ L/well of CaCl2"free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCl, 2 mM CaCl2, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 ⁇ l of test supernatants (diluted 1:3) or standards.
  • Standards consisted of eleven 1.5 -fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems) . Plates were incubated at room temperature for 1 h on orbital shaker (300 rpm) , washed and replenished with 100 ⁇ l/well of 0.5 ⁇ g/ml goat anti -human TNFa (R&D systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubate for 40 min, washed and replenished with 100 ⁇ l/well of alkaline phosphatase- conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 ⁇ g/ml.
  • Standard curve data were fit to a second order polynomial and unknown TNF-a concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted Vs test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production.
  • compounds of this invention can also be shown to inhibit LPS induced release of IL-lbeta, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL- lbeta, IL-6 and/or IL-8 by methods well known to those skilled in the art.
  • Selected compounds from this invention have demonstrated antiinflammatory properties in models of inflammation including the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents,
  • mice Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection.
  • vehicle the vehicle consisting of 0.5% tragacanth in 0.03 N HCl
  • lipopolysaccharide 2 mg/kg, I.V.
  • the reagents can be prepared as follows: (a) prepare fresh IM o- Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X) : 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 ⁇ M human glucagon (Peninsula): solubilize 0.5 mg vial in 575 ⁇ l 0.
  • the determination of inhibition of glucagon binding can be carried out by measuring the reduction of I 125 - glucagon binding in the presence of compounds of Formula I.
  • the reagents are combined in 120 ⁇ L of assay buffer as follows:
  • the mixture is incubated for 60 min. at 22 °C on a shaker at 275 rpm.
  • the mixture is filtered over pre- soaked (0.5% polyethylimine (PEI) ) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8).
  • the radioactivity in the filters is determined by a gamma- scintillation counter.
  • compounds of this invention can also be shown to inhibit LPS induced release of IL-lbeta, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-lbeta, IL-6 and/or IL-8 by methods well known to those skilled in the art.
  • THP-1 The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2.
  • THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM- 10%FBS) ; all cell incubations are at 37 °C in a humidified environment containing 5% C0 2 .
  • COX-1 Assay In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA), and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 x 10 6 cells/mL and plated in 96-well culture plates at a density of 5 x 10 s cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below.
  • HBS Hank's Buffered Saline
  • Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours.
  • subconfluent HOSC are trypsinized and resuspended at 3 x 10" cells/mL in MEM- FBS containing 1 ng human IL-lb/mL, plated in 96-well tissue culture plates at a density of 3 x 10 4 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment.
  • the media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-lb/mL, and the cells incubated for 18-22 hours.
  • test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours.
  • the supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37 °C, and enzyme activity determined as described below.
  • the following compounds exhibit activities in the Cyclooxygenase assay with IC 50 values of 20 ⁇ M or less: 6 - ( 6 ' - amino - 1 ' - oxo-hexylamino) - 3 - (4 -pyridyl ) - 2 - ( 4 - fluoro phenyl) -7-aza-indole; and 6 - (1 ' -oxo- 2 ' S-N-methylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole.
  • the following compounds exhibit activities in the Cyclooxygenase assay with IC 50 values of 5 ⁇ M or less: 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' -D, L- aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole; 6- (methyl sulfonylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole; and 3 - (4-pyridyl) -2- (4-fluorophenyl) indole.
  • This invention further relates to the use of a compound of this invention in the manufacture of a medicament for the prophylaxis and treatment, either acutely or chronically, of TNF-a mediated disease states.
  • the compounds of this invention are useful in the manufacture of a medicament for treating disease states in which IL-1, IL-6 and/or IL-8 play a role.
  • the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia.
  • the compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.
  • This invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of this invention and a pharmaceutically acceptable carrier, and if desired other active ingredients.
  • the compounds of this invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art.
  • All of the compounds of this invention are useful in the prophylaxis and treatment of TNF-a mediated disease states.
  • the compounds are also useful in the prophylaxis and treatment of disease states in which IL- 1, IL-6, and IL-8 play a role.
  • the compounds of this invention are useful in the prophylaxis and treatment of rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; antiviral therapy including those viruses sensitive to TNF-a inhibition - HIV-1, HIV- 2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, and the herpes viruses including HSV-1, HSV-2, and herpes zoster; muscle degeneration; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; brain trauma; atherosclerosis; Alzheimer's discease; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome
  • compounds of this invention can also reduce levels of other cytokines including but not limited to IL-1, IL-6 or IL-8. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, or possibly alleviating many disease states.
  • the present invention provides a method of treating a disease state in which cytokine levels are elevated which comprises administering an effective amount of a compound of this invention.
  • Compounds of this invention are of use in the prophylaxis and acute or chronic therapy of any disease state in a human, or other mammal, which is exacerbated by or mediated by elevated or unregulated IL-1, IL-6, IL-8 and/or TNF-a production by such mammal's cells, such as, but not limited to monocytes, macrophages, and glial cells.
  • this invention relates to a method of lowering the levels of TNF-a and/or IL-1 in a mammal in need thereof which comprises administering an effective dose of a compound of this invention or a pharmaceutical composition thereof.
  • this invention relates to a method of lowering the levels of IL-6 and/or IL-8 in a mammal in need thereof which comprises administering an effective dose of a compound of this invention or a pharmaceutical composition thereof.
  • the compounds of this invention or a pharmaceutical composition thereof are useful in the treatment or prophylaxis of a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis ; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic ⁇ cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs.
  • a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis ; multiple myeloma; uveititis; acute and chronic myelogenous le
  • HIV-1 host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection.
  • HIV-1 host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1,
  • HIV- 2 HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF- ⁇ and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.
  • CMV cytomegalovirus
  • influenza influenza
  • adenovirus the herpes viruses
  • herpes viruses including HSV-1, HSV-2
  • herpes zoster all of which are sensitive to TNF- ⁇ and/or IL-1 inhibition or glucagon antagonism
  • the compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1.
  • the compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety) .
  • the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.
  • this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF- ⁇ , IL-l ⁇ , IL-6, and/or IL-8 mediated disease state, including those described previously.
  • this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective TNF- ⁇ , IL-l ⁇ , IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients.
  • the compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods.
  • the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
  • parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal , infusion techniques or intraperitoneally .
  • the compounds of the present invention may be administered orally, parentally, or by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • the dosage regimen for treating a disease state with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex and medical condition of the patient, the severity of the condition, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination.
  • the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to 80 mg per kilogram of body weight per day, preferably from about 0.5 mg to 30 mg/kg, more preferably from about 1 mg to 15 mg/kg are useful for all methods of use disclosed herein.
  • the pharmaceutically active compounds of this invention can be processed in accordance with convential methods of pharmacy to produce medicinal agents for administration to patients, mammals including humans.
  • the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid.
  • the pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient.
  • these may contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg.
  • a suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors .
  • the compounds of this invention may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water.
  • suitable carriers including saline, dextrose, or water.
  • the daily parenteral dosage regimen wll be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.5 to about 30 mg/kg, and more preferably from about 1 mg to 15 mg/kg.
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 , 3 -butanediol .
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides .
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
  • a suitable topical dose of compounds of this invention is 0.1 mg to 150 mg administered one to four, preferably two or three times daily.
  • the active ingredient may comprise from 0.001% to 10% w/w, e.g.
  • Formulations suitable for topical administration include liquid or semi -liquid peparations suitable for penetration through the skin such as liniments, lotions, ointments, creams, or pastes and drops suitable for administration to the eye, ear, or nose.
  • the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration.
  • the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration.
  • the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, benzyl alcohol, and/or various buffers.
  • Other adjuvants and modes of administration are well known in the pharmaceutical art.
  • the carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
  • the pharmaceutical compositions may be made up in a solid form including granules, powders or suppositories or in a liquid form such as solutions, suspensions, or emulsions.
  • the pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules.
  • the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch.
  • Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water.
  • Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
  • Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non- racemic mixtures thereof.
  • optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base.
  • appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
  • a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
  • Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of this invention with an optically pure acid in an activated form or an optically pure isocyanate.
  • the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound.
  • the optically active compounds of this invention can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • the compounds of the present invention can be used in the form of salts derived from inorganic or organic acids.
  • These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2 -hydroxy- ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2 -naphthalenesulfonate, oxalate, palmoate, pectinate, pers
  • the basic nitrogen - containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl , and diamyl sulfates, long chain halides such as decyl , lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil -soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl , and diamyl sulfates
  • acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
  • organic acids such as oxalic acid, maleic acid, succinic acid and citric acid.
  • Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
  • the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents.
  • the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

Abstract

The present invention comprises a new class of novel aryl and heteroaryl substituted fused pyrrole compounds useful for the prophylaxis and treatment of diseases or conditions, such as TNF-α, IL-1β, IL-6 and/or IL-8 mediated diseases, and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of inflammation and other maladies, such as pain and diabetes, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Description

ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE ANTIINFLAMMATORY AGENTS
BACKGROUND OF THE INVENTION
The present invention comprises a new class of compounds useful in treating diseases, such as TNF-α, IL-lβ, IL-6 and/or IL-8 mediated diseases and other maladies, such as pain and diabetes. In particular, the compounds of the invention are useful for the prophylaxis and treatment of diseases or conditions involving inflammation. This invention, in particular, relates to novel aryl and heteroaryl substituted fused pyrrole compounds, compositions containing such compounds and methods of use of such compounds. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Interleukin- 1 (IL-1) and Tumor Necrosis Factor alpha (TNF-a) are proinflammatory cytokines secreted by a variety of cells including monocytes and macrophages in response to many inflammatory stimuli (e.g. lipopolysaccharide - LPS) or external cellular stress (e.g. osmotic shock, peroxide) . Elevated levels of TNF- α and/or IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1, HIV- 2, HIV- 3, cyto egalovirus (CMV) , influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster are also exacerbated by TNF-α.
Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome. Viruses sensitive to TNF-α inhibition, e.g., HIV-1, HIV- 2, HIV- 3, are also affected by IL-1. TNF-α and IL-1 appear to play a role in pancreatic β cell destruction and diabetes. Pancreatic β cells produce insulin which helps mediate blood glucose homeostasis. Deterioration of pancreatic β cells often accompanies type I diabetes. Pancreatic β cell functional abnormalities may occur in patients with type II diabetes. Type II diabetes is characterized by a functional resistance to insulin. Further, type II diabetes is also often accompanied by elevated levels of plasma glucagon and increased rates of hepatic glucose production. Glucagon is a regulatory hormone that attenuates liver gluconeogenesis inhibition by insulin. Glucagon receptors have been found in the liver, kidney and adipose tissue. Thus glucagon antagonists are useful for attenuating plasma glucose levels (WO 97/16442, incorporated herein by reference in its entirety). By antagonizing the glucagon receptors, it is thought that insulin responsiveness in the liver will improve, thereby decreasing gluconeogenesis and lowering the rate of hepatic glucose production.
Several approaches have been taken to block the effects of TNF-a. One approach involves utilizing soluble receptors for TNF-a (e.g., TNFR-55 or TNFR-75) which have demonstrated efficacy in animal models of TNF-a mediated disease states (for a PEG dimer of TNFR- 55 see Edwards CHI Meeting Nov. 13-15 (1995) and rhu sTNFR:Fc p-75 see Moreland) . A second approach to neutralizing TNF-a utilizing a monoclonal antibody specific to TNF-a, cA2 , has demonstrated improvement in swollen joint count in a Phase II human trial of rheumatoid arthritis (Feldmann et al Immunological Reviews p.195-223 (1995)). The above approaches block the effects of TNF-a and IL-1 by either protein sequesterazation or receptor antagonism, but an additional approach to blockade is to intervene in the cellular production and secretion of IL-1 and/or TNF. There are numerous points for intervention between the extracellular stimulus and the secretion of IL-1 and TNF-a from the cell including interfering with transcriptional processes, interfering with translational processes, blocking signal transduction which may alter protein translation and/or transcription; and blocking release of the proteins from the cells. The most reliable effect to document is upon applying a given stimulus to a cell in vi tro (eg. monocyte) , a certain amount of TNF or IL-1 (note: quantitated by enzyme linked immunoabsorbent assay, ELISA) is secreted over basal levels in the culture medium. Evidence as to the nature of intervention between the extracellular stimulus and the secretion of IL-1 and TNF-a from the cell can be provided by in vitro biochemical experiments, but it does not preclude the fact that the compounds may be intervening at a yet undetermined point on the pathway between extracellular stimulus and secretion of protein. Pentoxifylline is an example of a compound that is believed to intervene at the transcriptional level of IL-1 protein synthesis. Evidence suggests that the antiinflammatory glucocorticoids block at both the transcriptional and translational levels (Lee et al Circulatory Shock 44:97- 103 (1995)) of inflammatory mediators. Chloroquine (CQ) and hydroxychloroquine (HCQ) accumulate in lysosomes of monocytes (Borne Handbook of Cardiovascular and Antiinflammatory Agents p27-104 (1986)). CQ and HCQ inhibit cartilage cathepsin B and cartilage chondromucoprotease, and they may have membrane stabilizing effects on the lysozomes .
Since TNF-a is upstream in the cytokine cascade of inflammation wherein elevated levels of TNF-a lead to elevated levels of other cytokines including IL-1, IL-6 and IL-8, inhibiting the production of TNF-a may also reduce levels of other cytokines including but not limited to IL-1, IL-6 or IL-8. IL-8 is implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (e.g., ischemia) is mediated by the chemotactic nature of IL-8 including but not limited to the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis . In addition to the chemotaxis effect on neutrophils, IL-8 also has the ability to activate neutrophils. Thus, reduction in IL-8 levels would lead to diminished neutrophil infiltration. Evidence has been reported that suggests P-38 plays a role in TNF induced transcriptional activation of IL-6 production (see: Walter Fiers EMBO Journal 1996, vol. 15, p 1914-23) and of IL-8 production (Dinarello, Proc. Nat. Acad. Sci. 1995 Vol 92, 12230-4). In rheumatoid arthritis, both IL-1 and TNF-a induce synoviocytes and chondrocytes to produce collagenase and neutral proteases which leads to tissue destruction within the arthritic joints. In a model of arthritis, collagen- induced arthritis (CIA) in rats and mice, intraarticular administration of TNF-a either prior to or after the induction of CIA led to an accelerated onset of arthritis and a more severe course of the disease (Brahn et al Ly phokine Cytokine Res. (11):253- 256, (1992); and Cooper Clin. Exp. Immunol. 898:244-250, (1992) ) .
It has been reported that TNF-a plays a role in head trauma, stroke, and ischemia. For instance, in animal models of head trauma (rat) , TNF-a levels increased in the contused hemisphere (Shohami et al J. Cereb. Blood Flow Metab. 14:615-619 (1994)). In an model of ischemia wherein the middle cerebral artery was occluded in rats, the levels of mRNA of TNF-a increased (Feurstein et al Neurosci . Lett. 164: 125-128 (1993)). Administration of TNF-a into the rat cortex resulted in significant PMN accumulation in capillaries and adherance in small blood vessels. The TNF-a promotes the infiltration of other cytokines (IL-lb, IL-6), and also chemokines, which promote neutrophil infiltration into the infarct area (Feurstein Stroke 25:1481-1488 (1994) ) .
TNF-a may play a role in promoting certain viral life cycles and disease states associated with them. For instance, TNF-a secreted by monocytes induced elevated levels of HIV expression in a chronically infected T cell clone (Clouse et al, J. Immunol. 142: 431 (1989)). The role of TNF-a in the HIV associated states of cachexia and muscle degradation has been discussed (Lahdevirta et al The American J. Med. 85:289 (1988) ) .
Elevated levels of IL-1 over basal levels have been implicated in mediating or exacerbating a number of disease states including rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; ulcerative colitis; anaphylaxis; muscle degeneration; antiviral therapy including those viruses sensitive to TNF-a inhibition - HIV-1, HIV- 2, HIV- 3; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; ischemia reperfusion injury; atherosclerosis; brain trauma; multiple sclerosis; sepsis; septic shock; and toxic shock syndrome.
In rheumatoid arthritis models in animals, multiple intraarticular injections of IL-1 have lead to an acute and destructive form of arthritis (Chandrasekhar et al Clinical Immunol Immunopathol . 55:382-400 (1990)). In studies using cultured rheumatoid synovial cells, IL-1 is a more potent inducer of stromelysin than is TNF-a (Firestein Am. J. Pathol . 140:1309-1314, (1992)). At sites of local injection, neutrophil, lymphocyte, and monocyte emigration occurs. The emigration is attributed to the induction of chemokines (i.e. IL-8), and the up regulation of adhesion molecules (Dinarello Eur. Cytokine Netw. 5:517-531 (1994)).
IL-1 does play a role in promoting certain viral life cycles. Cytokine- induced increase of HIV expression in a chronically infected macrophage line has been associated with the concomittant and selective increase of IL-1 production (Folks et al J. Immunol. 136:40-49, (1986)). The role of IL-1 in cachexia has been discussed (Beutler et al J. Immunol. 135:3969-3971 (1985)). The role of IL-1 in muscle degeneration has been discussed (Baracos et al N. Eng. J. Med. 308:553- 558 (1983) ) .
IL-8 has been implicated in exacerbating and/or causing many disease states in which massive neutrophil infiltration into sites of inflammation or injury (eg ischemia) is mediated by the chemotactic nature of IL-8 including but not limited to the following: asthma, inflammatory bowel disease, psoriasis, adult respiratory distress syndrome, cardiac and renal reperfusion injury, thrombosis and glomerulonephritis . In addition to the chemotaxis effect on neutrophils, IL-8 apparently also has the ability to activate neutrophils. Thus, reduction in IL-8 levels could lead to diminished neutrophil infiltration.
Substituted imidazole and fused imidazole compounds have been described for use in the treatment of cytokine mediated diseases by inhibition of proinflammatory cytokines, such as IL-1, IL-6, IL-8 and TNF. Substituted imidazoles for use in the treatment of cytokine mediated diseases have been described in WO 93/14081; WO 96/21452; and WO 96/21654 (each of which is incorporated herein by reference in its entirety) . Substituted imidazoles for use in the treatment of inflammation has been described in US Pat. 3,929,807 (which is incorporated herein by reference in its entirety) . Substituted fused imidazole compounds for use in the treatment of cytokine mediated diseases have been described in WO 88/01169; WO 90/15534; WO 91/00092; WO 92/10190; WO 92/10498; WO 92/12154; and WO 95/35304 (each of which is incorporated herein by reference in its entirety) .
Several classes of diamino substituted azaindole compounds have been reported to be useful in the treatment of a variety of diseases including inflammation (US 5,502,187, which is incorporated herein by reference in its entirety) . Several classes of substituted indole and azaindole compounds are known to be useful as endothelin receptor antagonists for treating hypertension, renal failure and cerebrovascular disease (WO 94/14434 and WO 95/33748, each of which is incorporated herein by reference in its entirety) . A related class of substituted indoles has been reported as useful in the treatment of atherosclerosis (DE 2909779 Al , which is incorporated herein by reference in its entirety). Variously substituted 7-azaindoles have been prepared and reported for use as anti -ulcer drugs (JP 06247966, which is incorporated herein by reference in its entirety) .
The preparation of 3 - (4 -pyridyl) indole compounds has been reported (US 3,551,567; FR 1587692; DE 1795061; Ukr. Kim. Zh. (Russ. Ed.) (1982), 48(1), 76-9; Khim.
Geterotsikl. Soedin. (1980), (7), 959-64; each of which is incorporated herein by reference in its entirety) . The preparation of 2 , 3 -diphenylindole derivatives has been reported (US 3,654,308; US 3,565,912; and FR 1505197; each of which is incorporated herein by reference in its entirety) .
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to selected antiinflamatory compounds, analogs and pharmaceutically acceptable salts and prodrugs thereof. The subject compounds are characterized as aryl and heteroaryl substituted fused pyrrole compounds. The invention compounds advantageously treat inflammation related diseases. Therefore, this invention also encompasses pharmaceutical compositions and methods for prophylaxis and treatment of inflamation. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided an anti - inflammatory compound of the Formula:
Figure imgf000010_0001
or a pharmacutically acceptable salt thereof, wherein
Xi is N, CH or CRi; X2 is N, CH or CR2 ; X3 is N, CH or CR3 ; and X4 is N, CH or CR4 ; provided that at least one of Xi, X2 , X3 and X4 is N or CH, and that not more than two of Xi, X2, X3 and X4 are N; wherein Ri , R2 , R3 and R4 are each independently -Z-Y;
preferably, Xi is N; X2 is CH or CR2 ; X3 is CH or CR3 ; and X4 is CH or CR4 ; and more preferably, Xi is N; X2 is CR2; X3 is CH or CR ; and X4 is CH;
wherein R2 is independently -Z-Y; and preferably, R2 is independently Y; and R3 is independently -Z-Y; preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20/ -C(0)-OR2ι, -C (0) -NR5R21 , - S(O)2"R20 or -S (0) 2-NR5R21 radicals; more preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N,N- dimethylamido, methylsulfonyl or aminosulfonyl radicals; even more preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido or N,N-dimethylamido radicals; and most preferably, R3 is halo or trifluoromethyl radicals; and R4 is independently -Z-Y; and preferably, R4 is independently Y; or
alternatively, preferably, Xi is N; X2 is CH or CR2 ; X3 is CH or CR3; and X4 is N; and more preferably, Xi is N; X2 is CR2; X3 is CH or CR3 ; and X4 is N; wherein R2 is independently -Z-Y; and preferably, R2 is independently -Z-Y; and R3 is independently -Z-Y; preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20# -C(0)-OR2i, -C (0) -NR5R2ι , -S(O)2"R20 or "S (0) 2-NR5R21 radicals; and most preferably, R3 is halo, trifluoromethyl, phenyl, methyl, acetyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals; or
alternatively, preferably, Xi is N; X2 is CH or CR2 ; X3 is N; and X4 is CH or CR4 ; and more preferably, X! is N; X2 is CR2; X3 is N; and X4 is CH or CR ;
wherein R2 is independently -Z-Y; and preferably, R2 is independently Y; and R4 is independently -Z-Y; preferably, R4 is halo, trifluoromethyl, phenyl, methyl, hydroxyethyl, hydroxymethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-OR2i, -C (0) -NR5R21 , -S(O)2" 20 or - S (O) 2-NR5R21 radicals; more preferably, R4 is halo, phenyl, trifluoromethyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, N,N- dimethylamido, amido, methylsulfonyl or aminosulfonyl radicals; or
alternatively, preferably, Xi is N; X2 is N; X3 is CH or CR3; and X4 is CH or CR4 ; and more preferably, Xi is N; X2 is N; X3 is CR3; and X is CH or CR ;
wherein R3 is independently -Z-Y; and preferably, R3 is independently Y; and R4 is independently -Z-Y; preferably, R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20/ -C(0)-0R2i, -C (0) -NR5R21 , - S(0)2-R2o or -S (0) 2- R5R21 radicals; and more preferably, R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals; or
alternatively, preferably, Xi is CH or CRi ; X2 is CH or CR2; X3 is N; and X4 is N; and more preferably, X is CH or CRi; X2 is CR ; X3 is N; and X4 is N;
wherein Ri is independently -Z-Y; preferably, Ri is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20- -C(0)-0R2ι, -C(0) -NR5R21, -S(O)2-R20 or -S(0)2- NR5R21 radicals; and more preferably, Ri is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N,N- dimethylamido, methylsulfonyl or aminosulfonyl radicals; and R2 is independently -Z-Y; and preferably, R2 is independently Y; or
alternatively, preferably, Xi is CH or CRi; X2 is CH or CR2; X3 is CH or CR3; and X is CH or CR4 , provided that at least one of Xi, X , X3 and X4 is CH; more preferably, Xi is CH; X is CH; X3 is CH or CR3 ; and X is CH or CR4 ; and even more preferably, Xi is CH; X2 is CH; X3 is CR3; and X4 is CH or CR4 ;
wherein Ri is independently -Z-Y; and preferably, Ri is independently Y; and R2 is independently -Z-Y; and preferably, R2 is independently Y; and R3 is independently -Z-Y; and preferably, R3 is independently Y; and R4 is independently -Z-Y; preferably, R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20, -C(0)-OR2ι, -C(0) -NR5R21, -S(0)2-R2o or -S(0)2- NR5R21 radicals; and more preferably, R4 is halo, phenyl, trifluoromethyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, N,N- dimethylamido, amido, methylsulfonyl or aminosulfonyl radicals; or
alternatively, more preferably, Xi is CH? X2 is CH or CR2; X3 is CH or CR3 ; and X4 is CH; and even more preferably, Xi is CH; X2 is CR2 ; X3 is CH or CR3 ; and X is CH;
wherein R2 is independently -Z-Y; and preferably, R2 is independently Y; and R3 is independently -Z-Y; preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-0R2ι, -C (0) -NR5R21, - S(0)2-R2o or - S (0) 2 -NR5R21 radicals; and more preferably, R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals; and
provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri , R2 , R3 and R4 is 0-4, preferably 0-3; each Z is independently a (1) bond; (2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl; (3) heterocyclyl radical optionally substituted by 1 - 3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
preferably, each Z is independently a (1) bond; (2) C]_- C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C3.-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C:- C4 haloalkyl of 1-3 halo radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoyl amino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, Cι_- C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each Z is independently a (1) bond; (2) C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C -C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C'ι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C -C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; even more preferably, each Z is independently a (1) bond; (2) Ci-Cs alkyl or C2-Cs alkenyl radical optionally substituted by 1-3 radicals of amino, C1.-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, Ci- C4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, Cι_- C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ- C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
yet more preferably, each Z is independently a (1) bond; (2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, hydroxy, C1-C2 alkoxy, Cι-C2 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C3.-C4 alkylamino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; (3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cι-C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or C1-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ- C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
yet even more preferably, each Z is independently a (1) bond; (2) C1-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(Cχ- C2 alkyl) amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, hydroxy, Cι-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; or (3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonyl amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, Ci- C4 alkyl or trifluoromethyl radicals;
still more preferably, each Z is independently a (1) bond; or (2) C1-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cι-C2 alkyl)amino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C2 alkoxy, C1-C2 alkyl thio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, Cι-C alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; still even more preferably, each Z is independently a (1) bond; or (2) C1-C4 alkyl radical optionally substituted by 1 - 2 radicals of amino, t- butoxy carbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals; and most preferably, each Z is a bond; each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, cyano, nitro, -C(O)-R20 -C(0)-OR2ι, -C(0) -NR5R2ι, -C (NR5) -NR5R2ι , -0R2i, -0-C(0)- R2ι, -0-C(0) -NR5R21, -0-C(0) -NR22-S(O)2-R20, "SR2ι, -S(0)- R20, -S(O) -R20, -S(0)2-NR5R2ι, - S (0) 2 -NR22 -C (0) - R21 ,
-S(0)2-NR22-C(0) -OR20' -S(0)2-NR22-C(0) -NR5R21, - R5R21, -NR22-C(0) -R21, -NR2 -C(0) -OR20- -NR22-C(0) -NR5R21, -NR22"
C(NR5) -NR5R21, -NR22-S(O)2-R20 or -NR22 - S (0) 2 -NR5R21 radical ;
preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -C(0)-R2o, -C(0)-0R2ι, -C(0) -NR5R21, -C(NR5) -NR5R21, -OR21, -0-C(0)-
R2ι, -0-C(0) -NR5R21, -SR21, -S(O)-R20, -S(O) 2-R20, -S(0)2- NR5R21, -NR5R21, -NR22 "C (0) - R21 , -NR22 -C (0) -OR20 , "NR22-
C(0)-NR5R2ι, -NR22-C(NR5) -NR5R21, -NR22 " S (0) 2 -R20 or -
NR22-S (0) 2-NR5R21 radical;
more preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -
C(O)-R20, -C(0)-0R2ι, -C(0) -NR5R21, -OR21, -SR2ι, -S(O)- R20, -S(O)2-R20, -S(0)2-NR5R2ι, -NR5R21, -NR22-C(0) -R2ι, - NR22-C(0) -OR20, -NR2 -C(0) -NR5R21, -NR22-S(0)2-R2o or - NR22-S (0) 2-NR5R21 radical;
even more preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, - C(O)-R20, -C(0)-0R2ι, -C(0) -NR5R21, -OR21, -SR21, -S(0)- R20, -S(O)2-R20. -S(0)2-NR5R2ι, -NR5R2i, -NR22-C (0) -R2i, - NR22-S(0) -R2o or -NR 2-S(0)2-NR5R2i radical;
yet even more preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -C(0)-R2o, -C(0) -NR5R21, -0R2ι, -SR2ι, -S(O)-R20, -NR5R21, -NR22-C(0) -R2i, -NR22-S(O)2-R20 or -NR22-S(0)2- NR5R21 radical; and most preferably, each Y is independently a hydrogen radical, provided Z is other than a bond; or halo, -NR5R21, -NR22 -C (0) -R21 or -NR22- S(O) -R20 radical;
wherein each R5 is independently (1) hydrogen radicals; (2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano or halo; or (3) aryl, heteroaryl, aralkyl, heteroaralkyl , heterocyclyl, heterocyclylalkyl , cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
preferably, each R5 is independently (1) hydrogen radicals; (2) Cχ-C8 alkyl, C2-C8 alkenyl or C2-Cs alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di - (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano or halo; or (3) aryl, heteroaryl, aryl -Ci -C4 -alkyl , heteroaryl -Ci -C4 - alkyl, heterocyclyl, heterocyclyl -Ci -C4 -alkyl , C3-C8 cycloalkyl or C3 -Cs - cycloalkyl -Ci -C4 -alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di - (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R5 is independently (1) hydrogen radicals; (2) C1-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di - (C1-C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or halo; or (3) aryl, heteroaryl, aryl -C1-C4 -alkyl , heteroaryl -Ci -C4 -alkyl , heterocyclyl, heterocyclyl -Ci -C4 -alkyl , C3-C8 cycloalkyl or C3 -Cs -cycloalkyl-Cι-C4 -alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di - (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
even more preferably, each R5 is independently (1) hydrogen radicals; (2) C1-C4 alkyl or C2-Cs alkenyl radicals optionally substituted by 1-3 radicals of amino, di - (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, Ci- C4 alkylthio or halo; or (3) phenyl -Ci -C -alkyl , heteroaryl -Ci -C2-alkyl , heterocyclyl -Ci -C2 -alkyl or C3- Cς -cycloalkyl -Ci -C2 -alkyl radicals optionally substituted by 1-3 radicals of amino, di-(Cι-C4- alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
yet even more preferably, each R5 is independently (1) hydrogen radical; (2) C1-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2- alkyl) amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio or halo; or (3) phenyl -Ci -C2 -alkyl , heteroaryl -Ci -C2 - alkyl , heterocyclyl -C1-C2- alkyl or C3 -C6 -cycloalkyl -Ci -C2 - alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Ci -C2 -alkyl) amino, hydroxy, C1-C2 alkoxy, Ci- C2 alkylthio, methoxy, methylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals;
still more preferably, each R5 is independently (1) hydrogen radical; (2) C1-C4 alkyl radical optionally substituted by 1-3 halo radicals; or (3) phenyl -Ci -C2 - alkyl or heteroaryl -Cι-C2 -alkyl , radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals; still even more preferably, each R5 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R5 is a hydrogen radical;
wherein each R20 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1 - 3 radicals of -CO2R23/ amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N- (alkoxycarbonyl ) - N- (alkyl) amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl , cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonyl amino, alkylsulfonylamino, alkanoyl, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
preferably, each R20 is independently (1) Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl ) - N-(Ci-C4 alkyl) amino, aminocarbonylamino, C1-C4 alkyl sulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio,
C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo or aryl -Ci -C4 -alkoxy, aryl -Ci -C4 -alkylthio, aryl-Cι-C4- alkylsulfonyl , C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C -C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1- 3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R20 is independently (1) Ci-Cs alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C1-C4 alkyl amino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-UC1-C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl sulfinyl, Ci- C4 alkylsulfonyl , halo or aryl -Ci -C4 -alkoxy, aryl-Cι-C4- alkylthio, aryl -Ci -C4 -alkylsulfonyl , C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkyl sulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
even more preferably, each R20 s independently (1) Ci- Cδ alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) mino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , halo or aryl -C1-C4 -alkoxy, aryl -Ci -C4 -alkylthio, aryl-Ci- C4 -alkylsulfonyl , C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoyl amino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonyl amino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C2 haloalkyl of 1- 3 halo radicals;
yet more preferably, each R20 is independently (1) Ci-Cs alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C1-C4 alkylamino, di - (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (Ci -C4 alkyl) amino, aminocarbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , halo or aryl -C1-C4 -alkoxy, aryl-C -C4- alkylthio, aryl -Ci -C4 -alkylsulfonyl , C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or Ci- C2 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di- (C1-C4 alkyl) amino, (C1-C4 alkoxy) carbonylamino, (Ci- C4 alkoxy) carbonyl, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1 - 2 radicals of amino, di-(Cι-C4 alkyl) amino, acetamido, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
still more preferably, each R20 is independently (1) Ci- C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, -((Cι-C4 alkoxy) carbonyl) -N- (Ci- C4 alkyl) amino, aminocarbonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, Ci- C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or trifluoromethyl radicals;
still even more preferably, each R20 s independently (1) Ci-Cς alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl , hydroxy, or C1-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t- butoxycarbonyl , hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals; and
most preferably, each R2o is independently (1) Ci-Cg alkyl radicals optionally substituted by 1-3 radicals of -C02R23, amino, methylamino, dimethylamino, t-butoxy carbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or C5- Cζ cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by t- butoxycarbonyl ; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxy carbonyl, hydroxy, methoxy, halo, azido, methyl or trifluoromethyl radicals;
each R2ι is independently hydrogen radical or R20;
each R22 is independently (1) hydrogen radical; (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl, cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; and
preferably, each R22 is independently (1) hydrogen radical; (2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkyl sulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R22 is independently (1) hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(Cι- C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals; even more preferably, each R22 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R22 is independently hydrogen or methyl radical; each R23 is independently hydrogen or alkyl, or aryl, heteroaryl, aralkyl or heteroaralkyl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl , cyano, halo, alkyl or haloalkyl; and
preferably, each R 3 is independently hydrogen or C1-C4 alkyl, or aryl, heteroaryl, aryl -Ci -C4 -alkyl or heteroaryl -C1-C4 -alkyl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl -Ci -C2 -alkyl or heteroaryl -C1-C2 -alkyl optionally substituted by 1-3 radicals of amino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C2 haloalkyl of 1-3 halo radicals;
even more preferably, each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl -Ci -C2 - alkyl or heteroaryl -Ci -C2 -alkyl optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; yet more preferably, each R23 is independently hydrogen or C1-C4 alkyl, or phenyl -Ci -C - alkyl or heteroaryl -Ci - C2-alkyl optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) mino, acetamido, (C1-C4 alkoxy) carbonyl amino, hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; still more preferably, each R23 is independently hydrogen or C1-C4 alkyl, or phenyl -Ci -C2 - alkyl optionally substituted by 1-2 radicals of hydroxy, C1-C2 alkoxy, C1-C2 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; and most preferably, each R23 is independently hydrogen or C1-C4 alkyl radicals;
Rio is a hydrogen, R30, -C(0)-R29/ -C(O)-OR30, -C(O)- NR3 R32, -S(O)2"R30 or -S (0) 2-NR31R32 radical; preferably, Rio is a hydrogen, R30, -C(0)-R2g, -C (0) -NR31R32 , -S(0) - R30 or -S (0) 2-NR31R32 radical; more preferably, Rio is a hydrogen, R30, -C(0)-R29 or -C (0) -NR31R32 radical; and most preferably, Rio is a hydrogen or methyl radical;
R11 and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of R30, halo, cyano, -C(0)-R3o, -C(0)-OR29, -C (0) -NR3ιR32 , -C(NR3ι) -NR31R32, -OR29, -0-C(0)-R29, -0-C(0) -NR31R32, -0- C(0) -NR33-S(O)2-R30, -SR29, -S(O)-R30, -S(O) 2-R30, -S(0) 2- NR31R32, -S(0)2-NR33-C(0) -R30, - S (0) 2 -NR33 -C (0) -OR30 , -S(0)2-NR33-C(0) -NR31R32, -NR31R32, -NR33-C(0) -R29, -NR33- C(O)-OR30, -NR33-C(0) -NR31R32, -NR33-C(NR3ι) -NR31R32, - NR33-S (0) 2-R30 or -NR33-S (0) 2-NR31R32 radicals;
preferably, Rn and Rχ2 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R30, halo, cyano radicals, -C(0)-R3o, -C(0) 0R29, -C(0) -NR31R32, -C(NR3i) -NR31R32, -OR29, -SR29, " S(O)-R30, -S(O)2-R30, -S(0)2-NR31R32, -NR3ιR32, -NR33- C(0)-R29 or -NR33 -C (0) -OR3o radicals;
more preferably, Ru and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R30, halo, cyano, -C(0)-R3o, -C(0)-0R2g, -C(0) -NR3iR32, -C(NR3ι) -NR3ιR32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(0)2-NR3ιR32, -NR3ιR32 or - R33 -C (0) - R29 radicals;
even more preferably, Ru and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of R3o, halo, cyano, -C (0) -NR31R32 , -OR29, -SR29, -S(O)-R30, -S(O)2-R30, -S(0)2-NR3ιR32, -NR3ιR32 or -NR33-C (0) -R29 radicals;
yet more preferably, Ru is a heteroaryl radical optionally substituted by 1-2 radicals of R30 halo, cyano, -C (0) -NR31R32 , -OR29, -SR2g, -NR31R32 or -NR33- C(0)-R29 radicals; and Rχ2 is an aryl radical optionally substituted by 1-2 radicals of R30, halo, cyano, -C(0)- NR31R32, -OR29, -SR29, -S(O)-R30, -S(O) 2-R30, -S(0) 2- NR31R32, -NR31R32 or -NR33-C (0) -R29 radicals;
still more preferably, Rn is a heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R12 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals;
still even more preferably, Ru is a 4 -pyridyl, 4- quinolinyl, 4-imidazolyl or 4 -pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R12 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals; and
most preferably, Ru is a 4 -pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and R12 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl , methyl or trifluoromethyl radicals; and
provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Ru and R12 is 0-1; and provided that when each of Xl, X2 X3 and X4 represent carbon atoms, then Rχι is a substituted aryl radical and R12 is heteroaryl radical, or Rχι is a heteroaryl radical and R12 is a substituted aryl radical;
wherein each R30 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23 hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo 'or aralkoxy, aralkylthio, aralkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1 - 3 radicals of amino, alkylamino, dialkylamino, alkanoyl amino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonyl amino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonyl amino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
preferably, each R30 is independently (1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -CO2R23, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C -C4 alkylsulfonyl , cyano, halo or aryl - C1-C4 -alkoxy, aryl -Ci -C4 -alkylthio, aryl-Cι-C4- alkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(C -C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonyl amino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, Ci- C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; more preferably, each R30 is independently (1) C -C4 alkyl radical optionally substituted by 1-3 radicals of
(a) -NR31R31; (b) C1-C4 alkoxy -carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1 - 3 radicals of amino, alkylamino, di - (Cι-C4-alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkyl sulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, Ci- C4 alkyl or trifluoromethyl; or (c) hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, or phenyl -Ci -C4 -alkoxy, phenyl - Cι-C4-alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) C1-C4 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C -C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, Ci- C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
even more preferably, each R30 is independently (1) Ci* C4 alkyl radical optionally substituted by (a) amino, C1-C4 alkylamino or di - (Ci -C4 -alkyl) amino radicals; or
(b) hydroxy, C1-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C -C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals; (2) C1-C2 haloalkyl of 1-3 halo radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or trifluoromethyl radicals;
yet more preferably, each R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, hydroxy, Cι-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, hydroxy, Cι-C2 alkoxy, halo, Ci- C4 alkyl or trifluoromethyl radicals;
still more preferably, each R30 is independently (1) Ci- C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and most preferably, R30 is independently (1) C1-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R3o; and preferably, R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R3ι is independently (1) hydrogen radicals; (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl;
preferably, each R3ι is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by an C3-Cs cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoyl amino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, Ci- C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R31 is independently (1) hydrogen radicals; or (2) C1-C4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or trifluoromethyl radicals; even more preferably, each R31 is independently hydrogen or C1-C4 alkyl radicals; and most preferably, R31 is independently hydrogen, methyl or ethyl radicals;
each R32 is independently (1) hydrogen radicals; (2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or (3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl ;
preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by an C3-C8 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoyl amino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, Ci- C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by an C3-C6 cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1 - 3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoyl amino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonyl amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, Ci- C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
even more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamin , hydroxy, Ci- C4 alkoxy, C1-C4 alkyl or trifluoromethyl radicals;
yet more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical or C1-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl)amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cι-C2 alkyl) amino, acetamido, hydroxy, C1-C2 alkoxy, C1-C4 alkyl or trifluoromethyl radicals;
still more preferably, each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical or C -C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or (3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and
most preferably, each R32 is independently (1) hydrogen or C1-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; and
each R33 is independently (1) hydrogen radical; or (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; preferably, each R33 is independently (1) 'hydrogen radical; or (2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; more preferably, each R3 is independently hydrogen or C1-C4 alkyl radical; and most preferably, each R33 is independently hydrogen or methyl radical.
Compounds of interest include the following:
3 - (4 -pyridyl) -2 - (4 -fluorophenyl) indole;
3 - (4 - fluorophenyl) -2 - (4 -pyridyl) indole;
6-amino-3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6-amino-3- (4 - fluorophenyl) -2- (4-pyridyl) - 7 -aza- indole,•
6- (4 ' - t-butoxycarbonylamino- 1 ' -oxo-butylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole,•
6- (4 ' - amino -1 ' -oxo-butylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole ; 6 - (5 ' -ureido- 1 ' -oxo -2 ' - t-butoxycarbonylaminopentyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (5 ' -ureido- 1 ' -oxo-2 ' - aminopentylamino) -3 - (4 -pyridyl) - 2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (6 ' - t-butoxycarbonylamino- 1 ' -oxo-2 ' - t-butoxycarbonyl aminohexylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7 -azaindole ;
6 - (6 ' -amino- 1 ' -oxo-2 ' -aminohexylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (5 ' - t-butoxycarbonylamino- 1 ' -oxo -2 ' - t-butoxycarbonyl aminopentylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza- indole;
6 - (5 ' -amino- 1 ' -oxo -2 ' -aminopentylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (3 ' - (4 - iodophenyl) - 1 ' -oxo -2 ' - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7 -azaindole;
6- (3 ' - (4 -iodophenyl) - 1 ' -oxo -2 ' -aminopropylamino) -3 - (4- pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (3 ' -methyl- 1 ' -oxo-2 ' - t-butoxycarbonylaminobutylamino) - 3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (3 ' -methyl -1 ' -oxo-2 ' -aminobutylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole ;
6- (4 ' , 4 ' - dimethyl -1 ' -oxo -2 ' -t-butoxycarbonylamino pentylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7-aza - indole;
6- (4 ' , 4 ' -dimethyl- 1 ' -oxo -2 ' -aminopentylamino) -3 - (4- pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6 - ( 5 ' - t-butoxycarbonylamino- 1 ' -oxo -pentylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) - 7 - aza - indole,•
6 - (5 ' - mino- 1 ' -oxo -pentylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole; 6 - (6 ' - -butoxycarbonylamino- 1 ' -oxo -hexylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (6 ' -amino- 1 ' -oxo-hexylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' - cyclohexyl - 1 ' -oxo-2 ' - 1 -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' - cyclohexyl - 1 ' -oxo-2 ' -aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (4 ' - -butoxycarbonyl - 1 ' -oxo- 2 ' - t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole;
6 - (4 ' -carboxy- 1 ' -oxo- 2 ' -aminobutylamino) - 3 - (4 -pyridyl) - 2- (4 - fluorophenyl) - 7 - aza- indole,•
6 - (3 ' -O- 1 -butoxy- 1 ' -oxo- 2 ' - -butoxycarbonylaminobutyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6 - (3 ' -hydroxy- 1 ' -oxo -2 ' -aminobutylamino) - 3 - (4 -pyridyl) -
2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' -phenyl - 1 ' -oxo-2 ' - 1 -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' -phenyl - 1 ' -oxo- 2 ' -D, L- aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' - (4 - t-butoxyphenyl) - 1 ' -oxo-2 ' - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6 - (3 ' - (4 - hydroxyphenyl ) - 1 ' -oxo- 2 ' -aminopropylamino) - 3 - (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole ;
6 - (3 ' - t-butoxycarbonylamino- 1 ' -oxo-propylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole ;
6- (3 ' -amino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole ; 6- (2 ' - t-butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' -amino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (methylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole;
6- (1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' - (5 - chlorothienyl) sulfonylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole; 6- (phenylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 - aza- indole,•
6- (2 ' -N-phthaloyl- 1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole; 6- (3 ' -N-phthaloyl -1 ' -oxo -propylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
3- (4-pyridyl) -2- (4 - fluorophenyl) -4 , 7 -diaza- indole;
6- (2 ' -N- t-butoxycarbonyl -L-prolylamino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6- (2 ' -L-prolylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza- indole;
6 - (2S ' -dimethylamino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl) -
2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' -dimethylamino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl ) - 7 -aza- indole;
6 - (2 ' -N-methyl - 1 -butoxycarbonylamino- 1 ' -oxo- ethylamino) -
3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (2 ' -N-methyl -amino- 1 ' -oxo-ethylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6- (4 ' -N- t-butoxycarbonylisonipecotylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (4 ' - isonipecotylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole ;
6 - (4 ' -methylsulfoxo- 1 ' -oxo-2 ' S- t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6 - (4 ' -methylsulfoxo- 1 ' -oxo-2 ' S- aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole ;
6 - (3 ' - (3 -pyridyl) - 1 ' -oxo-2 ' S- -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole;
6- (3 ' - (3 -pyridyl) - 1 ' -oxo-2 ' S- aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (N,N-Di- t-butoxycarbonyl -L-histidinylamino) -3- (4- pyridyl) -2- (4 - fluorophenyl) -7 -aza- indole; 6- (L-histidinylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6- (N- t-butoxycarbonyl -3 (S) l',2',3',4' - tetrahydro- 3 ' - isoquinolinyloxo- amino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole; 6-(3(S) 1' ,2' , 3' , 4' - tetrahydro- 3 ' -isoquinolinyloxo amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' -phenyl- 1 ' -oxo-2 'R-N- 1 -butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole,•
6- (2 ' -phenyl- 1 ' -oxo-2 ' R-aminoethylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl ) - 7 - aza - indole ; 6 - (2 ' -phenyl - 1 ' -oxo-2 ' S-N- 1 -butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole;
6 - (2 ' -phenyl - 1 ' - oxo - 2 ' S - aminoethy1amino) - 3 - (4 -pyridyl) - 2- (4 - fluorophenyl) - 7 -aza- indole; 6 - (2 ' -phenyl - 1 ' -oxo-2 'R-N- t-butoxycarbonyl -N-methylamino ethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6- (2 ' -phenyl - 1 ' -oxo-2 ' R-N-methylaminoethylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 - aza- indole; 6- (1 ' -oxo-2 ' S- t-butoxycarbonylaminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 - aza- indole;
6 - ( 1 ' - oxo - 2 ' S - aminopropylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 7 - aza- indole;
6 - (3 ' -phenyl - 1 ' -oxo- 2 ' - (L) - 1-butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' -phenyl - 1 ' -oxo-2 ' - (L) -aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 - aza- indole;
6 - (1 ' -oxo- 2 ' S - t-butoxycarbonyl -N-methylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6 - (1 ' -oxo-2 ' S-N-methylaminopropylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6 - (1 ' -oxo-2 ' S- t-butoxycarbonyl -N-methyl -4 -methyl - 2 -amino pentyl -amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -azaindole,• 6- (1 ' -oxo-2 ' S- N-methyl -4 -methyl -2 -aminopentylamino) - 3 - (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (1 ' -oxo- 2 ' R- t-butoxycarbonylaminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole,•
6 - (1 ' -oxo-2 ' R- aminopropylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) - -butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole;
6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) -aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (3 ' - (4 -azidophenyl) - 1 ' -oxo- 2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6 - (3 ' - (4 -azidophenyl) - 1 ' -oxo-2 ' S -aminopropylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - ( 3 ' - ( 3 -benzothienyl ) - 1 ' - oxo - 2 ' S - 1 -butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6- (3 ' - (3 -benzothienyl) - 1 ' -oxo-2 ' S- aminopropylamino) - 3 - (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6 - (4 ' -phenyl - 1 ' -oxo-2 ' - (L) - -butoxycarbonylaminobutyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole,•
6 - (4 ' -phenyl - 1 ' -oxo-2 ' - (L) -aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6 - (4 ' -phenyl - 1 ' - oxo - 2 ' - (D) - 1 -butoxycarbonylaminobutyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole,•
6 - (4 ' -phenyl - 1 ' -oxo-2 ' - (D) -aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' -amino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 1 - isobutoxycarbonyl - 7 -aza- indole;
6- (phenylmethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole;
6- (diethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7 -azaindole,• 6- (3' -phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole;
6- (2 ' (R, S) -phenylpropylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (2' (R,S) -ethylhexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole;
6 -Amino- 5 -chloro- 3 - (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole;
6 -Amino- 5 - fluoro- 3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole; 6 -Amino- 5 -bromo- 3 - (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole;
6- (di - isoamylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7- aza- indole;
6- (2' ,2' -dimethylpropylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (isoamylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole;
6- (2' -ethylbutylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole; 6- (2' - thienylmethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole;
6- (3' , 3 ' di -phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole;
6- (ethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole;
6- (3 ' -phenyl- 1 ' -oxo-2 ' - (R, S) -methylpropylamino) -3 - (4- pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole;
6 - (2 ' - amino - 1 ' - oxo - ethylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 1 -methyl -7-aza- indole; 6 - (3 ' , 3 ' -dimethyl - 1 ' -oxo-butylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole;
6- (ethoxycarbonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole; 6 - (2 ' S- amino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 1 -methyl - 7 -aza- indole;
6- (2 ' S - amino -1 ' -oxo-propylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 1 - isobutyl - 7 -aza- indole; and
6- (2 ' S- amino- 1 ' -oxo -propylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl) - 1 -cyclohexylmethyl - 7 -aza- indole.
As utilized herein, the following terms shall have the following meanings:
"Alkyl", alone or in combination, means a straight - chain or branched- chain alkyl radical containing preferably 1- 15 carbon atoms (C1-C15), more preferably 1-8 carbon atoms (C -Cβ), even more preferably 1-6 carbon atoms (C - Cβ ) , yet more preferably 1-4 carbon atoms (C1-C4), still more preferably 1-3 carbon atoms (C1-C3), and most preferably 1-2 carbon atoms (C1-C2). Examples of such radicals include methyl, ethyl, n -propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl and the like.
"Hydroxyalkyl", alone or in combination, means an alkyl radical as defined above wherein at least one hydrogen radical is replaced with a hydroxyl radical, preferably 1-3 hydrogen radicals are replaced by hydroxyl radicals, more preferably 1-2 hydrogen radicals are replaced by hydroxyl radicals, and most preferably one hydrogen radical is replaced by a hydroxyl radical. Examples of such radicals include hydroxymethyl, 1-, 2 -hydroxyethyl , 1-, 2-, 3 - hydroxypropyl , 1 , 3 -dihydroxy- 2 -propyl , 1,3- dihydroxybutyl , 1 , 2 , 3 , 4 , 5 , 6 -hexahydroxy- 2 -hexyl and the like.
"Alkenyl", alone or in combination, means a straight- chain or branched- chain hydrocarbon radical having one or more double bonds, preferably 1-2 double bonds and more preferably one double bond, and containing preferably 2-15 carbon atoms (C2-C15), more preferably 2-8 carbon atoms (C2-C8), even more preferably 2-6 carbon atoms (C2-C6), yet more preferably 2-4 carbon atoms (C2-C4), and still more preferably 2-3 carbon atoms (C2-C3). Examples of such alkenyl radicals include ethenyl, propenyl, 2 -methylpropenyl , 1,4- butadienyl and the like.
"Alkynyl", alone or in combination, means a straight- chain or branched chain hydrocarbon radical having one or more triple bonds, preferably 1-2 triple bonds and more preferably one triple bond, and containing preferably 2-15 carbon atoms (C2-C15), more preferably 2-8 carbon atoms (C2-Cβ), even more preferably 2-6 carbon atoms (C2-Cg), yet more preferably 2-4 carbon atoms (C2-C4), and still more preferably 2-3 carbon atoms (C2-C3) . Examples of such alkynyl radicals include ethynyl , propynyl (propargyl), butynyl and the like.
"Alkoxy", alone or in combination, means a radical of the type "R-0-" wherein "R" is an alkyl radical as defined above and "0" is an oxygen atom. Examples of such alkoxy radicals include methoxy, ethoxy, n -propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert- butoxy and the like.
"Alkoxycarbonyl", alone or in combination^ means a radical of the type "R-O-C(O)-" wherein "R-0-" is an alkoxy radical as defined above and "C (0) " is a carbonyl radical .
"Alkoxycarbonylamino", alone or in combination, means a radical of the type "R-O-C (0) -NH- " wherein "R-O-C(O)" is an alkoxycarbonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Alkylthio", alone or in combination, means a radical of the type "R-S-" wherein "R" is an alkyl radical as defined above and "S" is a sulfur atom. Examples of such alkylthio radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert -butylthio and the like.
"Alkylsulfinyl " , alone or in combination, means a radical of the type "R-S(O)-" wherein "R" is an alkyl radical as defined above and "S (0) " is a mono -oxygenated sulfur atom. Examples of such alkylsulfinyl radicals include methylsulfinyl , ethylsulfinyl , n-propylsulfinyl , isopropylsulfinyl , n-butylsulfinyl , iso-butylsulfinyl , sec-butylsulfinyl , tert-butylsulfinyl and the like.
"Alkylsulfonyl " , alone or in combination, means a radical of the type "R-S(0)2-" wherein "R" is an alkyl radical as defined above and "S (0) 2" is a di -oxygenated sulfur atom. Examples of such alkylsulfonyl radicals include methylsulfonyl , ethylsulfonyl , n-propylsulfonyl , isopropylsulfonyl , n-butylsulfonyl , iso-butylsulfonyl , sec-butylsulfonyl, tert-butylsulfonyl and the like.
"Alkylsulfonylamino" , alone or in combination, means a radical of the type "R- S (0) 2-NH- " wherein "R-S(0)2-" is an alkylsulfonyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Aryl", alone or in combination, means a phenyl or naphthyl radical which is optionally substituted with one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, azido, nitro, cyano, haloalkyl, carboxy, alkoxycarbonyl, cycloalkyl, heterocyclo, alkanoylamino, amido, amidino, alkoxycarbonylamino, N- alkylamidino, alkylamino, dialkylamino, N-alkylamido, N,N- dialkylamido, aralkoxycarbonylamino, alkylthio, alkylsulfinyl , alkylsulfonyl and the like. Examples of aryl radicals are phenyl, p-tolyl, 4-methoxyphenyl, 4- (tert -butoxy) phenyl , 3 -methyl - 4 -methoxyphenyl , 4-CF3- phenyl, 4 - fluorophenyl , 4-chlorophenyl, 3 -nitrophenyl , 3 -aminophenyl , 3 -acetamidophenyl , 4 -acetamidophenyl , 2- ethyl - 3 -acetamidophenyl , 2 -methyl - 3 -aminophenyl , 3- methyl -4 -aminophenyl , 2 -amino- 3 -methylphenyl , 2,4- dimethyl - 3 -aminophenyl , 4 -hydroxyphenyl , 3 -methyl -4- hydroxyphenyl, 1- naphthyl, 2 -naphthyl, 3 -amino- 1- naphthyl , 2 -methyl - 3 -amino- 1 -naphthyl , 6 -amino- 2- naphthyl , 4 , 6 -dimethoxy- 2 -naphthyl , piperazinylphenyl and the like.
"Aralkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyl, 1-, 2 -phenylethyl , dibenzylmethyl , hydroxyphenylmethyl , methylphenylmethyl , diphenylmethyl , dichlorophenylmethyl , 4- methoxyphenylmethyl and the like.
"Aralkoxy", alone or in combination, means an alkoxy radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by an aryl radical as defined above, such as benzyloxy, 1-, 2 -phenylethoxy, dibenzylmethoxy, hydroxyphenylmethoxy, methylphenylmethoxy, dichlorophenylmethoxy, 4- methoxyphenylmethoxy and the like.
"Aralkoxycarbonyl " , alone or in combination, means a radical of the type "R-O-C(O)-" wherein "R-0-" is an aralkoxy radical as defined above and "-C(O) -" is a carbonyl radical .
"Aryloxy" , alone or in combination, means a radical of the type "R-0-" wherein "R" is an aryl radical as defined above.
"Alkanoyl", alone or in combination, means a radical of the type "R-C(O)-" wherein "R" is an alkyl radical as defined above and "-C(O)-" is a carbonyl radical. Examples of such alkanoyl radicals include acetyl, trifluoroacetyl , hydroxyacetyl , propionyl, butyryl, valeryl, 4 -methylvaleryl , and the like.
"Alkanoylamino", alone or in combination, means a radical of the type "R-C(0)-NH-" wherein "R-C(O)-" is an alkanoyl radical as defined above, wherein the amino radical may optionally be substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl and the like.
"Aminocarbonyl", alone or in combination, means an amino substituted carbonyl (carbamoyl) radical, wherein the amino radical may optionally be mono- or di - substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like. "Aminocarbonylamino", alone or in combination, means an amino substituted carbonyl substituted on a second amino (ureido) radical, wherein each amino radical may optionally be mono- or di- substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
"Aminoalkanoyl " , alone or in combination, means an alkanoyl radical as defined above derived in which at least one, preferably 1-2, hydrogen atom is replaced by an amino radical, wherein each amino radical may optionally be mono- or di - substituted, such as with alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, alkanoyl, alkoxycarbonyl, aralkoxycarbonyl and the like.
"Benzo", alone or in combination, means the divalent radical CgH4= derived from benzene.
"Bicyclic" as used herein is intended to include both fused ring systems, such as naphthyl and β - carbolinyl , and substituted ring systems, such as biphenyl, phenylpyridyl , naphthyl and diphenylpiperazinyl .
"Cycloalkyl", alone or in combination, means a saturated or partially saturated, preferably one double bond, monocyclic or bicyclic alkyl radical, preferably monocyclic, containing preferably 3-10 carbon atoms (C3- C10) more preferably 3-8 carbon atoms (C3-C8), even more preferably 3-6 carbon atoms (C3-Cg) which is optionally be benzo fused and which is optionally substituted as defined herein with respect to the definition of aryl. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, dihydroxycyclohexyl , cycloheptyl, octahydronaphthyl , tetrahydronaphthyl, dimethoxytetrahydronaphthyl , 2 , 3 -dihydro- IH- indenyl and the like.
"Cycloalkylalkyl", alone or in combination, means an alkyl radical as defined above which is substituted by a cycloalkyl radical as defined above. Examples of such cycloalkylalkyl radicals include cyclopropylmethyl , cyclobutylmethyl , cyclopentylmethyl , cyclohexylmethyl ,
1 -cyclopentylethyl , 1 -cyclohexylethyl , 2- cyclopentylethyl, 2 -cyclohexylethyl , hydroxycyclopentylpropyl , tetrahydronaphthylpropyl , cyclohexylbutyl and the like. "cycloalkylcarbonyl" means an acyl radical of the formula cycloalkyl -C (0) - in which the term "cycloalkyl" has the significance give above, such as cyclopropylcarbonyl , cyclohexylcarbonyl , adamantylcarbonyl , 1 , 2 , 3 , 4 - tetrahydro-2 -naphthoyl , 2- acetamido -1,2,3,4- tetrahydro - 2 - naphthoyl , 1 - hydroxy- 1, 2 , 3 , 4 - tetrahydro- 6 -naphthoyl and the like.
"Heteroatoms " means nitrogen, oxygen and sulfur heteroatoms .
"Heterocyclyl", alone or in combination, means a saturated or partially unsaturated, preferably one double bond, monocyclic or bicyclic, preferably monocyclic, heterocycle radical containing at least one, preferably 1 to 4 , more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 3-8 ring members in each ring, more preferably 5-8 ring members in each ring and even more preferably 5-6 ring members in each ring. "Heterocyclyl" is intended to include sulfone and sulfoxide derivatives of sulfur ring members and N- oxides of tertiary nitrogen ring members, and carbocyclic fused, preferably 3-6 carbon atoms and more preferably 5-6 carbon atoms, and benzo fused ring systems. "Heterocyclyl" radicals may optionally be substituted on at least one, preferably 1-4, more preferably 1-3, even more preferably 1-2, carbon atoms by halogen, alkyl, alkoxy, hydroxy, oxo, thioxo, aryl, aralkyl, heteroaryl, heteroaralkyl, amidiήo, N- alkylamidino, alkoxycarbonylamino, alkylsulfonylamino and the like, and/or on a secondary nitrogen atom by hydroxy, alkyl, aralkoxycarbonyl, alkanoyl, alkoxycarbonyl, heteroaralkyl, aryl or aralkyl radicals.
More preferably, "heterocyclyl", alone or in combination, is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo- fused and optionally substituted by 1-2 oxo or thioxo radicals. Examples of such heterocyclyl radicals include pyrrolidinyl , piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl , 4 -benzyl -piperazin- 1 -yl , pyrimidinyl, tetrahydrofuryl , pyrazolidonyl, pyrazolinyl, pyridazinonyl , pyrrolidonyl, tetrahydrothienyl and its sulfoxide and sulfone derivatives, 2 , 3 -dihydroindolyl , tetrahydroquinolinyl , 1,2,3,4- tetrahydroisoquinolinyl , 1,2,3,4- tetrahydro- 1 - oxo- isoquinolinyl , 2 , 3 -dihydrobenzofuryl , benzopyranyl , methylenedioxyphenyl , ethylenedioxyphenyl and the like.
"Heterocyclylalkyl " , alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heterocyclyl radical as defined above, such as pyrrolidinylmethyl , tetrahydrothienylmethyl , piperidinylethyl and the like.
"Heteroaryl", alone or in combination, means a monocyclic or bicyclic, preferably monocyclic, aromatic heterocycle radical, having at least one, preferably 1 to 4, more preferably 1 to 3 , even more preferably 1-2, nitrogen, oxygen or sulfur atom ring member and having preferably 5-6 ring members in each ring, which is optionally benzo fused or saturated carbocyclic fused, preferably 3-4 carbon atoms (C3-C4) and which is optionally substituted as defined above with respect to the definitions of aryl and heterocyclyl. More preferably, "heteroaryl", alone or in combination, is a radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo- fused or saturated C3 -C4 - carbocyclic - fused. Examples of such heteroaryl groups include imidazolyl,
1 -benzyloxycarbonylimidazol - 4 -yl , pyrrolyl , pyrazolyl , pyridyl, 2 - (1 -piperidinyl) pyridyl , 2-(4-benzyl piperazin- 1 -yl) - 1 -pyridinyl , pyrazinyl, triazolyl, furyl , thienyl, oxazolyl, thiazolyl, indolyl , quinolinyl, 1 -oxido- 2 -quinolinyl , isoquinolinyl, 5,6,7,8- tetrahydroquinolyl ,
5,6,7,8- tetrahydroisoquinolinyl , quinoxalinyl , benzothiazolyl , β-carbolinyl , benzofuryl , benzimidazolyl , benzoxazolyl and the like.
"Heteroaralkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-2, is replaced by a heteroaryl radical as defined above, such as 3 - furylpropyl , 2- pyrrolyl propyl, chloroquinolinylmethyl , 2 - thienylethyl , pyridylmethyl , 1 - imidazolylethyl and the like.
"Halogen" and "halo", alone or in combination, means fluoro, chloro, bromo or iodo radicals.
"Haloalkyl", alone or in combination, means an alkyl radical as defined above in which at least one hydrogen atom, preferably 1-3, is replaced by a halogen radical, more preferably fluoro or chloro radicals. Examples of such haloalkyl radicals include 1 , 1 , 1 - trifluoroethyl , chloromethyl , 1-bromoethyl , fluoromethyl , difluoromethyl , trifluoromethyl, bis (trifluoromethyl) methyl and the like.
"Leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.
"Protecting group" generally refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl , 9 - (9 -phenylfluorenyl) , phenanthrenyl , durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl , t- butoxycarbonyl , iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri - fluoroacetyl , tri -chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example,
1, 2 -bis (methylene) benzene, phthalimidyl , succinimidyl , maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di - or tri - substituted, such as nitrophthalimidyl . Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, aralkyl groups. Alkyl groups are also sutiable groups for protecting hydroxy and mercapto groups, such as tert-butyl.
Silyl protecting groups are silicon atoms optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl , triethylsilyl , tri - isopropylsilyl , tert- butyldimethylsilyl , dimethylphenylsilyl , 1,2- bis (dimethylsilyl) benzene, 1 , 2 -bis (dimethylsilyl) ethane and diphenylmethylsilyl . Silylation of an amino groups provide mono- or di - silylamino groups. Silylation of aminoalcohol compounds can lead to a N, , 0- tri - silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium flouride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-buty-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.
Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4- methoxyphenylmethyl and the like, can be removed under hydroylsis and hydrogenolysis conditions well known to those skilled in the art.
Procedures for preparing the compounds of this invention are set forth below. It should be noted that the general procedures are shown as it relates to preparation of compounds having unspecified stereochemistry. However, such procedures are generally applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R) . In addition, the compounds having one stereochemistry (e.g., (R) ) can often be utilized to produce those having opposite stereochemistry (i.e., (S) ) using well-known methods, for example, by inversion. Preparation of Compounds of Formula I
The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedures as schematically shown in Schemes I and II.
SCHEME I
Figure imgf000057_0001
SCHEME II
Figure imgf000057_0002
H
Via W = H
VIb W = ( t - But) (Me) 2Si
Several types of indole and azaindole synthesis can be used to prepare the compounds of this invention which are included by reference (for reviews of indole synthesis see G. Gribble Recent Developments in Indole Ring Synthesis -Methodology and Applications in Contemporary Organic Synthesis p- 145 -172; R. Sundberg and P. V. Nguyen Five Membered Ring Systems: Pyrroles and Benzo Derivatives, Chapter 5, Comprehensive Heterocyclic Chemistry) and the schemes shown below. A general synthesis of indoles and azaindoles useful for the preparation of the novel compounds of this invention is illustrated in Scheme I whereby an appropriately substituted acetylene (II) is coupled with an ortho iodoaniline (I) or a 1 , 2 - iodoaminoheterocycle (for example, 2 -amino- 3 - iodopyridine) using a palladium (0) mediated coupling under the conditions of Larock and coworkers (tetrabutylammonium chloride 1 eq. , potassium acetate 5 eq. , and triphenylphosphine (5 mol%) , Tet. Lett. 1993, 2823-2826) to afford a mixture of regioisomeric indoles or azaindoles (III and IV) that can be separated by chromatography. Preferably, when utilizing the general synthesis of Scheme I in the preparation of the novel compounds of this invention, Ri , R2 , R3 and R4 will not contain halogen substituted aryl or heteroaryl and other radicals well known to those skilled in the art which have the potential of interfering with, competing with or inhibiting the ring formation reaction.
A second general synthesis of indoles and azaindoles useful for the preparation of the novel compounds of this invention is illustrated in Scheme II whereby an appropriately substituted alpha -hydroxyketone (VI) or alpha- silyloxyketone (Via) is coupled with an appropriately substituted aniline or amino substituted heterocycle (V) (for example, 2 -aminopyridine, 3- aminopyridine, 4 -aminopyridine, 3 -amino- 6 -chloro pyridazine, 3 -phenyl - 6 -aminopyridazine, 4 -amino pyridazine, 3 -methoxy- 4 -amino- 6 - chloropyridazine, 4- amino-2 , 6 -dichloropyridine, 4 -amino- 2 - chloropyridine, 4- amino- 5 -cyano -2 -methoxy-pyridine, 4 -amino- 2 -methyl pyridine, 4 -amino- 5 -cyano- 2 -methoxypyridine, 2 -amino- 4- methylpyridine, 2 -amino-4 , 6 -dimethylpyridine, 2 -amino- 5- bromopyridine, 6 - aminonicotinamide, 3 -amino- 2 - chloro pyridine, 5 - amino- 2 - chloropyridine, 5 -amino- 2 -methoxy pyridine, 3 -amino- 2 , 6 - dimethoxypyridine, 2,6-diamino pyridine, 2 -aminopyrazine and 2,4-diamino pyrimidine, which are commercially available) under acid catalysis (in concentrated sulfuric acid at 190°C see: Herbert et al J. Chem. Soc. C 1969, p. 1505 or preferably under catalysis by p- toluenesulfonic acid in xylene with heat, see J. Szmuskovicz US Pat. 3,565,912) to afford the regioisomeric indoles (III and IV) that can be separated by chromatography. Preferably, when utilizing the general synthesis of Scheme II in the preparation of the novel compounds of this invention, Ri , R2 , R3 and R will not contain an amino substituted aryl or heteroaryl and other radicals well known to those skilled in the art which have the potential of interfering with, competing with or inhibiting the ring formation reaction. The yields for the general reaction of Scheme II are more favorable when the substituted aniline or amino substituted heterocycle (V) is electron rich. Preferably, when Ri , R2 , R or R4 represent an electron withdrawing group directly attached to the aromatic ring, the electron withdrawing substituent should be introduced after the ring formation of Scheme II. In a third general synthesis of indoles and azaindoles useful for the preparation of the novel compounds of this invention is illustrated in Scheme III whereby the appropriate grignard reagent is added to the cyano functional goup of a 2 -amino- 1 -cyanoaryl or heteroaryl (for example, 3 -amino-4 -cyanopyridine, 2- amino- 5 -nitrobenzonitrile, 2 -amino- 6 - fluorobenzonitrile
SCHEME Ila
Figure imgf000059_0001
SCHEME lib
Figure imgf000060_0001
SCHEME III
Figure imgf000060_0002
VII VIII
Figure imgf000060_0003
XI X and 2 -amino- 5 - chlorobenzonitrile, which are commercially available) system (VII) to afford the corresponding imine which upon hydrolysis affords the ketone (VIII) . Alternatively, an ortho nitrobenzonitrile (for example, 2 -methyl - 6 -nitrobenzonitrile, 5 -chloro -2 - nitrobenzonitrile, 4 -cyano- 3 -nitrobenzotrif louride, 4,5- dimethoxy-2 -nitrobenzonitrile, 4 -chloro -2 - nitrobenzonitrile, 6 -nitro-o-anisonitrile and 6-bromo-2- cyano-4 -nitroaniline, which are commercially available) can be converted into a 2 -aminobenzonitrile as described by Jacini et al (Gazz. Chim. Ital. 1947, vol 77, 308) . Acylation of the amino aryl or aminoheterocycle with the appropriate acid chloride (IX) (for example, benzoyl chloride, 3 , 5 -bis (trifluoromethyl) benzoyl chloride, 2- bromobenzoyl chloride, 2 - fluorobenzoyl chloride, pentafluorobenzoyl chloride, 2 , 4 -difluorobenzoyl chloride, 2 , 6 -difluorobenzoyl chloride, 2,6- dichlorobenzoyl chloride, o- oluoyl chloride, m-anisoyl chloride, 3 , 4 , 5 - trimethoxybenzoyl chloride, 4- biphenylcarbonyl chloride, 4 - tert-butylbenzoyl chloride, 4 -n-butylbenzoyl chloride, 4 - cyanobenzoyl chloride, 2- naphthoyl chloride, 2 , 5 -difluorobenzoyl chloride, 5- (dimethylsulfamoyl) -2 -methoxybenzoyl chloride, 2,3- dichlorobenzoyl chloride, 1- naphthoyl chloride, 2- ethoxy- 1 -naphthoyl chloride and 2 -naphthoyl chloride, which are commercially available) as shown in Scheme III affords the fused bicycle (III) after treatment with titanium (0) as described in the literature (Furstner et al Tet. Lett. 1991, 6695-6696) . Such substituted benzoyl chlorides can be prepared from the corresponding commercially available benzoic acids by treatment with oxalyl chloride or thionyl chloride (Tet. Lett. 1993, 3543-3546; and Julia et al J. Chem. Soc. Perkin Trans I 1991, Vol 5, 1101-1105, respectively) .
SCHEME IV
Figure imgf000061_0001
A general preparation of acetylenes for use in coupling in Scheme I is illustrated in Scheme IV. The appropriate aryl or heteroaryl aldehyde (XI) is reacted with diphenyl phosphite (XII) to afford the carbinol derivative (XIII) which is subsequently converted to the chloro derivative (XIV) by treatment with phosphorous oxychloride. Treatment of the chloromethanephosphonate with two equivalents of potassium t-butoxide followed by addition of the appropriate aldehyde (XV) affords the desired acetylene derivative (II) for use in Scheme I. For purposes of illustration, examples of commercially available aryl aldehydes (XI) include 3- phenoxybenzaldehyde, 6 -bromoveratraldehyde, 2 -bromo benzaldehyde, 2 - fluorobenzaldehyde, 4 -fluoro benzaldehyde, 2 -chlorobenzaldehyde, 2,4-dichloro benzaldehyde, 2 -chloro- 6 - fluorobenzaldehyde, o- anisaldehyde, 2 , 3 -dimethoxybenzaldehyde, 3 - cyano benzaldehyde, 3 - fluoro-p-anisaldehyde, 3- (3,4- dichlorophenoxy) benzaldehyde, 3- (3- (trifluoromethyl) phenoxy) benzaldehyde, 3- (4 -methoxyphenoxy) benzaldehyde, 3 -methyl -p-anisaldehyde, 4,4'- ethylbiphenyl - 4 - carboxaldehyde, 2 - chloro- 4 - dimethylaminobenzaldehyde, 2,4,5- triethoxybenzaldehyde, 1 -naphthaldehyde, 2 -methoxy- 1- naphthaldehyde, 4 -methoxy- 1 naphthaldehyde, 4- dimethylamino- 1 -naphthaldehyde, 4 -methyl - 1 - naphthaldehyde, 2 -benzyloxy- 1 -naphthaldehyde, 2- (2,4- dichlorobenzyloxy) - 1 -naphthaldehyde, 2- naphthaldehyde, 1 -bromo -2 -naphthaldehyde, 6-methoxy-2- naphthaldehyde and 7 -methyl -2 -naphthaldehyde.
For purposes of illustration, examples of commercially available heteroaryl aldehydes (XI) include 2 , 6 -diphenyl -4 -pyridinecarboxaldehyde, quinoline- 3 -carboxaldehyde, 2 -chloro- 3 - quinolinecarboxaldehyde, 2 -chloro- 6 -methoxy- 3 - quinolinecarboxaldehyde, 2 - imidazolecarboxaldehyde, N- 1 -benzyl -2 - imidazole carboxaldehyde, 2-methyl-3- imidazolecarboxaldehyde, 3- imidazolecarboxaldehyde,
2 -ethyl -4 -methyl -3 - imidazolecarboxaldehyde, 4 -methyl - 5 -imidazole carboxaldehyde and 2 -phenyl -4- imidazolecarboxaldehyde .
Further, commercially available heteroaryl carboxylic acids or derivatives thereof can be converted to heteroaryl aldehydes by standard synthetic transformations well known to those skilled in the art. For example, heteroarylester can be reduced to the aldehyde by treatment with diisobutylaluminum hydride. For purposes of illustration, commercially available heteroaryl - carboxylic acids or derivatives thereof that can be converted into heteroaryl aldehydes (XI) include methyl 2 - chloro- 6 -methyl - 4 -pyrimidinecarboxylate; 4- carboxypyrimidine; methyl 2 , 6 -dimethylamino- 4 - pyrimidine carboxylate; and methyl 4 , 6 -diphenyl - 2 - pyrimidine carboxylate. Alternatively, heteroaryl - halides can be converted into heteroaryl aldehydes (XI) by lithium-halogen exchange and quenching of the anion with dimethylformamide . For purposes of illustration, commercially available heteroarylhalides that can be converted into heteroaryl aldehydes (XI) include 6 -chloro -2 , 4 -dimethoxypyrimidine; 4 -chloro- 2- methylthio pyrimidine; 2 -amino- 4 -chloro- 6 - methylpyrimidine; 4 - chloro- 2 -phenylquinazoline; 4- chloro- 2 -methylquinoline; 4 -chloro- 2 -methylquinoline;
4 -chloro- 7 - (trifluoromethyl) quinoline; 4-chloro-6- methoxyquinoline; 4 -chloro- 2 -picoline; 2 , 5 -dimethyl -4 - bromopyridine; 2 - ethoxy- 4 -bromopyridine; 3 -amino- 4- chloroquinoline; and 3 -amino-4 -chloropyridine (note: the amino group of the substituted heteroaryl halide derivatives would first be suitably protected) .
The alphahydroxyketone (Via) or alphasilyloxyketone
(Vlb) of Scheme II can be prepared, for example when Rχι is 4-pyridyl or 4 -quinolinyl , by generating the anion of the protected silyl ether (XVI) and reacting it with the
N-methyl -N-methoxyamide (XVII) as shown in Scheme Va
(Gallagher et al Biorg. Med. Chem. Lett. 1995, 1171- 1176) . The N-methyl -N-methoxyamide (XVII) can be obtained through reaction of Rι2-C(0)Cl (for example, 3 , 5 -bis (trifluoromethyl) benzoyl chloride; 2 -bromobenzoyl chloride; 2 - fluorobenzoyl chloride; pentafluorobenzoyl chloride; 2 , 4 -difluorobenzoyl chloride; 2,6-difluoro benzoyl chloride; 2 , 6 -dichlorobenzoyl chloride; o- toluoyl chloride; m-anisoyl chloride; 3 , 4 , 5 - trimethoxy benzoyl chloride; 4 -biphenylcarbonyl chloride; 4 -tertbutyl benzoyl chloride; 4 -n-butylbenzoyl chloride; 4- cyano benzoyl chloride; 2 -naphthoyl chloride; 2,5- difluoro benzoyl chloride; 5 - (dimethylsulfamoyl) -2 - methoxybenzoyl chloride; 2 , 3 -dichlorobenzoyl chloride; 1 -naphthoyl chloride; 2 - ethoxy- 1 -naphthoyl chloride; and 2 -naphthoyl chloride, which are commercially available) with N, O-dimethylhydroxylamine in the presence of triethylamine. Such acid chlorides can be prepared from the corresponding Ri2"C(0)OH by treatment with oxalyl chloride or thionyl chloride (Tet. Lett. 1993, 3543-3546 and Julia et al J. Chem. Soc. Perkin Trans. I 1991, Vol 5, 1101-1105, respectively).
SCHEME Va
Figure imgf000064_0001
SCHEME Vb
Figure imgf000064_0002
Alternatively, the dimethylketal XX, prepared according to Scheme Vb, can be used in the process of Scheme II in place of the alphahydroxyketone (Via) and alphasilyloxyketone (Vlb) . The dimethylketal XX can be prepared by reacting the anion of the dimethoxyacetal XIX with the aldehyde XV. The dimethoxyacetal XIX can be readily prepared from the corresponding aldehyde XI (for example, 2 , 6 -diphenyl -4 -pyridinecarboxaldehyde; quinoline- 3 -carboxaldehyde; 2 -chloro- 3 -quinoline carboxaldehyde; 2 - chloro- 6 -methoxy- 3 - quinoline carboxaldehyde; 2 - imidazolecarboxaldehyde; N- 1 -benzyl - 2 - imidazolecarboxaldehyde; 2 -methyl - 3 - imidazole carboxaldehyde; 3- imidazolecarboxaldehyde; 2 -ethyl -4- methyl - 3 - imidazolecarboxaldehyde; 4 -methyl - 5 - imidazole carboxaldehyde; and 2 -phenyl - 4 - imidazolecarboxaldehyde, which are commercially available) using methods well know to those skilled in the art.
Alternatively, indoles or azaindoles (III) can be prepared (Scheme VI) by reacting 2 - substituted indoles or azaindoles (XIX) (for example, 2 - (4 - fluorophenyl) indole; 2 - (2 -naphthyl) indole; and 2 - (4 -chlorophenyl ) indole, which are commercially available) with Rn-L, where L is a leaving group such as chloro, bromo, iodo, and the like radicals (for example, 4- chloropyridine, 4 -chloroquinoline or 4- chloropyrimidine, which are commercially available) . The 2 - substituted indole or azaindole (XIX) can be treated with methyl magnesium bromide in ether followed by the addition of Rlχ-L and heated in a metal bomb at 160°C for 20 hours to afford the indole or azaindole (III) (US Pat. 3,551,567). SCHEME VI
Figure imgf000065_0001
XIX III The following is included to further illustrate synthetic procedures useful in the preparation of the novel compounds of this invention. A specific example of a palladium mediated coupling as described in Scheme I is illustrated in Scheme VII wherein 1 - (4 -pyridyl) - 2 - (4 -fluorophenyl) ethyne (1) and 2 - iodoaniline (2) affords the regioisomeric 2 , 3 -disubstituted indoles (3) and (4) as a 1:4 mixture, respectively. Compound (4) can be separated from compound (3) via flash chromatography.
SCHEME VII
Figure imgf000066_0001
Alternatively, substituted acetylenes and iodoanilines can be coupled via a palladium mediated process as described in Scheme I. Substituted 2- iodoanilines can either be purchased or prepared by standard methods well known to those skilled in the art. For instance, monoiodination of a substituted aniline derivative would afford the 2 - iodoaniline derivative using a variety of iodination reagents, such as N-iodo succinimide. Substituted acetylenes can be obtained as described in Scheme IV as illustrated in Scheme VIII for 1- (4 -pyridyl) -2 - (4 - fluorophenyl) ethyne (1). The adduct (6) of diphenylphosphite and 4 -pyridinecarboxaldehyde (5) is treated with phosphorous oxychloride to afford the chloro derivative (7). Condensation and elimination to the alkyne (1) is effected by treating the chloro derivative (7) and 4 - fluorobenzaldehyde (8) with 2.1 equivalents of potassium t-butoxide.
SCHEME VIII
(5) (6)
Figure imgf000067_0002
Scheme IX illustrates the preparation of substituted indoles according to the method of Scheme III, a titanium oxide mediated coupling. The grignard of 4 -bromopyridine (10) is prepared by low temperature treatment (-78°C) with n-butyl lithium followed by treatment with magnesium bromide etherate. A cooled solution of the grignard of (10) is added to anthranilonitrile (9) at low temperature {-50°C) followed by warming to room temperature. The resultant imine (11) is hydrolyzed by treatment with sulfuric acid to the anilinoketone (12) . Acylation of the anilinoketone (12) with 4 - fluorobenzoyl chloride (13) affords the ketoamide (14) . The regiospecific synthesis of indole (3) is completed by treatment of the ketoamide (14) with titanium oxide. SCHEME IX
Figure imgf000068_0001
11
Figure imgf000068_0002
Scheme X illustrates the preparation of indoles and azaindoles according to the method of Scheme II, acid mediated condensation of an aminoaryl or aminoheteroaryl and a substituted benzoin. Condensation of 2,6- diaminopyridine (15) with 1- (4 -fluorophenyl) -2 - 1- butyldimethylsiloxy-2- (4-pyridyl) ethanone (16) is effected by treatment with an excess of p- toluenesulfonic acid in xylene at high temperatures to afford the azaindoles (17) and (18) which can be separated by flash chromatography.
Further fuctionalization of the 2 , 3 -disubstituted indoles or azaindoles can be readily accomplished by reaction at an appropriately positioned group, such as an amino, carboxy, halo, substituted alkyl and the like group, on the 2 , 3 -disubstituted indoles or azaindoles. Scheme XI illustrates functionalizing a 6 -amino derivative (17) of a 2 , 3 -disubstituted azaindole. Reaction of the 6 -amino group of (17) with the mixed anhydride of N-4 - t-butoxycarbonylaminobutyric acid (20) affords the N-4 - t-butoxycarbonylaminobutanoyl compound (21) , which can be readily converted into the aminobutanoyl compound (22) by exposure to 90% trifluoroacetic acid and water for 1 hour. Similarly, the aminoalkylsulfonyl compound (26) can be prepared according to the method shown in Scheme XII .
SCHEME X
Figure imgf000069_0001
SCHEME XI
BOCNH
Figure imgf000069_0002
Further functionalization of 2 , 3 -disubstituted indoles or azaindoles can be readily accomplished by site specific electrophilic substitution, and subsequent elaboration at the point of attachment of a newly introduced electrophile . For example, in Scheme XIII, N-bromosuccinimide (NBS) is reacted with compound (17) to introduce a bromo radical at the 5 -position of (17) affording the bromo derivative (27) . The bromo compound (27) can also be used to introduce other substituents at the 5 -position using methods and reagents well known to those skilled in the art. Similarly, a fluoro radical can be introduced at the 5 -position of (17) through the use of N- fluorobenzenesulfonimide to afford the fluoro derivative (28) . Alternatively, a bromo compound like (27), or an appropriately 6-amino and indole NH protected derivative thereof, can be converted into the fluoro derivative by lithium halogen exchange followed by quenching of the lithio anion with N- fluorobenzene sulfonimide (Synlett. 187 (1991) and Tetrahedron Lett. 1631 (1992)). These reactions exemplify in a specific fashion the further substitution of an azaindole system after the indole has been formed by electrophilic substitution. In a more general sense, they demonstrate how other electrophilic agents (for example, iodine, Vilsmeier reagent, nitric acid and the like) can be used to substitute azaindoles and indoles in a specific fashion. SCHEME XII
Figure imgf000070_0001
SCHEME XIII
Figure imgf000071_0001
SCHEME XIV
Figure imgf000071_0002
SCHEME XV
Figure imgf000071_0003
Further, functionalization of 2 , 3 -disubstituted indoles or azaindoles can be readily accomplished at the indole nitrogen by utilizing the conditions of Mitsunobu wherein an appropriate alcohol is activated by treatment with triphenylphosphine and diethylazodicarboxylate (DEAD) and then reacted with the indole or azaindole compound. For example, in Scheme XV, the indole nitrogen of (29) is N-methylated under the Mitsunobu conditions and then reacted with NBS to afford the 5- bromo-N- 1 -methylderivative followed by deprotection affording (32) .
SCHEME XVI
BocNH
Figure imgf000072_0001
SCHEME XVII
Figure imgf000072_0002
SCHEME XVIII
Figure imgf000072_0003
Further, functionalization of 2 , 3 -disubstituted indoles or azaindoles can be readily accomplished by site specific electrophilic halogenation followed by palladium mediated coupling to introduce aryl substituent. Alternatively, an aryl halide can be converted into an aryl stannane by lithium halogen exchange followed by quenching with a trialkylstannyl chloride (for example, tributylstannyl chloride or trimethylstannyl chloride) . The aryl stannane can then be reacted in the presence of palladium (0) in a coupling process. Those skilled in the art are well versed in the diverse conditions and methods available for palladium (0) assisted couplings (Palladium Reagents and Catalysts - Innovations in Organic Synthesis by Jiro Tsuji, Wiley (1995); and Palladium Reagents in Organic Syntheses by Heck, Academic Press (1985) ) .
SCHEME XIX
Figure imgf000073_0001
SCHEME XX
BocNH
Figure imgf000073_0002
Schemes XVI -XXIII illustrate the use of palladium mediated couplings to prepare compounds of this invention. For example, bromo compound (31) can be coupled to aniline (other amines work as well, see Buchwald et al . , J. Am. Chem. Soc. 7901 (1994); Buchwald et al., Angew. Chem. Int. Ed. Engl . 1348 (1995); Hartwig et al., J. Am. Chem. Soc. 5969 (1994)) in. a palladium (0) mediated coupling to afford compound (33) as illustrated in Scheme XVI. Alternatively, compound (31) can be coupled with an aryl boronic acid to afford a phenyl substituted derivative (43) as illustrated in Scheme XVII SCHEME XXI
Figure imgf000074_0001
31 42
SCHEME XXII
Figure imgf000074_0002
SCHEME XXIII
Figure imgf000074_0003
(see Chem. Lett. 1405 (1989); Bull. Chem. Soc. Jpn 3008 (1988); Synthesis 184 (1989); Tetrahedron Lett 1523 (1990)) . Bromo compound (34) can be coupled to a heterocycle like imidazole as exemplified in Scheme XVIII which has been demonstrated in the literature for similar systems ((35) plus 2 -bromopyridine using tetrakistriphenylphosphine palladium (0), A. S. Bell et al., Tetrahedron Lett. 5013 (1988) and Synthesis 843 (1987)). Compound (37) (Scheme IXX) can be prepared from 4 -amino-2 -mercapto-6 -methylpyrimidine by conversion to the corresponding 2 - iodo derivative (iodine and hydrogen iodide in analogy to the conditions of bromine and HBr found in Zh. Org. Khim. (1991) 2235-2236) then converted into (37) in the manner illustrated in Scheme X. The Reformatsky reagent (38) can be coupled to the iodo derivative (37) using tetrakistriphenylphosphine SCHEME XXIV
Figure imgf000075_0001
palladium (0) as in a similar manner to the previously described coupling with 4 , 6 -dimethyl - 2 - iodopyrimidine (see: Yamanaka et al . , Chem. Pharm. Bull. 4309 (1985)). An unnatural amino acid can be prepared directly from compound (41) of Scheme XX by reduction (for example, hydrogen gas in the presence of Rh(DIPAMP)) . Compound (41) itself can be obtained through a palladium (0) mediated coupling of eneamide (40) directly with bromo derivative (41) utilizing the previously employed conditions for similar transformations (Pd2(dba)3, (o- tol)3P, Et3N, acetonitrile, see J Org. Chem. 2584 (1991); Synthesis 414 (1989); J. Org. Chem. 1289 (1991); Tetrahedron 7151 (1990)). The bromo derivative (31) can be converted to the carboxymethyl derivative (42) as illustrated in Scheme XXI utilizing the previously employed conditions for similar transformations (Pd2(dba)3, triphenylphosphine, methanol, carbon monoxide used with 2 , 6 -dichloropyrazine, see Synthesis 923 (1990)) . An acetylenic group can be direcly coupled to the azaindole or indole as illustrated in Scheme XXII utilizing the previously employed conditions for similar transformations (tetrakistriphenylphosphine palladium (0), Cul, Et3N - see: Synthesis 728 (1984)). Compound (44) can be obtained utilizing commercially available 3- methoxy-4 -amino-6-chloro-pyridazine in the manner of Scheme X. Vinyl functionalization of the appropriate 2 , 3 -disubstituted indoles or azaindoles can be readily
SCHEME XXV
Figure imgf000076_0001
58 accomplished as illustrated in Scheme XXIII. Conversion of the bromo derivative (47) of Scheme XXIII to the tributyl stannyl derivative as described above can be followed by a palladium (0) mediated coupling to a vinyl triflate utilizing the previously employed conditions for similar transformations (Pd2(dba)3, Ph3As, NMP, see Tetrahedron Lett. 4243 (1991)). Compound (47) can be obtained from 3 -amino-2 -bromoaniline in a similar manner to Scheme X.
SCHEME XXVI
Figure imgf000077_0001
62
Further functionalization of the appropriate 2,3- disubstituted indoles or azaindoles can be readily accomplished by introduction of a sulfide group as illustrated in Scheme XXIV or alternatively the thiol can be introduced prior to indole formation. Examples of thiol introduction include alkyl thiol (Rumler et al., Pharmazie (1990) 657-659) and thiol itself (Pascual et al., Bull. Soc. Chim. Belg. 101:297-302 (1992)). For example, the chlorogroup of compound (50) can be displaced by a thiol reagent. The sulfide (51) can be oxidized to the sulfoxide (52) by treatment with t- butylhydroperoxide in the presence of the pyridine (Kagan et al . , Tetrahedron asymmetry (1990) 597-610) or further oxidized to the sulfone (53) (Trost et al . , Tetrahedron Lett (1981) 1287) .
A sulfonamide radical can be introduced prior to the indole forming process (Schemes I or II) and then further fuctionalized as illustrated in Scheme XXV. Reaction of the sulfonamide (56) with excess chloroformates results in formation of compound (57) wherein CR3 = - S (0) 2 -NR22 -C (0) -OR20 (J. Med. Chem. (1990) 2393-2407) . Reaction of the sulfonamide (56) with acid chlorides after deprotonation of the sulfonamide with sodium hydride results in formation of compound (58) wherein CR3 = - S (0) -NR22 -C (0) -R2ι (Curran, J. Org. Chem. (1990) 4584-4595) . Reaction of the sulfonamide (56) with isocyanates results in the formation of compound (59) wherein CR3 = - S (0) 2 -NR22 -C (0) -NR5R2ι where R5 = hydrogen (Howbert et al . , J. Med. Chem. (1990) 2393- 2407) .
Introduction of the substituent CR3 = -NR22-S(0)2- NR5R2ι can be accomplished as illustrated in Scheme XXVI. First, the amino group of compound (60) can be alkylated in a reductive amination to afford compound
(61) . Then the alkylated amino substituent of compound
(61) can be reacted with o-phenylene sulfate to afford
(62) followed by further reaction with a second amine as illustrated in Scheme XXVI to afford compound (63) wherein CR3 = -NR22- S (0) 2 -NR5R2ι (Lee et al . , Bull. Korean Chem. Soc. (1992) , 357) .
Additional methods of indole and azaindole preparation are included by reference: G. Gribble Recent Developments in Indole Ring Synthesis -Methodology and Applications in Contemporary Organic Synthesis p-145- 172; R. Sundberg and P. V. Nguyen Five Membered Ring Systems: Pyrroles and Benzo Derivatives, Chapter 5, Comprehensive Heterocyclic Chemistry. It will be understood that these novel compounds are not limited to the disclosed methods of making them.
Sulfonyl halides can be prepared by the reaction of a suitable alkyl, aryl, heteroaryl, heterocyclyl and the like Grignard or lithium reagents with sulfuryl chloride, or sulfur dioxide followed by oxidation with a halogen, preferably chlorine. Alkyl, aryl, heteroaryl, heterocyclyl and the like Grignard or lithium reagents can be prepared from their corresponding halide (such as chloro or bromo) compounds which are commercially available or readily prepared from commercially available starting materials using known methods in the art. Alternatively, mercaptans may be oxidized to sulfonyl chlorides using chlorine in the presence of water under carefully controlled conditions. Additionally, sulfonic acids may be converted into sulfonyl halides using reagents such as PCI5, S0C12, C1C(0)C(0)C1 and the like, and also to anhydrides using suitable dehydrating reagents. The sulfonic acids are either commercially available or may be prepared using procedures well known in the art from commercially available starting materials. In place of the sulfonyl halides, sulfinyl halides or sulfenyl halides can be utilized to prepare compounds wherein the sulfonyl moiety is replaced by an sulfinyl or thio moiety, respectively. Arylsulfonic acids, benzo fused heterocyclyl sulfonic acids or heteroaryl sulfonic acids can be prepared by sulfonation of the aromatic ring by well known methods in the art, such as by reaction with sulfuric acid, S0 , S03 complexes, such as DMF(S03), pyridine (SO3) , N, -dimethylacetamide (SO3) , and the like. Preferably, such sulfonyl halides are prepared from such aromatic compounds by reaction with DMF(S03) and S0C12 or C1C (0) C (0)C1. The reactions may be performed stepwise or in a single pot. Alkyl sulfonic acids, aryl sulfonic acids, heterocyclyl sulfonic acids, heteroaryl sulfonic acids, alkylmercaptans , arylmercaptans , heterocyclylmercaptans , heteroarylmercaptans, alkylhalides , arylhalides, heterocyclylhalides, heteroarylhalides, and the like are commercially available or can be readily prepared from starting materials commercially available using standard methods well known in the art.
Thioether derivatives can be converted into the corresponding sulfone or sulfoxide by oxidizing the thioether derivative with a suitable oxidation agent in a suitable solvent. Suitable oxidation agents include, for example, hydrogen peroxide, sodium meta- perborate, oxone (potassium peroxy monosulfate) , meta- chloroperoxybenzoic acid, periodic acid and the like, including mixtures thereof. Suitable solvents include acetic acid (for sodium meta-perborate) and, for other peracids, ethers such as THF and dioxane, and acetonitrile, DMF and the like, including mixtures thereof.
The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily prepared from known starting materials.
Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in vivo physicological action, such as hydrolysis, metabolism and the like, into a compound of this invention following adminstration of the prodrug to a patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl, ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p- methoxybenzyl) , and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl) . Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of
Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. All reagents were used as received without purification. All proton and carbon NMR spectra were obtained on either a Varian VXR-300 or VXR-400 nuclear magnetic resonance spectrometer.
The following Examples illustrate the preparation of compounds of the present invention and intermediates useful in preparing the compounds of the present invention.
Example 1
Figure imgf000082_0001
Section A
1- (4 -pyridyl) -2- (4 - fluorophenyl) ethyne (1)
4 -pyridinecarboxaldehyde (5) (25.0 g, 0.232 mol) was added dropwise over 1 h to a cooled solution (0°C) of diphenylphosphite (54.0 g, 0.23 mol) and THF (100 mL) . After complete addition, the reaction was allowed to warm to 23°C. After 16 h, the reaction was concentrated in vacuo and purified by direct application to flash chromatography (100% ethyl acetate) which afforded 4- pyridyl -hydroxymethyldiphenylphosphonate (6): Mass Spectrum (CI) 342 (MH+) .
4 -pyridyl -hydroxymethyldiphenylphosphonate (6) (15.3 g, 46 mmol), diethylaniline (4 mL) , and phosphorous oxychloride (50 mL) were warmed to 90°C for 16h. The reaction was quenched by pouring the reaction mixture over ice (400 g) . Potassium carbonate was added until a pH of 8 was obtained for the solution followed by extraction with methylene chloride (3 x 200 mL) . After drying ( MgS04), the reaction was concentrated to afford crude 4 -pyridyl -chloromethyldiphenylphosphonate (7) as a solid which was used in the next step without further purification: Mass Spectrum (CI) 360 (MH+) . Potassium t-butoxide (3.30 g, 29.2 mmol) was added as a solid to 4 -pyridyl - chloromethyldiphenylphosphonate (7) (5.00 g, 13.9 mmol), 4 - fluorobenzaldehyde (8) (2.00 g, 15.3 mmol), and THF (70 mL) at 23°C under argon. After 16 h, the reaction was quenched by adding to water (200 mL) over 3 min. After adjusting the pH of the solution to 7 with 1 N HCl, the mixture was extracted with ethyl acetate (3 x 350 mL) , and dried (MgS04) . After concentration in vacuo, the residue was purified by flash chromatography (ethyl acetate :methylene chloride 1:1) to afford 1 - (4 -pyridyl) - 2 - (4 - fluorophenyl) ethyne (1) as a solid: Mass Spectrum (CI) 198 (MH+) .
3- (4-pyridyl) -2- (4 - fluorophenyl ) indole (3)
2 -Iodoaniline (2) (525 mg, 2.40 mmol) was added to palladium acetate (26.9 mg, 0.120 mmol), triphenyl phosphine (31.5 mg, 0 .120 mmol), potassium acetate (1.18 g, 12.0 mmol), tetrabutylammonium chloride (547 mg, 2.40 mmol), 1 - (4 -pyridyl) - 2 - (4 - fluorophenyl) ethyne (1) (1.0 g, 4.8 mmol), and DMF (20 mL) . The reaction was warmed to 100°C for 17 h under argon. After cooling to 23°C, the reaction was poured into water (200 mL) , extracted with ethyl acetate (3 x 100 mL) , and dried (MgS04) . After concentration in vacuo, the residue was purified by flash chromatography on silica gel (methanol : ethyl acetate 1:19) to afford indoles (3) and (4) as a mixture of regioisomers (4:1) : Mass Spectrum (CI) 289 (MH+) .
Section B
4 - (2 -aminobenzoyl) pyridine (12)
4 -Bromopyridine (10) (49.38 g, 0.254 mol, free based from the hydrochloride by partitioning between ether and saturated bicarbonate) and diethyl ether (200 mL) was added over 1 h to a cooled solution (-78°C) of n-butyl lithium (0.381 mol of a 2.5 M solution in hexane) under argon. After 30 min at (-78°C) , magnesium bromide diethyl etherate (98.37 g, 0.381 mol) was added via a dry powder addition funnel. After 1 h at -78°C, the reaction mixture was transfered to a jacketed addition funnel at -50°C, the solution was added to a cooled solution (-50°C) of anthranilonitrile (15.0 g, 0.127 mol) and benzene (400 mL) over 10 minutes. The reaction was allowed to warm to 23°C. After 16 h, the reaction was poured into 18% sulfuric acid (100 mL) , and was digested for 1 h. The resultant mixture was extracted with ethyl acetate ( (400 mL) , washed with water (3 x 400 mL) , and dried (MgS04) . After concentration in vacuo, the residue was purified by flash chromatography in a step gradient fashion (one liter methylene chloride; one liter ethyl acetate :methylene chloride 1:9; one liter ethyl acetate :methylene chloride 2:8; one liter ethyl acetate :methylene chloride 3:7; one liter ethyl acetate :methylene chloride 4:6) which afforded 4- (2- aminobenzoyl) pyridine (12) as a solid : Mass Spectrum (CI) 199 (MH+) .
Alternatively, to a solution of l-iodo-2- nitrobenzene (3.76 g, 15.1 mmol) in dry THF (80 mL) at -78°C was added n-butyl lithium (7.54 mL, 18.9 mmol) over 5 min. After 40 min at -78°C, ethyl isonicotinate was added in one portion in dry THF (70 mL) . After 10 min, the reaction was allowed to warm to 0°C for 10 min then quenched with 20 mL of glacial acetic acid: 30 mL of water. After adjusting the pH to 8 with saturated bicarbonate solution, the mixture was extracted with ethyl acetate (1 x 500 mL) , washed with brine (2 x 500 mL) , dried (Na2S04) . After concentration in vacuo, the reaction mixture was treated with 120 mL of 5 N NaOH: methanol: water (1:1:1). After removal of methanol in vacuo, the reaction mixture was extracted with ethyl acetate (1 x 500 mL) , then dried (Na.SO.) . After concentration in vacuo, the residue was purified by applying flash chromatography (step gradient methylene chloride 100% ; the 20% ethyl acetate: methylene chloride: then 40% ethyl acetate : methylene chloride) to afford 4 - (2 -nitobenzoyl) pyridine. 4 - (2 -Nitrobenzoyl) pyridine (100 mg, 0.44 mmol), stannous chloride dihydrate (297 mg, 1.32 mmol), and 1.1 mL of concentrated hydrochloric acid were warmed to 100°C for 10 minutes. After cooling to 23°C, the reaction was poured into water (10 mL) and 5 N sodium hydroxide (14 mL) followed by extraction with ethyl acetate (2 x 50 mL) . The ethyl acetate layer was washed with brine (1 x 20 mL) , dried (Na2S04) , and conentarted in vacuo to afford 4 - (2 -aminobenzoyl) pyridine (12).
4- (2- (4 - fluoro-N-benzoylamino) benzoyl) pyridine (14) 4 -Fluorobenzoyl chloride (78.0 mg, 0.55 mmol) was added to 4 - (2 -aminobenzoyl) yridine (12) (100 mg, 0.50 mmol), triethylamine (0.35 mL, 2.52 mL) , and chloroform (5.0 mL) at 23°C under argon. After 24 h at 23°C, the reaction was poured into water (50 mL) , extracted with ethyl acetate (3 x 50 mL) , and dried (MgS04) . After concentration in vacuo, the residue was purified by flash chromatography (ethyl acetate: methylene chloride 1:1) to afford 4 - (2 - (4 - fluoro-N-benzoylamino) benzoyl) pyridine (14) : Mass Spectrum (CI) 321 (MH+) .
3 - (4 -pyridyl) -2- (4 - fluorophenyl) indole (3) Graphite (272 mg, 3.63 mmol) and potassium (100 mg, 0.33 mmol) were warmed to 150°C under argon in a 250 mL round bottom flask with stirring for 25 min. THF (30 mL) was added via syringe to the hot bronze colored solid followed by a suspension of titanium (III) chloride (254 mg, 1.65 mmol) in THF (20 mL) . The resultant black solution was allowed to reflux for lh. 4 - (2 - (4 - fluoro- N-benzoylamino) benzoyl) pyridine (14) (100 mg, 0.33 mmol) and THF (20 mL) were then added to the hot (65°C) reaction mixture over 5 min. After 1 h at 65°C, the reaction was cooled to 23 °C the filtered through a silica gel pad (20 g) . After concentration in vacuo, the residue was purified by flash chromatography (ethyl acetate :methylene chloride 1:1) to afford 3 - (4 -pyridyl) 2- (4 -fluorophenyl) indole (3): Mass spectrum (CI) 289 (MH+) .
The following compounds were made using the above titanium (0) mediated ring closure with the appropriate acid chlorides to afford amide (X) which was closed to indole XI. It should be noted that in the case of 2- (3- bromothiophene) carbonyl chloride the amide X contains the bromo atom on the thiophene, but the ring closing (Ti) process removed the bromo from the thiophene resulting in the hydrido replacement.
Figure imgf000086_0001
3 - trifluoromethylphenyl 371 (MH+) 339 (MH+) - chlorophenyl 335 (M-H) 303 (M-H) 3 -methylphenyl 315 (M-H) 285 (MH+) 4 -pyridyl 304 (MH+) 272 (MH+)
1 - naphthyl 353 (MH+) 321 (MH+) -benzofuranyl 341 (M-H) 311 (MH+) -methylsulfinylphenyl 347 (M-H) - (3 -bromothiophene) 385 (M-H) -thiophene 275 (M-H) Exampl e 2
Figure imgf000087_0001
4
3- (4 -fluorophenyl) -2- (4 -pyridyl) indole (4) A portion of the 4:1 regioisomers from Section A of example 1, compounds (4): (3), was submitted to purification via flash chromatography (100% ethyl acetate) affording (4) in a pure state: Mass Spectrum (CI) 289 (MH+) .
Example 3
Figure imgf000087_0002
17
6-Amino-3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole (17)
1- (4 -Fluorophenyl) -2 - t-butyldimethylsiloxy- 2 - (4- pyridyl) ethanone (16) (3.45 g, 10.0 mmol), 2,6- diaminopyridine (1.09 g, 10.0 mmol), p- toluenesulfonic acid monohydrate (13.3 g, 70.0 mmol), and xylene (140 mL) were warmed to 60 °C under argon (note: all condensation reactions of this type were conducted behind an explosion shield) . After 1 h at 60 °C, the reaction was warmed to 135°C for 3 h. After allowing the reaction to cool to 23 °C, the top layer of xylene and p- toluenesulfonic acid was decanted from the bottom layer of gummy product residue. The lower product layer was partitioned between saturated bicarbonate (100 mL) , and ethyl acetate (250 mL) . The ethyl acetate layer was washed with brine (1 x 100 mL) , and dried (Na2S04) . After concentration in vacuo, the residue was purified by applying flash chromatography (2 liters of ethyl acetate: hexane 7:3 followed by 100% ethyl acetate) to afford the cleanly separated regioisomer (17): Mass Spectrum (CI) 305 (MH+) .
Example 4
Figure imgf000088_0001
6-Amino-3- (4 - fluorophenyl) -2- (4-pyridyl) - 7 -aza- indole
(18)
A lower RF product from Example 3 was repurified by flash chromatography (100% ethyl acetate) to afford (18) as a solid: Mass Spectrum (CI) 305 (MH+) .
Example 5
Figure imgf000088_0002
6 - (4 ' - 1 -butoxycarbonylamino- 1 ' -oxo-butylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (20)
General Procedure for mixed anhydride coupling - Isobutyl chloroformate (32 ml, 0.24 mmol) was added dropwise to a -20-30 oC solution of 4 - t-butoxycarbonyl aminobutyric acid (19) (50.1 mg, 0.247 mmol), 4- methylmorpholme (124 ml, 1.23 mmol), and THF (2 mL) . After 20 min at -20-30°C, 6 -Amino- 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7 -aza- indole (17) (75 mg, 0.24 mmol) and THF (3 mL) was added in one portion. The reaction was allowed to warm to 23°C. After 16 h at 23°C, the reaction was poured into saturated bicarbonate (80 mL) , extracted with ethyl acetate (2 x 100 mL) , washed with brine (1 x 100 mL) , and dried (Na2S04) . After concentration in vacuo, the residue was purified by application to two preparative chromatography plates (silica gel 2 mm thickness, 100% ethyl acetate) to afford 6 - (4 ' - t-butoxycarbonylamino- 1 ' -oxo-butylamino) - 3 - (4-pyridyl) -2- (4 - fluorophenyl) -7 -aza- indole (20) as a solid: Mass Spectrum (CI) 489 (MH+) . Ethyl chloroformate can be used in place of isobutyl chloroformate in this process.
Example 6
Figure imgf000089_0001
6 - (4 ' -amino- 1 ' -oxo-butylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole (21)
A solution of trifluoroacetic acid:water: anisole (900 ml:100 ml: 39 ml) was added to 6 - (4 '- t-butoxy carbonylamino -2 ' -oxo-amino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole (20) (38 mg, 0.078 mmol) at 23°C. After 1 h at 23 °C, the reaction was concentrated with a stream of nitrogen in a ventilated hood. The residue was triturated with 2 mL of ether, the resultant solid filtered and washed with ether (3 x 2 mL) . The TFA salt of (21) was dissolved in 2 mL of water containing 3 equivalents of 1 N HCl and subsequently freeze-dried to afford the HCl salt of 6 - (4 ' -amino-2 ' -oxo-amino) - 3 - (4 - pyridyl) -2- (4 -fluorophenyl) -7 -aza- indole (21). The HCl salt was used in biological testing or alternatively the free base can be used in biological testing which was obtained by partioning the hydrochloride salt between ethyl acetate and saturated bicarbonate. The ethyl acetate layer was dried (Na2S04), and concentrated in vacuo to afford 6 - (4 ' -amino- 1 ' -oxo-butylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole (21) as a solid: Mass Spectrum (CI) 389 (MH+) .
Example 7
Figure imgf000090_0001
6 - ( 5 ' - ureido - 1 ' - oxo - 2 ' - 1 - butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (26)
Compound (26) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-citrulline was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (5 ' -ureido- 1 ' -oxo-2 ' - t-butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (26) after preparative plate chromatography: Mass Spectrum (CI) 562 (MH+) .
Example 8
Figure imgf000090_0002
6- (5 ' -ureido- 1 ' -oxo-2 ' -aminopentylamino) -3 - (4 -pyridyl) ■ 2- (4 - fluorophenyl) - 7 -aza- indole (27) Compound (27) was prepared from compound (26) in the manner of example 6 which afforded 6 - (5 ' -ureido- 2 ' -oxo- 3 ' - aminopentylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl ) - 7 - aza-indole (27) : Mass Spectrum (CI) 462 (MH+) .
Example 9
Figure imgf000091_0001
6- (6 ' - t-Butoxycarbonylamino-1 ' -oxo-2 ' - t-butoxycarbonyl aminohexylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (28)
Compound (28) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc- e-Boc- lysine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (6 ' - t-Butoxycarbonylamino- 1 ' -oxo-2 ' - t- butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4- fluoro-phenyl) -7 -aza-indole (28) after preparative plate chromatography: Mass Spectrum (CI) 633 (MH+) .
Example 10
Figure imgf000091_0002
6- (6 ' - amino -1 ' -oxo-2 ' -aminohexylamino) -3 - (4 -pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (29)
Compound (29) was prepared from compound (28) in the manner of example 6 which afforded 6 - (6 ' -amino- 1 ' -oxo- 2 ' -aminohexylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (29): Mass Spectrum (CI) 433 (MH+) . Example 11
Figure imgf000092_0001
6- (5 ' - t-Butoxycarbonylamino- 1 ' -oxo-2 ' - -butoxycarbonyl aminopentylamino) -3- (4-Pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (30)
Compound (30) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-d-Boc- ornithine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (5 ' - 1 -Butoxycarbonylamino- 1 ' -oxo- 2 ' - t-butoxycarbonylaminopentylamino) -3 - (4-pyridyl) -2 - (4 ■ fluorophenyl) -7 -aza- indole (30) after preparative plate chromatography: Mass Spectrum (CI) 619 (MH+) .
Example 12
Figure imgf000092_0002
6 - (5 ' - amino-1 ' -oxo-2 ' -aminopentylamino) -3 - (4 -pyridyl) -2 (4 -fluorophenyl) - 7 -aza- indole (31)
Compound (31) was prepared from compound (30) in the manner of example 6 which afforded 6 - (5 ' -amino- 1 ' -oxo- 2 ' -aminopentylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl ) -7 aza-indole (31) : Mass Spectrum (CI) 419 (MH+) . Example 13
Figure imgf000093_0001
6- (3 ' - (4 - iodophenyl) - 1 ' -oxo-2 ' - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (32)
Compound (32) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-p- iodo- phenylalanine was used in place of N-t-Boc-g- aminobutyric acid which afforded 6 - (3 '- (4 - iodophenyl) - 1 ' -oxo- 2 ' - t-butoxycarbonylaminopropylamino) - 3 - (4 - pyridyl) -2- (4 -fluorophenyl) - 7 -aza- indole (32) after preparative plate chromatography: Mass Spectrum (CI) 678 (MH+) .
Figure imgf000093_0002
6- (3 ' - (4 - iodophenyl) - 1 ' -oxo-2 ' -aminopropylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (33) Compound (33) was prepared from compound (32) in the manner of example 6 which afforded 6 - (3 '- (4 - iodophenyl; 1 ' -oxo-2 ' -aminopropylamino) -3 - (4-pyridyl) -2 - (4 -fluoro phenyl) -7 -aza- indole (33): Mass Spectrum (CI) 578 (MH+) Example 15
Figure imgf000094_0001
6- (3 ' -Methyl - 1 ' -oxo-2 ' - t-butoxycarbonylaminobutylamino) - 3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (34) Compound (34) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-valine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (3 ' -Methyl - 1 ' -oxo- 2 ' - t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (34) after preparative plate chromatography: Mass Spectrum (CI) 504 (MH+) .
Example 16
Figure imgf000094_0002
6- (3 ' -Methyl -1 ' -oxo-2 ' -aminobutylamino) -3- (4 -pyridyl) -2 (4 - fluorophenyl) - 7 -aza- indole (35)
Compound (35) was prepared from compound (34) in the manner of example 6 which afforded 6 - (3 ' -Methyl - 1 ' -oxo- 2 ' -aminobutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (35): Mass Spectrum (CI) 404 (MH+) . Example 17
Figure imgf000095_0001
6- (4 ' , 4 ' -Dimethyl - 1 ' -oxo-2 ' - t-butoxycarbonylaminopentyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (36)
Compound (36) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-b- t - butylalanine was used in place of N- t-Boc- g-aminobutyric acid which afforded 6- (4 ' , 4 ' - Dimethyl -1 ' -oxo-2 ' - 1- butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (36) after preparative plate chromatography: Mass Spectrum (CI) 532 (MH+) .
Example 18
Figure imgf000095_0002
6- (4 ' , 4 ' -Dimethyl - 1 ' -oxo-2 ' -aminopentylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (37) Compound (37) was prepared from compound (36) in the manner of example 6 which afforded 6- (4 ' , 4 ' -Dimethyl - 1 oxo-2 ' -aminopentylamino) - 3 - (4-pyridyl) -2 - (4 - fluoro phenyl) -7 -aza- indole (37): Mass Spectrum {CD 432 (MH+) BocNH
Figure imgf000096_0001
6- (5 ' - t-butoxycarbonylamino- 1 ' -oxo-pentylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (38) Compound (38) was prepared in the manner of example 5 with the following substitution: N- t-Boc- 5 - aminovaleric acid was used in place of N- t-Boc -g-aminobutyric acid which afforded 6 - (5 ' - 1 -butoxycarbonylamino- 1 ' -oxo- pentylamino) -3- (4-pyridyl) -2- (4 - fluoro-phenyl ) -7-aza- indole (38) after preparative plate chromatography: Mass Spectrum (CI) 504 (MH+) .
Example 20
Figure imgf000096_0002
6- (5 ' -amino- 1 ' -oxo-pentylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (39)
Compound (39) was prepared from compound (38) in the manner of example 6 which afforded 6 - (5 ' -amino- 1 ' -oxo- pentylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (39): Mass Spectrum (CI) 404 (MH+) ,
Figure imgf000097_0001
6 - (6 ' - t-butoxycarbonylamino- 1 ' -oxo-hexylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole (40) Compound (40) was prepared in the manner of example 5 with the following substitution: N- t-Boc- 6 -aminocaproic acid was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (6 '- t-butoxycarbonylamino- 1 ' -oxo- hexylamino) -3- (4-pyridyl) -2- (4 - fluoro -phenyl) -7-aza- indole (40) after preparative plate chromatography: Mass Spectrum (CI) 518 (MH+) .
Example 22
Figure imgf000097_0002
6 - (6 ' -amino- 1 ' -oxo -hexylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7 -aza- indole (41)
Compound (41) was prepared from compound (40) in the manner of example 6 which afforded 6- (6 ' -amino- 1 ' -oxo- hexylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7-aza - indole (41) : Mass Spectrum (CI) 418 (MH+) . Example 23
Figure imgf000098_0001
6 - (3 ' -cyclohexyl - 1 ' -oxo- 2 ' - 1 -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (42)
Compound (42) was prepared in the manner of example 5 with the following substitution: N-a-t-Boc-b- cyclohexylalanine was used in place of N-t-Boc-g- aminobutyric acid which afforded 6 - (3 ' -cyclohexyl - 1 ' - oxo-2' - t-butoxycarbonylaminopropylamino) -3- (4-pyridyl) ■ 2 - (4 - fluorophenyl) - 7 -aza- indole (42) after preparative plate chromatography: Mass Spectrum (CI) 558 (MH+) .
Example 24
Figure imgf000098_0002
6 - (3 ' -cvclohexyl - 1 ' -oxo- 2 ' -aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7 -aza- indole (43)
Compound (43) was prepared from compound (42) in the manner of example 6 which afforded 6- (3 ' -cyclohexyl - 1 ' oxo-2 ' -aminopropylamino) -3 - (4 -pyridyl) -2- (4 - fluoro phenyl) -7 -aza- indole (43): Mass Spectrum (CI) 458 (MH+; Example 25
Figure imgf000099_0001
6 - (4 ' - 1 - butoxycarbonyl - 1 ' - oxo - 2 ' - 1 - butoxycarbonylaminobutylamino) -3- (4 -pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (44)
Compound (44) was prepared in the manner of example 5 with the following substitution: N-a- t -Boc-b- t- butylglutamic acid was used in place of N-t-Boc-g- aminobutyric acid which afforded 6 - (4 '- t-butoxycarbonyl - 1 ' -oxo- 2 ' - t-butoxycarbonylaminobutylamino) - 3 - (4 - pyridyl) -2 - (4 -fluorophenyl) -7 -aza- indole (44) after preparative plate chromatography: Mass Spectrum (CI) 590 (MH+) .
Example 26
Figure imgf000099_0002
6- (4 ' - carboxy-1 ' -oxo-2 ' -aminobutylamino) -3- (4 -pyridyl) - 2- (4-fluorophenyl) - 7 -aza- indole (45)
Compound (45) was prepared from compound (44) in the manner of example 6 which afforded 6- (4 ' -carboxy- 1 ' -oxo- 2 ' -aminobutylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7- aza- indole (45) : Mass Spectrum (CI) 434 (MH+) .
Figure imgf000100_0001
6- (3 ' -O-t-butoxv-l" -oxo-2 ' - t-butoxvcarbonvlaminobutvl amino) -3- (4-pvridvl) -2- (4- fluorophenyl ) - 7 - aza - indole
(46)
Compound (46) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-O- t - butylthreonine was used in place of N-t-Boc-g- aminobutyric acid which afforded 6 - (3 ' -0- t-butoxy- 1 ' - oxo-2 '- t-butoxycarbonylaminobutylamino) -3- (4-pyridyl) ■ (4 -fluorophenyl) -7 -aza- indole (46) after preparative plate chromatography: Mass Spectrum (CI) 562 (MH+) .
Example 28
Figure imgf000100_0002
6 - (3 ' -hvdroxy- 1 ' -oxo-2 ' -aminobutylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) - 7 -aza- indole (47)
Compound (47) was prepared from compound (46) in the manner of example 6 which afforded 6 - (3 ' -hydroxy- 1 ' -oxo- 2 ' -aminobutylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (47) : Mass Spectrum (CI) 406 (MH+) .
Figure imgf000101_0001
6 - ( 3 ' -phenyl - 1 ' - oxo - 2 ' - 1 -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (48)
Compound (48) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-D, L- phenylalanine was used in place of N-t-Boc-g- aminobutyric acid which afforded 6 - (3 ' -0- t-butoxy- 1 ' - oxo-2' - t-butoxycarbonylaminobutylamino) -3- (4-pyridyl) • (4 - fluorophenyl) -7 -aza- indole (46) after preparative plate chromatography: Mass Spectrum (CI) 552 (MH+) .
Example 30
Figure imgf000101_0002
6- (3 ' -phenyl - 1 ' -oxo-2 ' -D, L- aminopropylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (49) Compound (49) was prepared from compound (48) in the manner of example 6 which afforded 6 - (3 ' -phenyl- 1 ' -oxo- 2 ' -aminopropylamino) - 3 - (4 -pyridyl) -2 - (4 -fluorophenyl) -7 aza-indole (49) : Mass Spectrum (CI) 452 (MH+) .
Figure imgf000102_0001
6- (3 ' - (4 - 1 -Butoxyphenyl) - 1 ' -oxo-2 ' - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (50)
Compound (50) was prepared in the manner of example 5 with the following substitution: N-a- t-Boc-O- t- butyltyrosine was used in place of N-t-Boc-g- aminobutyric acid which afforded 6-(3'-(4-t- Butoxyphenyl) -1' -oxo-2' - t -butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (50) after preparative plate chromatography: Mass Spectrum (CI) 624 (MH+) .
Example 32
Figure imgf000102_0002
6- (3 ' - (4 -hydroxyphenyl) - 1 ' -oxo-2 ' -aminopropylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7 -aza- indole (51) Compound (51) was prepared from compound (50) in the manner of example 6 which afforded 6- (3 '- (4 -hydroxy phenyl) -1 ' -oxo-2 ' -aminopropylamino) -3 - (4-pyridyl) -2- (4 fluorophenyl) -7 -aza- indole (51): Mass Spectrum (CI) 46i (MH+) .
Figure imgf000103_0001
6- (3 ' - t-butoxycarbonylamino- 1 ' -oxo-propylamino) -3 - (4- pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (52) Compound (52) was prepared in the manner of example 5 with the following substitution: N-Boc-b-alanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (3 ' - t-butoxycarbonylamino- 1 ' -oxo- propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (52) after preparative plate chromatography: Mass Spectrum (CI) 476 (MH+) .
Example 34
Figure imgf000103_0002
6 - (3 ' -amino- 1 ' -oxo -propylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza-indole (53)
Compound (53) was prepared from compound (52) in the manner of example 6 which afforded 6- (3 ' -amino- 1 ' -oxo- propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7-aza- indole (53) : Mass Spectrum (CI) 376 (MH+) .
Example 35
Figure imgf000103_0003
6 - (2 ' - -butoxycarbonylamino- 1 ' -oxo- ethylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) - 7 -aza- indole (54) Compound (54) was prepared in the manner of example 5 with the following substitution: N-Boc-glycine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (2 ' - t-butoxycarbonylamino -1 ' -oxo-ethylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole (54) after preparative plate chromatography: Mass Spectrum (CI) 461 (MH+) .
Figure imgf000104_0001
6- (2 ' -amino- 1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole (55) An HCl dioxane solution (4N, anhydrous, 0.27 mL) was added to 6 - (2 '- t-butoxycarbonylamino- 1 ' -oxo- ethylamino) • 3- (4-pyridyl) -2- (4 - fluoro-phenyl) - 7 -aza- indole (54) (50.0 mg, 0.11 mmol), anisole (59 ml, 0.55 mmol), and dioxane (4 mL) in one portion. After 30 min at 23°C, the reaction was concentrated with a stream of nitrogen in a hood. The residue was diluted with saturated bicarbonate (30 mL) , extracted with ethyl acetate ( 3 x 50 mL) , and dried ( a2Sθ4) . After concentration in vacuo, the residue was purified by application of preparative plate chromatography (two 2 mm silica gel plates, ethyl acetate: methanol 19:1) to afford 6-(2'- amino-1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2- (4-fluoro phenyl) -7 -aza- indole (55): Mass Spectrum (CI) 362 (MH+) . Exampl e 3 7
Figure imgf000105_0001
6- (methylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (56) Methanesulfonyl chloride (5 ml, 0.07 mmol) was added dropwise to 6 -amino- 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7 - aza-indole (17) (20 mg, 0.066 mmol), dimethylamino pyridine (1 mg, 0.007 mmol), and chloroform (3 mL) .
After 24 h at 23 °C, an additional 4 equivalents of methanesulfonyl chloride was added. After 4 h at 23 °C, NaOH (ION, 3 mL) was added. After 3 h, the mixture was extracted with ethyl acetate (50 mL) , washed with water (3 x 15 mL) , and dried (Na2S04) . After concentration in vacuo, the residue was purified by application of preparative plate chromatography (two 2 mm silica gel plates, ethyl acetate) to afford 6 - (methylsulfonyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7 -aza- indole
(56) : Mass Spectrum (CI) 383 (MH"1") .
Example 38
Figure imgf000105_0002
6- (1 ' -oxo -ethylamino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) - 7-aza-indole (57)
6-Amino-3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (17) (50 mg, 0.164 mmol) and acetic anhydride (0.5 mL) were warmed to 60°C for 1 h. After cooling to 23°C, the reaction was diluted with ethyl acetate (50 mL) , washed with NaOH (1 N, 50 mL) , and dried (Na2Sθ4) . Concentration in vacuo afforded 6 - (1 ' -oxo-ethylamino) - 3 - (4-pyridyl) -2- (4-f luorophenyl) -7-aza-indole (57) : Mass
Spectrum (CI) 347 (MH+) .
Example 39
Figure imgf000106_0001
6 - (2 ' - (5 -chlorothienyl) sulfonylamino) - 3 - (4 -pyridyl) -2 - (4 -fluorophenyl) -7-aza-indole (58) Compound (58) was prepared in the manner of example 37 with the following substitution: 5 -chlorothienyl - 2 - sulfonyl chloride (4 equivalents) was used in place of methanesulfonyl chloride which afforded 6 - (2 ' - ( 5 - chlorothienyl) sulfonylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (58) after preparative plate chromatography: Mass Spectrum (CI) 485 (MH+) .
Example 40
Figure imgf000106_0002
6- (Phenylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza-indole (59)
Compound (59) was prepared in the manner of example 37 with the following substitution: phenylsulfonyl chloride (4 equivalents) was used in place of methanesulfonyl chloride which afforded 6 - (2 • - (5 - chlorothienyl) sulfonylamino) -3 - (4 -pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (58) after preparative plate chromatography: Mass Spectrum (CI) 445 (MH+) . Example 41
Figure imgf000107_0001
6- (2 ' -N-Phthaloyl-1 ' -oxo- ethylamino) -3- (4 -pyridyl) -2- (4- fluorophenyl) -7-aza- indole (60)
Compound (60) was prepared in the manner of example 5 with the following substitution: N-phthaloylglycine was used in place of N- t-Boc- g-aminobutyric acid which afforded 6- (2 ' -N- Phthaloyl - 1 ' -oxo-ethylamino) -3 - (4- pyridyl) -2- (4 -fluorophenyl) -7-aza-indole (60) after preparative plate chromatography: Mass Spectrum (CI) 492
(MH+) .
Example 42
Figure imgf000107_0002
6- (3 ' -N- Phthaloyl -1 ' -3 - (4 -pyridyl) -2 - (4 -fluorophenyl) -7-aza-indole (61)
Compound (60) was prepared in the manner of example 5 with the following substitution: N-phthaloyl -b-alanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (2 ' -N-Phthaloyl- 1 ' -oxo-ethylamino) -3- (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole (61) after preparative plate chromatography: Mass Spectrum (CI) 506
(MH+) . Exampl e 43
Figure imgf000108_0001
3- (4-pyridyl) -2- (4 - fluorophenyl ) -4 , 7 -diaza- indole (62) 1- (4 - Fluorophenyl) - 2 - t-butyldimethylsiloxy-2 - (4-pyridyl) ethanone (16) (5.44 g, 15.77 mmol), 2 -aminopyrazine
(1.00 g, 10.5 mmol), and concentrated HCl (30 mL) were heated in a sealed tube to 190 °C behind an explosion shield. After 3 h at 190°C, the reaction was allowed to cool to 23°C then diluted with water (100 mL) . After further dilution with concentrated ammonium hydroxide to pH of 12, the reaction was extracted with methylene chloride (3 x 200 mL) , and dried (MgS04) . After concentration in vacuo, the residue was purified by applying flash chromatography (100% ethyl acetate) to afford 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -4 , -diaza- indole (62) : Mass Spectrum (CI) 291 (MH+) .
Figure imgf000108_0002
6- (2 ' -N- t-Butoxycarbonyl-L-prolylamino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (63)
Compound (63) was prepared in the manner of example 5 with the following substitution: N- t-Boc-proline was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (2 ' -N- t-Butoxycarbonyl -L-prolylamino) - 3 - (4 - pyridyl) -2- (4 -fluorophenyl) -7-aza-indole (63) after preparative plate chromatography: Mass Spectrum (CI) 502 (MH+) .
Example 45
Figure imgf000109_0001
6- (2 ' -L-prolyl amino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (64)
Compound (64) was prepared from compound (63) in the manner of example 6 which afforded 6 - (2 ' -L-prolylamino) - 3 - (4 -pyridyl) -2- (4-fluorophenyl) -7-aza-indole (64): Mass
Spectrum (CI) 402 (MH+) .
Example 46
Figure imgf000109_0002
6 - (2S ' -Dimethylamino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) - 2- (4 - fluorophenyl) -7-aza-indole (65)
Compound (65) was prepared in the manner of example 5 with the following substitution: N,N-dimethylalanine was used in place of N- t-Boc-g-aminobutyric aeid which afforded 6- (2 ' -Dimethylamino- 1 ' -oxo-propylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (65) after preparative plate chromatography: Mass Spectrum (CI) 404
(MH+) . Exampl e 47
Figure imgf000110_0001
6 - (2 ' -Dimethylamino- 1 ' -oxo -ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole (66) Compound (66) was prepared in the manner of example 5 with the following substitution: N,N-dimethylglycine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (2 ' -Dimethylamino- 1 ' -oxo-ethylamino) -3 - (4- pyridyl) -2 - (4-fluorophenyl) -7 -aza- indole (66) after preparative plate chromatography: Mass Spectrum (CI) 389 (MH+) .
Figure imgf000110_0002
6- (2 ' -N-Methyl - 1 -butoxycarbonylamino- 1 ' -oxo -ethylamino) - 3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (67) Compound (67) was prepared in the manner of example 5 with the following substitution: N-Boc-N-methyl -glycine was used in place of N- t-Boc -g-aminobutyric acid which afforded 6 - (2 ' -N-Methyl - t-butoxycarbonylamino- 1 ' -oxo- ethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (67) after preparative plate chromatography: Mass Spectrum (CI) 476 (MH+) .
Figure imgf000111_0001
6- (2 ' -N-Methyl -amino- 1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2- (4-fluorophenyl) -7-aza-indole (68) Compound (68) was prepared from compound (67) in the manner of example 6 which afforded 6 - (2 ' -N-Methyl -amino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 - aza-indole (68) : Mass Spectrum (CI) 376 (MH+) .
Example 50
Figure imgf000111_0002
6- (4 ' -N- t-Butoxycarbonylisonipecotylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (69) Compound (69) was prepared in the manner of example 5 with the following substitution: N-Boc- isonipecotic acid was used in place of N- t-Boc -g-aminobutyric acid which afforded 6- (4 ' -N- t-Butoxycarbonylisonipecotylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (69) after preparative plate chromatography: Mass Spectrum (CI) 516 (MH+) .
Figure imgf000112_0001
6- (4 ' - isonipecotylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (70)
Compound (70) was prepared from compound (69) in the manner of example 6 which afforded 6-(4'- isonipecotylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7 aza-indole (70) : Mass Spectrum (CI) 416 (MH+) .
Example 52
Figure imgf000112_0002
6 - (4 ' -methylsulfoxo - 1 ' - oxo - 2 ' S - 1 - butoxycarbonylaminobutylamino) -3- (4 -pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (71)
Compound (69) was prepared in the manner of example 5 with the following substitution: N-Boc-L-methionine sulfoxide (diasteromeric mixture) was used in place of N- t-Boc -g-aminobutyric acid which afforded 6-(4'- methylsulfoxo-1 ' -oxo-2 ' S- t-butoxycarbonylaminobutyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (71) after preparative plate chromatography: Mass Spectrum (CI) 552 (MH+) .
Figure imgf000113_0001
6 - (4 ' -methylsulfoxo- 1 ' -oxo- 2 ' S- aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (72) Compound (72) was prepared from compound (71) in the manner of example 6 which afforded 6 - (4 ' -methylsulfoxo- 1 ' -oxo- 2 ' S- aminobutylamino) - 3 - (4 -pyridyl) -2 - (4 - fluoro phenyl) -7-aza-indole (72): Mass Spectrum (CI) 452 (MH+)
Figure imgf000113_0002
6 - (3 ' - (3 -pyridyl) - 1 ' -oxo- 2 ' S- t-butoxycarbonylamino propylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (73) Compound (73) was prepared in the manner of example 5 with the following substitution: N-Boc-L-b- (3 -pyridyl) - alanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (3 ' - (3 -pyridyl) - 1 ' -oxo-2 ' S- 1- butoxycarbonylaminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (73) after preparative plate chromatography: Mass Spectrum (CI) 553 (MH+) .
Figure imgf000114_0001
6- (3 ' - (3 -pyridyl) -1 ' -oxo-2 ' S- aminopropylamino) -3 - (4- pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (74) Compound (74) was prepared from compound (73) in the manner of example 6 which afforded 6 - (3 ' - (3 -pyridyl) - 1 oxo-2 ' S- aminopropylamino) -3 - (4 -pyridyl) -2 - (4 - fluoro phenyl) -7-aza-indole (74): Mass Spectrum (CI) 453 (MH+)
Example 56
Figure imgf000114_0002
6- (N,N-Di - t-Butoxycarbonyl -L-histidinylamino) -3- (4- pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (75)
Compound (73) was prepared in the manner of example 5 with the following substitution: 2'-N,N-Di-t-
Butoxycarbonyl-L-histidine was used in place of N-t-Boc g-aminobutyric acid which afforded 6 - (2 ' -N,N-Di- 1- Butoxycarbonyl-L-histidinyl) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (75) after preparative plate chromatography: Mass Spectrum (CI) 642 (MH+) .
Figure imgf000115_0001
6- (L-histidinylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7-aza-indole (76)
Compound (76) was prepared from compound (75) in the manner of example 6 which afforded 6-(L- histidinylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (76) : Mass Spectrum (CI) 542 (MH+) .
Example 58
Figure imgf000115_0002
6- (N-t-Butoxycarbonyl-3 (S) 1' .2' .3' .4' - tetrahydro- 3 ' - isoquinolinyloxo-amino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (114)
Compound (114) was prepared in the manner of example 5 with the following substitution: N- t-Butoxycarbonyl - 3 (S) 1, 2 , 3 , 4- tetrahydro-3 - isoquinolinylcarboxylic acid was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (N- t-Butoxycarbonyl - 3 (S) l',2',3',4'- tetrahydro-3' -isoquinolinyloxo-amino) -3 - (4-pyridyl) -2- (4-fluorophenyl) -7 -aza-indole (114) after preparative plate chromatography: Mass Spectrum (CI) 564 (MH+) . Exampl e 59
Figure imgf000116_0001
6 - (3 (S) l',2',3',4'- tetrahydro -3 ' -isoquinolinyloxo amino) -3- (4 -pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (115)
Compound (115) was prepared from compound (114) in the manner of example 6 which afforded 6-(3(S) l',2',3',4'- tetrahydro- 3 ' - isoquinolinyloxoamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (115): Mass Spectrum (CI) 464 (MH+) .
Example 60
Figure imgf000116_0002
6- (2 ' -phenyl- 1 ' -oxo-2 'R-N- t-butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (116)
Compound (116) was prepared in the manner of example 5 with the following substitution: N-Boc-R-phenylglycine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (2 ' -phenyl - 1 ' -oxo-2 * R-N- t-butoxycarbonylamino ethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (116) after preparative plate chromatography: Mass Spectrum (CI) 538 (MH+) .
Figure imgf000117_0001
6 - (2 ' -phenyl - 1 ' -oxo-2 ' R-aminoethylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole (117) Compound (117) was prepared from compound (116) in the manner of example 6 which afforded 6 - (2 ' -phenyl - 1 ' -oxo- 2 ' R-aminoethylamino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) -7 aza-indole (117): Mass Spectrum (CI) 438 (MH*) .
Example 62
Figure imgf000117_0002
6 - (2 ' -phenyl - 1 ' -oxo-2 'S-N- t-butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (118) Compound (118) was prepared in the manner of example 5 with the following substitution: N-Boc- S-phenylglycine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (2 ' -phenyl -1 ' -oxo-2 ' S-N- t-butoxycarbonylamino ethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (118) after preparative plate chromatography: Mass Spectrum (CI) 538 (MH+) . Example 63
Figure imgf000118_0001
6 - (2 ' -phenyl - 1 ' -oxo-2 ' S-aminoethylamino) -3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole (119)
Compound (119) was prepared from compound (118) in the manner of example 6 which afforded 6 - (2 ' -phenyl - 1 ' -oxo- 2 ' S-aminoethylamino) -3 - (4 -pyridyl) -2 - (4 -fluorophenyl) - 7 aza-indole (119) : Mass Spectrum (CI) 438 (MH) .
Figure imgf000118_0002
6 - (2 ' -phenyl - 1 ' -oxo- 2 'R-N- t-butoxycarbonyl -N-methylamino ethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (120) Compound (120) was prepared in the manner of example 5 with the following substitution: N-Boc -R-N-methylphenyl glycine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - (2 ' -phenyl - 1 ' -oxo-2 ' R-N- t-butoxy carbonyl -N-methylaminoethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (120) after preparative plate chromatography: Mass Spectrum (CI) 552 (MH*) . Example 65
Figure imgf000119_0001
6 - (2 ' -phenyl - 1 ' -oxo-2 ' R-N-methylaminoethylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (121) Compound (121) was prepared from compound (120) in the manner of example 6 which afforded 6 - (2 ' -phenyl - 1 ' -oxo- 2 ' R-N-methylaminoethylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluoro phenyl) -7-aza-indole (121): Mass Spectrum (CI) 452 (MH+) .
Example 66
Figure imgf000119_0002
6- (1 ' -oxo- 2 ' S- t-butoxycarbonylaminopropylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (122) Compound (122) was prepared in the manner of example 5 with the following substitution: N-Boc-L-alanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (1' -oxo-2 ' S- t-butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (122) after preparative plate chromatography: Mass Spectrum (CI) 476 (MH+) . Example 67
Figure imgf000120_0001
6 - (1 ' -oxo-2 ' S- aminopropylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole (123) Compound (123) was prepared from compound (122) in the manner of example 6 which afforded 6 - (1 ' -oxo- 2 ' S - aminopropylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (123) : Mass Spectrum (CI) 376 (MHT) .
Example 68
Figure imgf000120_0002
6 - (3 ' -phenyl -1 ' -oxo-2 ' - (L) - 1 -butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (124) Compound (124) was prepared in the manner of example 5 with the following substitution: N-Boc -L-phenylalanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (3 ' -phenyl -1 ' -oxo-2 ' - (L) -t-butoxycarbonyl aminopropylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (124) after preparative plate chromatography: Mass Spectrum (CI) 552 (MH+) . Example 69
Figure imgf000121_0001
6- (3 ' -phenyl-1 ' -oxo-2 ' - (L) -aminopropylamino) -3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (125) Compound (125) was prepared from compound (124) in the manner of example 6 which afforded 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' - (L) -aminopropylamino) -3 - (4-pyridyl) -2- (4-fluoro phenyl) -7-aza-indole (125) :Mass Spectrum (CI) 452 (MH*)
Example 70
Figure imgf000121_0002
6- (1 ' -oxo-2 ' S- t-butoxycarbonyl -N-methylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (126) Compound (126) was prepared in the manner of example 5 with the following substitution: N-Boc-L-N-methylalanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6 - ( 3 ' -phenyl - 1 ' - oxo - 2 ' - (L) - 1 -butoxycarbonyl aminopropylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (126) after preparative plate chromatography: Mass Spectrum (CI) 489 (MH+) . Example 71
Figure imgf000122_0001
6- (1 ' -oxo-2 ' S-N-methylaminopropylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole (127)
Compound (127) was prepared from compound (126) in the manner of example 6 which afforded 6 - (1 ' -oxo-2 ' S-N- methylaminopropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (127): Mass Spectrum (CI) 389 (MH*) .
Example 72
Figure imgf000122_0002
6- (1 ' -oxo-2 ' S- t-butoxycarbonyl-N-methyl-4-methyl-2- aminopentyl -amino) -3- (4 -pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (128)
Compound (128) was prepared in the manner of example 5 with the following substitution: N-Boc-L-N-methylleucine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (1 ' -oxo-2 ' S- t-butoxycarbonyl -N-methyl -4 - methyl -2 -aminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (128) after preparative plate chromatography: Mass Spectrum (CI) 532 (MH*) . Example 73
Figure imgf000123_0001
6 - (1 ' -oxo-2 ' S-N-methyl -4 -methyl -2 -aminopentylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (129) Compound (129) was prepared from compound (128) in the manner of example 6 which afforded 6 - (1 ' -oxo-2 ' S-N- methyl -4 -methyl -2 -aminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (129) : Mass Spectrum (CI) 432 (MH+) .
Figure imgf000123_0002
6- (1 ' -oxo-2 ' R- t-butoxycarbonylaminopropylamino) -3 - (4 • pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (130) Compound (130) was prepared in the manner of example with the following substitution: N-Boc-D-alanine was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (1' -oxo- 2 ' R- t-butoxycarbonylaminopropyl amino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (130) after preparative plate chromatography: Mass Spectrum (CI) 476 (MH+) .
Figure imgf000124_0001
6 - (1 ' -oxo- 2 ' R- aminopropylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (131)
Compound (131) was prepared from compound (130) in the manner of example 6 which afforded 6- (1 ' -oxo-2 ' R- aminopropylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7- aza-indole (131) : Mass Spectrum (CI) 376 (MH*) .
Figure imgf000124_0002
6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) - -butoxycarbonylamino propylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (132) Compound (132) was prepared in the manner of example 5 with the following substitution: N-Boc-L-b- (2 - thienyl ) alanine was used in place of N- t -Boc-g-aminobutyric acid which afforded 6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) - 1- butoxycarbonylaminopropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (132) after preparative plate chromatography: Mass Spectrum (CI) 558 (MH+) . Example 77
Figure imgf000125_0001
6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) -aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (133) Compound (133) was prepared from compound (132) in the manner of example 6 which afforded 6 - (3 ' - (2 - thienyl) - 1 ' oxo-2 ' - (L) -aminopropylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) -7 -aza-indole (133): Mass Spectrum (CI) 45i (MH*) .
Example 78
Figure imgf000125_0002
6 - (3 ' - (4 -azidophenyl) - 1 ' -oxo- 2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (134)
Compound (134) was prepared in the manner of example 5 with the following substitution: (3 '- (4 -azidophenyl) - 1 ' ■ oxo- 2 ' S- t-butoxycarbonylaminopropionic acid was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (3 ' - (4 -azidophenyl) -1 ' -oxo-2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (134) after preparative plate chromatography: Mass Spectrum (CI) 609 (MH) .
Figure imgf000126_0001
6 - (3 ' - (4 -azidophenyl) - 1 ' -oxo-2 ' S -aminopropylamino) - 3 - (4 pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (135) Compound (135) was prepared from compound (134) in the manner of example 6 which afforded 6-(3'-(4- azidophenyl) - 1 ' -oxo-2 ' S- aminopropylamino) -3 - (4 -pyridyl) • 2- (4 -fluoro phenyl) -7-aza-indole (135): Mass Spectrum (CI) 509 (MH*) .
Example 80
Figure imgf000126_0002
6- (3 ' - (3 -benzothienyl) - 1 ' -oxo-2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (136)
Compound (136) was prepared in the manner of example 5 with the following substitution: 3 - (3 ' -benzothienyl) - 1 - oxo-2S- t-butoxycarbonylaminopropionic acid was used in place of N- t-Boc-g-aminobutyric acid which afforded 6- (3 ' - (3 -benzothienyl) - 1 ' -oxo-2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (136) after preparative plate chromatography: Mass Spectrum (CI) 608 (MH+) . Exampl e 81
Figure imgf000127_0001
6- (3 ' - (3 -benzothienyl) - 1 ' ' S- aminopropylamino) - 3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (137) Compound (137) was prepared from compound (136) in the manner of example 6 which afforded 6-(3'-(3- benzothienyl ) - 1 ' - oxo - 2 ' S - aminopropylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (137) :Mass Spectrum (CI) 508 (MH+) .
Figure imgf000127_0002
6- (4 ' -phenyl-1 ' -oxo-2 ' - (L) - t- butoxycarbonylaminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (138)
Compound (138) was prepared in the manner of example 5 with the following substitution: N-a-t-Boc-L- homophenylalanine was used in place of N- t-Boc-g- aminobutyric acid which afforded 6 - (4 ' -phenyl - 1 ' -oxo- 2 ' - (L) - t-butoxycarbonylaminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (138) after preparative plate chromatography: Mass Spectrum (CI) 566 (MH*) .
Figure imgf000128_0001
6- (4 ' -phenyl - 1 ' -oxo-2 ' - (L) -aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (139) Compound (139) was prepared from compound (138) in the manner of example 6 which afforded 6 - (4 ' -phenyl - 1 ' -oxo- 2 ' - (L) - aminobutylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 7 -aza- indole (139): Mass Spectrum (CI) 466 (MH*) .
Example 83B
Figure imgf000128_0002
5 -bromo- 3 - (4 -pyridyl) - 2 - (3 - trifluoromethylphenyl ) indole 3 - (4 - Pyridyl) -2 - (3 - trifluoromethylphenyl ) indole was treated with NBS in the same manner as 6 -amino- 5 -bromo - 3 - (4 -pyridyl) -2 - (4 -fluorophenyl) -7 -aza- indole to afford the title compound: Mass Spectrum (CI) 417 (MBr81-H) .
Example 84
Figure imgf000129_0001
6- (4 ' -Phenyl-l ' -oxo-2' - (D) -t- butoxycarbonylaminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (140)
Compound (140) was prepared in the manner of example 5 with the following substitution: N-a-t-Boc-D- homophenylalanine was used in place of N- t-Boc-g- aminobutyric acid which afforded 6 - (4 ' -phenyl - 1 ' -oxo-2 ' - (D) - t-butoxycarbonylaminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (140) after preparative plate chromatography: Mass Spectrum (CI) 566 (MH*) .
Example 85
Figure imgf000129_0002
6- (4 ' -phenyl - 1 ' -oxo-2 ' - (D) -aminobutylamino) - 3 - (4 - pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (141) Compound (141) was prepared from compound (140) in the manner of example 6 which afforded 6 - (4 ' -phenyl - 1 ' -oxo- 2 ' - (D) -aminobutylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (141): Mass Spectrum (CI) 466 (MH*) . Exampl e 86
Figure imgf000130_0001
6 - (2 ' - amino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 1 - isobutoxycarbonyl - 7 -aza- indole (143) 6 - (2 ' - t-butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3 - (4 - pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole (29) (50 mg, 0.108 mmol), isobutyl chloroformate (42 ml, 0.325 mmol), N-methylmorpholme (119 ml, 1.08 mmol), potassium carbonate (74.9 mg, 0.542 mmol), and DMF (4 mL) were warmed at 80 °C for 16 h. After cooling to 23 C, the reaction was diluted with water (20 mL) , extracted with ethyl acetate (2 x 20 mL) , and dried (Na2S04) . After concentration in vacuo, the residue was purified by preparative plate chromatography to afford 6-(2'-t- butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 1 - isobutoxycarbonyl - 7 -aza- indole (142) . Compound (104) was converted to 6 - (2 ' -amino- 1 ' -oxo- ethylamino) -3.- (4-pyridyl) -2- (4 - fluorophenyl) -1- isobutoxycarbonyl - 7 -aza- indole (143) in the manner of example 6: Mass Spectrum (CI) 462 (MH*) .
Example 87
Figure imgf000130_0002
6- (phenylmethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl ) - 7-aza-indole (144)
6-Amino-3- (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza-indole (17) (100 mg, 0.329 mmol), benzaldehyde (100 ml, 0.987 mmol), and 1 , 2 -dichloroethane (20 mL) were allowed to stir for 15 min followed by the addition of sodium triacetoxyborohydride (139 mg, 0.658 mmol) as a solid. After 16 h at 23°C, the reaction was partitioned between ethyl acetate (200 mL) and satd bicarbonate (80 mL) . The organic layer was washed with brine (80 mL) , and dried (Na2S04) . After concentration in vacuo, a portion of the residue was purified by preparative chromatography to afford 6 - (phenylmethylamino) - 3 - (4 - pyridyl) -2 - (4 -fluoro phenyl )- 7 -aza- indole (144):Mass Spectrum (CI) 395 (MH) .
Example 88
Figure imgf000131_0001
6- (diethylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (145)
Compound (145) was prepared in the manner of example 87 with the following substitution: acetaldehyde was used in place of benzaldehyde which afforded 6- (diethylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (145) after preparative plate chromatography: Mass Spectrum (CI) 361 (MH+) . Example 89
Figure imgf000132_0001
6 - (3 ' -phenylpropylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7 -aza- indole (146) Compound (146) was prepared in the manner of example 87 with the following substitution: phenylhydrocinnam- aldehyde was used in place of benzaldehyde which afforded 6- (3 ' -phenylpropylamino) -3 - (4 -pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole (146) after preparative plate chromatography: Mass Spectrum (CI) 423 (MH*) .
Example 90
Figure imgf000132_0002
6- (2' (R,S) -phenylpropy -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (147)
Compound (147) was prepared in the manner of example 87 with the following substitution: 2'- phenylpropionaldehyde was used in place of benzaldehyde which afforded 6- (2' (R,S) -phenylpropylamino) -3- (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole (147) after preparative plate chromatography: Mass Spectrum (CI) 423
(MH*) .
Figure imgf000133_0001
6- ( 2 ' (R.S) -ethylhexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (148) Compound (148) was prepared in the manner of example 87 with the following substitution: 2 ' -ethylhexanaldehyde was used in place of benzaldehyde which afforded 6- (2' (R,S) -ethylhexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (148) after preparative plate chromatography: Mass Spectrum (CI) 417 (MHT) .
Example 92
Figure imgf000133_0002
6 -Amino- 5 -chloro- 3 - (4-pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (149)
Compound (149) was prepared in the manner of example 3 with the following substitution: 3 -chloro-2 , 6 - diaminopyridine was used in place of 2 , 6 -diaminopyridine which afforded after 6 -Amino- 5 -chloro-3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7-aza-indole (149) after flash chromatography: Mass Spectrum (CI) 439 (MH+) . Example 93
Figure imgf000134_0001
6-Amino-5-fluoro-3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (28)
6-Amino-3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (17) (250 mg, 0.822 mmol), N- fluorobenzenesulphonamide (259 mg, 0.822 mmol), and DMF (4 mL) were warmed to 90°C behind an explosion shield. After 48 h, the reaction was concentrated in vacuo and the residue was purified by flash chromatography (ethyl acetate: hexane 1:1) to afford 6 -Amino- 5 - fluoro- 3 - (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (28): Mass Spectrum (CI) 323 (MH*) .
Example 94
Figure imgf000134_0002
6 -Amino- 5 -bromo- 3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (27)
6-Amino-3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (17) (250 mg, 0.822 mmol), N-bromosuccinamide (146 mg, 0.822 mmol), and DMF (4 mL) were allowed to stir at 23°C. After 24 h, the reaction was concentrated in vacuo and the residue was purified by flash chromatography (ethyl acetate: hexane 1:1) to afford 6- Amino- 5 -bromo- 3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (27) : Mass Spectrum (CI) 385 (MH+Br81) . Example 95
Figure imgf000135_0001
6- (di - isoamylamino) -3- (4 -pyridyl) -2- (4-fluorophenyl) -7- aza-indole (150) Compound (150) was prepared in the manner of example 87 with the following substitution: 3 -methylbutyraldehyde was used in place of benzaldehyde which afforded 6-(di- isoamylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (150) after preparative plate chromatography: Mass Spectrum (CI) 445 (MH*) .
Example 96
Figure imgf000135_0002
6- ( 2 ' , 2 ' -dimethylpropylamino) -3 - (4 -pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (151)
Compound (151) was prepared in the manner of example 87 with the following substitution: pivaldehyde was used in place of benzaldehyde which afforded 6-(2'.,2'- dimethylpropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (151) after preparative plate chromatography: Mass Spectrum (CI) 375 (MH*) . Example 97
Figure imgf000136_0001
6- (isoamylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) -7-aza- indole (152) Compound (152) was prepared in the manner of example 87 with the following substitution: 3 -methylbutyraldehyde was used in place of benzaldehyde which afforded 6- (isoamylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (152) after preparative plate chromatography: Mass Spectrum (CI) 375 (ME*) .
Example 98
Figure imgf000136_0002
6- (2' -ethylbutylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) 7-aza-indole (153)
Compound (153) was prepared in the manner of example 87 with the following substitution: 2 -ethylbutyraldehyde was used in place of benzaldehyde which afforded 6-(2'- ethylbutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (153) after preparative plate chromatography: Mass Spectrum (CI) 389 (MH*) .
Figure imgf000137_0001
6 - (2 ' - thienylmethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (154) Compound (154) was prepared in the manner of example 87 with the following substitution: 2 - thiophene carboxaldehyde was used in place of benzaldehyde which afforded 6- (2' - thienylmethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (154) after preparative plate chromatography: Mass Spectrum (CI) 401 (MH*) .
Example 100
Figure imgf000137_0002
6- (3' , 3 ' di- phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza- indole (155)
Compound (155) was prepared in the manner of example 87 with the following substitution: phenylhydrocinnam- aldehyde was used in place of benzaldehyde which afforded 6- (3 ' , 3 ' di -phenylpropylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza-indole (155) after preparative plate chromatography: Mass Spectrum (CI) 541 (MH+) . Example 101
Figure imgf000138_0001
6- (ethylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl ) -7-aza- indole (156)
Compound (156) was prepared in the manner of example 87 with the following substitution: acetaldehyde was used in place of benzaldehyde which afforded 6- (diethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (156) after preparative plate chromatography: Mass Spectrum (CI) 361 (MH+) .
Example 102
Figure imgf000138_0002
6 - (3 ' -phenyl - 1 ' -oxo-2 ' - (R, S) -methylpropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (157)
Compound (157) was prepared in the manner of example 5 with the following substitution: 3 -phenyl -2- methylpropionic acid was used in place of N- t-Boc-g- aminobutyric acid which afforded 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' - (R, S) -methylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (157) after preparative plate chromatography: Mass Spectrum (CI) 451 (MH+) . Example 103
Figure imgf000139_0001
6- (2 ' -amino- 1 ' -oxo -ethylamino) -3- (4-pyridyl) -2 - (4 - fluorophenyl) - 1 -methyl - 7 -aza- indole (158) To a solution of 6 - (2 '- 1 -butoxycarbonylammo- 1 ' -oxo- ethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (29) (50.0 mg, 0.108 mmol), triphenylphosphine (85 mg, 0.325 mmol), methanol (13 ml, 0.791 mmol) and methylene chloride (5 mL) was added diethyl azodicarboxylate (51 ml, 0.325 mmol) at 0°C. The reaction was allowed to warm to 23 °C. After 2.5 h, an additional 2 equivalents of methanol, triphenylphosphine, and diethyl azodicarboxylate were added. After 16 h, the reaction was concentrated in vacuo and the residue was purified by preparative plate chromatography to afford 6 - (2 '- t-butoxycarbonylamino- 1 ' ■ oxo-ethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -1- methyl -7 -aza- indole (30) which was converted to 6-(2'- amino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 1 -methyl -7 -aza-indole (158) as described in example 6: Mass Spectrum (CI) 376 (MH+) .
Example 104
Figure imgf000139_0002
6- (3 ' .3' - dimethyl- 1' -oxo-butylamino) -3- (4 -pyridyl) -2- (4 fluorophenyl) - 7 -aza- indole (159) Compound (159) was prepared in the manner of example 5 with the following substitution: 3 , 3 -dimethylbutyric acid was used in place of N- t -Boc-g-aminobutyric acid which afforded 6 - (3 ', 3 ' -dimethyl - 1 ' -oxo-butylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza-indole (159) after preparative plate chromatography: Mass Spectrum (CI) 403 (MH*) .
Example 105
Figure imgf000140_0001
6- (ethoxycarbonylamino) -3- (4 -pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (160)
Compound (160) was obtained as a side product from example 104 wherein a small amount of unreacted ethyl chloroformate resulted in acylation of the 6 -amino function to afford 6 - (ethoxycarbonylamino) - 3 - (4 - pyridyl) - 2 - (4 - fluorophenyl) - 7 -aza- indole (160) after preparative plate chromatography: Mass Spectrum (CI) 377 (MH*) .
Example 106
Figure imgf000140_0002
6 - (2 ' S- amino- 1 ' -oxo -propy amino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 1 -methyl - 7 -aza- indole (161) Compound (161) was prepared in the manner of example 87 with the following substitution: 6 - (2 ' S- t-butoxycarbonyl amino- l1 -oxo -propyl mino) -3- (4-pyridyl) -2- (4 -fluoro phenyl) -7 -aza-indole was used in place of 6-(2'-t- butoxycarbonylamino-1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7 -aza-indole which afforded 6-(2'S- amino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluoro phenyl) - 1 -methyl -7 -aza- indole (161) after preparative plate chromatography: Mass Spectrum (CI) 390 (MH+) .
Figure imgf000141_0001
6 - (2 ' S- amino- 1 ' -oxo-propylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) - 1 - isobutyl - 7 - aza- indole (162) Compound (162) was prepared in the manner of example 87 with the following substitutions: 6-(2'S-t- butoxycarbonyl amino- 1' -oxo -propylamino) -3- (4-pyridyl) - 2- (4 -fluoro phenyl) - 7 -aza- indole was used in place of 6- (2 ' - t-butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3 - (4 - pyridyl) -2 - (4 - fluorophenyl) - 7 -aza-indole and isobutanol was used in place of methanol which afforded 6-(2'S- amino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -1-isobutyl- 7 -aza-indole (162) after preparative plate chromatography: Mass Spectrum (CI) 432 ( H+) .
Exampl e 10 8
Figure imgf000142_0001
6 - (2 ' S- amino- 1 ' -oxo -propylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 1 -cvclohexylmethyl - 7 -aza- indole (163) Compound (163) was prepared in the manner of example 87 with the following substitutions: 6-(2'S-t- butoxycarbonylamino- 1 ' -oxo-propylamino) -3- (4-pyridyl) -2- (4 - fluorophenyl) - 7 -aza- indole was used in place of 6- (2 ' - t-butoxycarbonylamino- 1 ' -oxo- ethylamino) - 3 - (4 - pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole and cyclohexymethanol was used in place of methanol which afforded 6 - (2 ' S -amino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 1 - isobutyl - 7 - aza- indole (163) after preparative plate chromatography: Mass Spectrum (CI) 472 (MH*) .
Example 109
Using the procedures of the above general description and the above examples, the compounds of Tables 1-7 can be prepared. SSPG UPON TIME OF PUBLICATION
-pyridyl -pyridyl CH3 -pyridyl -quinolinyl 2 - (2 -aminopyridyl) - ( 2 - aminopyridyl ) - (2 -aminopyridyl) -quinolinyl -quinolinyl -pyridyl -quinolinyl - (2 -aminopyridyl) -quinolinyl - ( 2 - aminopyridyl ) )CH3 - (2 -aminoimidazoyl) - (2 -aminoimidazoyl) -pyrimidinyl -pyrimidinyl -pyrimidinyl -pyrimidinyl )CH3 -pyrimidinyl
Figure imgf000144_0001
Table 3
Figure imgf000145_0001
Ru R40 R11 R40 - pyridyl -NH2 4- (2 -aminoimidazoyl ) -CH3 - pyridyl -NHPh 4- (2 -aminoimidazoyl ) -Ph - pyridyl -NHCH3 4 -quinolinyl -Ph -quinolinyl -NH(4-MeOP ) 4 -pyridyl -Ph 2 - thienyl - ( 2 - aminopyridyl ) -NH2 4 -pyridyl (2 -aminopyridyl) -NHPh 4 -quinolinyl CH2NH2 - ( 2 - aminopyridyl ) -NHCH3 4 -pyridyl n-Bu -quinolinyl -NH2 4 -pyridyl -CH2N(CH3)2 -NHPh 4 (2 -aminopyridyl) CH3 -quinolinyl OPh) 4 -pyridyl -CH3 -pyridyl -NH(4-Me
4 -quinolinyl -CH3 -quinolinyl CH2N(CH3)2
4 quinolinyl n- propyl - ( 2 - aminopyridyl ) CH2N(CH3)2
4 -pyridyl -CH2CH2N(CH3) -quinolinyl -CH2CH2N(CH3)
4 2 - acetamidopyπdyl ) - (2 -aminopyridyl) -CH2NH2 -CH2CH2N(CH3) 2 - (2 -aminoimidazoyl) -CH2CH2N(CH3) 4 -pyridyl -CH2NH2 - (2 -aminoimidazoyl) -CH2N(CH3)2 4- (2 -aminopyridyl) -CH2NH2 -pyrimidinyl -NH2 4 -pyrimidinyl 2 - thienyl -pyrimidinyl -NHPh 4 -pyrimidinyl -CH2NH2 -pyrimidinyl -NHCH3 4 -pyrimidinyl n-Bu - pyrimidinyl NH(4-MeOPh) 4 pyrimidinyl CH2N(CH3) -pyrimidinyl Ph 4 pyrimidinyl -CH3
CH3
2
3
Figure imgf000146_0001
CH3 2
-
CH3
Figure imgf000147_0001
Table 6
Figure imgf000148_0001
R41 χ3 R41 χ3 methyl CF methyl C-CH3
-CH2NH2 N -CH2NH2 C -CH(0H)CH3 - ( 5 - chlorothienyl ) C-Br 2 - ( 5 - chlorothienyl ) C-CH20H
-CH2NMe2 N -CH2NMe2 C-N(CH3) 2 phenyl C-F phenyl C-0CH3 methyl C-CF3 methyl C-CH3
1 -naphthyl N 1 -naphthyl C-0CF3 - (5 -chlorothienyl) 2 - ( 5 - chlorothienyl )
C-F C-OH
-CH2CH2NH2
-CH2CH2NH2 C-CH3
C-CF3 phenyl 4 - carboxymethylphenyl C-CH3
C-Ph
4 - -butoxyphenyl methyl C-OH
C-Ph
-CH2NH2 C-Ph 1 -naphthyl C-0CH3 phenyl C-Cl methyl C-CF3 methyl C-Cl -CH2NH2 C-F (0H)CH3 methyl methyl c :-CH
C-F
-CH2NH2 C-Br -CH2CH2NH2 C-0CH3 n-butyl C-CF3 3- (1 -piperidinyl) propyl C-CH3
4 -methoxyphenyl N 3- (1 -piperizinyl) propyl C-OH
4 - cyanophenyl C-F 2 - ( 5 - chlorothienyl ) C-0CH3
4 -n-butoxyphenyl C-Cl -CH2NH2 C-CH(0H)CH3 methyl C-Ph n-butyl C-Br
Table 7
Figure imgf000149_0001
χ2 χ3 χ2 χ3
N C-CH3
-C-C(0)Ph C-F
C-F C-CH(0H)CH3
-C-C (O)NHMe N
-C-C (O)NHMe C-Br C-CF3 C-CH20H
-C-S(02) -Et N N C-N(CH3) 2
-C-C(O) -Bu C-F C-Br C-0CH3
-CH C-CF3 N C-CH3
-C-S (02) -NHEt N -CH C-0CF3
-CH C-OH
C-NH-S (02) -NHCH3 C-F
C-C(02)Me C-CH3
-C-C (02)Me C-CF3
-CH C-Ph -CH C-CH3 C-S(02) -Et -CH C-OH
- C-Ph
C-NHEt C-0CH3
-C-C(0)Ph C-Ph
-CH C-CF3
-CH C-Cl
-C-NHEt C-Cl -CH C-F
-C-NHPr C-F -CH C-CH(0H)CH3
-CH
-CH C-Br C-0CH3
-CH
-C - HMe C-CF3 C-CH3
-C-C(0)NHPh N C-C(02)Me C-OH
C-*- IF. C-0CH3
-C-N(Me) -C(0) -Me C-F e C-Cl C-CF3 C-CH(0H)CH3
-C-N-S (02)M
-C-NHEt C-Ph C-S (02) -Et C-Br Table 8
Figure imgf000150_0001
Table 9
Figure imgf000151_0001
Tabl e 10
Figure imgf000152_0001
Example 110 The following assays were used to characterize the ability of compounds of the invention to inhibit the production of TNF-α and IL-l-β. The second assay measured the inhibition of TNF-α and/or IL-l-β in mice after oral administration of the test compounds. The third assay, a glucagon binding inhibition in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit glucagon binding. The fourth assay, a Cyclooxygenase enzyme (COX-1 and COX-2) inhibition activity in vitro assay, can be used to characterize the ability of compounds of the invention to inhibit COX-1 and/or COX-2.
Lipopolysaccharide-activated monocyte TNF production assay
Isolation of monocvtes
Test compounds were evaluated in vi tro for the ability to inhibit the production of tumor necrosis factor (TNF) by monocytes activated with bacterial lipopolysaccharide (LPS) . Fresh residual source leukocytes (a byproduct of plateletpheresis) were obtained from the local blood bank and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation on Ficol-Paque Plus (Pharmacia).
PBMCs were suspended at 2 x lO^/ml in DMEM supplemented to contain 2% FCS (10 mM) , 0.3 mg/ml glutamate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate (complete media) . Cells were plated into Falcon flatbottom 96 well culture plates (200 μl/well) and cultured overnight at 37°C and 6% Cθ2 • Nonadherent cells were removed by washing with 200 μl/well of fresh medium. Wells containing adherent cells (~70% monocytes) were replenished with 100 μl of fresh medium.
Preparation of test compound stock solutions
Test compounds were dissolved in DMZ . Compound stock solutions were prepared to an initial concentration of 10 - 50 μM. Stocks were diluted initially to 20 - 200 μM in complete media. Nine twofold serial dilutions of each compound were then prepared in complete medium. Treatment of cells with test compounds and activation of TNF production with lipopolysaccharide
One hundred microliters of each test compound dilution were added to microtiter wells containing adherent monocytes and 100 μl complete medium. Monocytes were cultured with test compounds for 60 min at which time 25 μl of complete medium containing 30 ng/ml lipopolysaccharide from E. coli K532 were added to each well. Cells were cultured an additional 4 hrs .
Culture supernatants were then removed and TNF present in the supernatants was quantified using an ELISA.
TNF ELISA Flat bottom 96 well Corning High Binding ELISA plates were coated overnight (4°C) with 150 μL/well of 3 μg/ml murine anti -human TNFa MAb (R&D Systems #MAB210) . Wells were then blocked 1 h at room temperature with 200 μL/well of CaCl2"free ELISA buffer supplemented to contain 20 mg/ml BSA (standard ELISA buffer: 20 mM, 150 mM NaCl, 2 mM CaCl2, 0.15 mM thimerosal, pH 7.4). Plates were washed and replenished with 100 μl of test supernatants (diluted 1:3) or standards. Standards consisted of eleven 1.5 -fold serial dilutions from a stock of 1 ng/ml recombinant human TNF (R&D Systems) . Plates were incubated at room temperature for 1 h on orbital shaker (300 rpm) , washed and replenished with 100 μl/well of 0.5 μg/ml goat anti -human TNFa (R&D systems #AB-210-NA) biotinylated at a 4:1 ratio. Plates were incubate for 40 min, washed and replenished with 100 μl/well of alkaline phosphatase- conjugated streptavidin (Jackson ImmunoResearch #016-050-084) at 0.02 μg/ml. Plates were incubated 30 min, washed and replenished with 200 μl/well of 1 mg/ml of p-nitrophenyl phosphate. After 30 min, plates were read at 405 nm on a Vmax plate reader. Data analysis
Standard curve data were fit to a second order polynomial and unknown TNF-a concentrations determined from their OD by solving this equation for concentration. TNF concentrations were then plotted Vs test compound concentration using a second order polynomial. This equation was then used to calculate the concentration of test compounds causing a 50% reduction in TNF production.
The following compounds had an IC50 of less than 20 μM: 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) indole (3); 6-amino- 3 - (4-fluorophenyl) -2- (4 -pyridyl) -7-aza-indole (18); 6- (4 ' - -butoxycarbonylamino- 1 ' -oxo-butylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (21); 6 - (4 • - amino- 1 ' -oxo-butylamino) -3 - (4 -pyridyl) -2 - (4 - fluoro phenyl) - 7 -aza- indole (22); 6 - (5 ' -ureido- 1 ' -oxo- 2 ' - 1- butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (64); 6 - (5 ' -ureido- 1 ' -oxo- 2 ' - aminopentylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (65); 6 - (6 '- t-butoxycarbonylamino- 1 ' -oxo- 2 ' - t-butoxycarbonylaminohexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza- indole (66); 6 - (6 ' -amino- 1 ' -oxo- 2 ' - aminohexylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (67); 6 - (4 ' -amino- 1 ' -oxo-butylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (22); 6-(5'-t- butoxycarbonylamino - 1 ' - oxo- 2 ' - 1 - butoxycarbonylaminopentyl amino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 7 -aza-indole (68); 6 - (5 ' -amino- 1 ' -oxo-2 ' - aminopentylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (69); 6 - (3 ' -Methyl - 1 ' -oxo-2 ' - aminobutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (73); 6- (4 ',4' -Dimethyl -1' -oxo-2' - aminopentylamino) -3- (4-pyridyl) -2- (4-fluoro phenyl) -7- aza-indole (75); 6 - (5 '- amino- 1 ' -oxo-pentylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (77); 6-(6'- amino- 1 ' -oxo-hexylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole (79); 6 - (3 ' -cyclohexyl - 1 I _ oxo-2 ' -aminopropylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole (81); 6 - (4 ' - carboxy- 1 ' -oxo- 2 ' -aminobutylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 - aza-indole (83); 6 - (3 ' -hydroxy- 1 ' -oxo- 2 ' - aminobutyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (85) ; 6- (3 ' -phenyl - 1 ' -oxo-2 ' -D, L- aminopropylamino) - 3 - (4 pyridyl) -2- (4-fluorophenyl) -7-aza-indole (87); 6- (3 ' - amino- 1' -oxo-propylamino) -3- (4-pyridyl) -2- (4 -fluoro phenyl) -7 -aza- indole (91); 6 - (2 '- t-butoxycarbonylamino - 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 - aza-indole (29); 6 - (methylsulfonylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole (93); 6- (1' -oxo- ethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7-aza - indole (94); 6 - (2 '- (5 -chlorothienyl) sulfonylamino) - 3 - (4 ■ pyridyl) -2- (4-fluorophenyl) -7-aza-indole (95); 6-(3'-N- phthaloyl- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole (98); 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -4, 7 -diaza -indole (99); 6-(2'-N-t- Butoxycarbonyl -L-prolylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole (100); 6 - (2 ' -L-prolylamino) - 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (101); 6- (2 ' -Dimethylamino- 1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7 -aza-indole (103); 6 - (4 ' -methylsulfoxo- 1 ' -oxo-2 ' S- t-butoxycarbonylaminobutylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (108); 6-(4'- methylsulfoxo- 1 ' -oxo-2 ' S- aminobutylamino) -3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole (109); 6-(3'-(3- pyridyl) - 1 ' -oxo-2 ' S- t-butoxycarbonylaminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (110); 6- (3 ' - (3 -pyridyl) - 1 ' -oxo-2 ' S -aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (111); 6-(N,N- Di- t-butoxycarbonyl -L-histidinylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (112); 6-(L- histidinylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (113); 6-(3(S) 1 ' , 2 ' , 3 ' , 4 ' - tetrahydro- 3 ' - isoquinolinyloxoamino) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7-aza-indole (115); 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' - (L) - aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (125); 6 - (1 ' -oxo- 2 ' S -N-methyl - 4 -methyl - 2 - aminopentylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (129); 6 - (3 ' - (2 - thienyl) - 1 ' -oxo- 2 ■ - (L) - aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (133); 6 - (3 ' - (4 -azidophenyl) - 1 ' -oxo- 2 ' S - aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (135); 6 - (3 '- (3 -benzothienyl) - 1 ' -oxo-2 ' S- aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (137); 6 - (4 ' -phenyl - 1 ■ -oxo- 2 ' - (L) - aminobutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (139); 6- (4 ' -phenyl- 1 ' -oxo-2 ' - (D) -amino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (141); 6 - (2 ' -amino- 1 ' -oxo-ethylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) - 1 - isobutoxycarbonyl - 7 -azaindole (143); 6- (2' (R,S) -phenylpropylamino) -3- (4 - pyridyl) -2 - (4 -fluoro phenyl) - 7 -aza- indole (147); 6- (2' (R,S) -ethylhexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7 -aza-indole (148); 6 -amino- 5 - fluoro- 3 - (4 - pyridyl) -2 - (4 - fluorophenyl) -7 -aza-indole (28); 6-amino- 5 -bromo- 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (27); 6- (2' ,2' - dimethylpropyl amino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole (151); 6 - (isoamylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole (152); 6-(2'- ethylbutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (153); 6- (2' - thienylmethylamino) -3 - (4-pyridyl) -2- (4 -fluorophenyl) -7 -aza- indole (154); 6 - (ethylamino) - 3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (156); and 6- (2' - amino- 1' -oxo-ethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) - 1 -methyl - 7 -aza- indole (158) '.
The following compounds had an IC50 of less than 1 μM: 6 -amino- 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole (17); 6- (3 '- (4 -iodophenyl) -1' -oxo-2' - aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza- indole (71); 6 - (3 '- (4 -hydroxyphenyl) - 1 ' -oxo-2 ' - aminopropylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza-indole (89); 6 - (2 ' -amino- 1 ' -oxo- ethylamino) - 3 - (4 - pyridyl) -2- (4-fluoro phenyl) -7 -aza-indole (92); 6-(2S'- dimethy1amino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) -7-aza-indole (102); 6 - (2 ' -N-methyl - 1- butoxycarbonylamino- 1 ' -oxo-ethylamino) -3- (4-pyridyl) -2- (4 -fluorophenyl) -7-aza-indole (104); 6 - (2 ' -N-methyl - amino- 1 ' -oxo- ethylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole (105); 6-(4'-N-t- butoxycarbonylisonipecotylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza- indole (106); 6 - (4 ' - isonipecotyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (107) ; 6- (2 ' -phenyl -1 ' -oxo-2 ' R-aminoethylamino) -3- (4- pyridyl) - 2 - (4 - fluorophenyl) -7 -aza- indole (117); 6-(2'- phenyl- 1 ' -oxo-2 ' S-aminoethylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole (119); 6 - (2 • -phenyl - 1 ' -oxo- 2 'R-N-methylaminoethylamino) -3- (4-pyridyl) -2- (4 -fluoro phenyl) -7 -aza-indole (121); 6 - (1 ' -oxo- 2 ' S-aminopropyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole (123) ; 6- (1 ' -oxo-2 ' S-N-methylaminopropylamino) -3- (4- pyridyl) -2 - (4 - fluorophenyl) -7 -aza- indole (127); and 6- (1 ' -oxo-2 ' R- aminopropylamino) -3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole (131) .
In a similar manner to the above described assay involving the LPS induced release of TNF-a from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-lbeta, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL- lbeta, IL-6 and/or IL-8 by methods well known to those skilled in the art. Selected compounds from this invention have demonstrated antiinflammatory properties in models of inflammation including the carageenan paw edema model (C. A. Winter et al Proc. Soc. Exp. Biol. Med. (1962) vol 111, p 544; K. F. Swingle, in R. A. Scherrer and M. W. Whitehouse, Eds., Antiinflammatory Agents,
Chemistry and Pharmacology, Vol. 13-11, Academic, New York, 1974, p. 33) and collagen induced arthritis (D. E. Trentham et al J. Exp. Med. (1977) vol. 146, p 857; J. S. Courtenay, Nature (New Biol.) (1980), Vol 283, p 666) . Also, selected compounds from the class have shown in vivo activity in a LPS mouse model in which serum levels of TNF-a were reduced in the presence of compounds of this invention.
Inhibition of LPS -Induced TNF-α production in mice
Male DBA/1LACJ mice were dosed with vehicle or test compounds in a vehicle (the vehicle consisting of 0.5% tragacanth in 0.03 N HCl) 30 minutes prior to lipopolysaccharide (2 mg/kg, I.V.) injection. Ninety minutes after LPS injection, blood was collected and the serum was analyzed by ELISA for TNF levels.
125I-Glucagon Binding Screen with CHO/hGLUR Cells
The assay is described in WO 97/16442, which is incorporated herein by reference in its entirety.
Reaσents
The reagents can be prepared as follows: (a) prepare fresh IM o- Phenanthroline (Aldrich) (198.2 mg/ml ethanol); (b) prepare fresh 0.5M DTT (Sigma); (c) Protease Inhibitor Mix (1000X) : 5 mg leupeptin, 10 mg benzamidine, 40 mg bacitracin and 5 mg soybean trypsin inhibitor per ml DMSO and store aliquots at -20°C; (d) 250 μM human glucagon (Peninsula): solubilize 0.5 mg vial in 575 μl 0. IN acetic acid (1 μl yields 1 μM final concentration in assay for non-specific binding) and store in aliquots at -20°C; (e) Assay Buffer: 20mM Tris (pH 7.8), 1 mM DTT and 3 mM o -phenanthroline; (f) Assay Buffer with 0.1% BSA (for dilution of label only; 0.01% final in assay): 10 μl 10% BSA (heat- inactivated) and 990 μl Assay Buffer; (g) 125I -Glucagon (NEN, receptor- grade, 2200 Ci/mmol) : dilute to 50,000 cpm/25 μl in assay buffer with BSA (about 50pM final concentration in assay) .
Harvesting of CHO/hGLUR Cells for Assay 1. Remove media from confluent flask then rinse once each with PBS (Ca, Mg-free) and Enzyme- free Dissociation Fluid (Specialty Media, Inc.).
2. Add 10 ml Enzyme- free Dissoc. Fluid and hold for about 4 min. at 37°C. 3. Gently tap cells free, triturate, take aliquot for counting and centrifuge remainder for 5 min. at 1000 rpm.
4. Resuspend pellet in Assay Buffer at 75000 cells per 100 μl . Membrane preparations of CHO/hGLUR cells can be used in place of whole cells at the same assay volume. Final protein concentration of a membrane preparation is determined on a per batch basis.
Assay
The determination of inhibition of glucagon binding can be carried out by measuring the reduction of I125- glucagon binding in the presence of compounds of Formula I. The reagents are combined in 120 μL of assay buffer as follows:
Compound/ 250 μM 125ι- CHO/hGLUR
Vehicle Glueagon Glucagon Cells
Total --/5 μl " ~ 25 μl 100 μl Binding
+ 5 μl/-- 25 μl 100 μl Compound
Nonspecif --/5 μl 1 μl 25 μl 100 μl ic
Binding
The mixture is incubated for 60 min. at 22 °C on a shaker at 275 rpm. The mixture is filtered over pre- soaked (0.5% polyethylimine (PEI) ) GF/C filtermat using an Innotech Harvester or Tomtec Harvester with four washes of ice-cold 20mM Tris buffer (pH 7.8). The radioactivity in the filters is determined by a gamma- scintillation counter.
In a similar manner to the above described assay involving the LPS induced release of TNF-a from monocytes, compounds of this invention can also be shown to inhibit LPS induced release of IL-lbeta, IL-6 and/or IL-8 from monocytes by measuring concentrations of IL-lbeta, IL-6 and/or IL-8 by methods well known to those skilled in the art.
Cyclooxygenase Enzyme Activity Assay
The human monocytic leukemia cell line, THP-1, differentiated by exposure to phorbol esters expresses only COX-1; the human osteosarcoma cell line 143B expresses predominantly COX-2. THP-1 cells are routinely cultured in RPMI complete media supplemented with 10% FBS and human osteosarcoma cells (HOSC) are cultured in minimal essential media supplemented with 10% fetal bovine serum (MEM- 10%FBS) ; all cell incubations are at 37 °C in a humidified environment containing 5% C02.
COX-1 Assay In preparation for the COX-1 assay, THP-1 cells are grown to confluency, split 1:3 into RPMI containing 2% FBS and 10 mM phorbol 12-myristate 13-acetate (TPA), and incubated for 48 hours on a shaker to prevent attachment. Cells are pelleted and resuspended in Hank's Buffered Saline (HBS) at a concentration of 2.5 x 106 cells/mL and plated in 96-well culture plates at a density of 5 x 10s cells/mL. Test compounds are diluted in HBS and added to the desired final concentration and the cells are incubated for an additional 4 hours. Arachidonic acid is added to a final concentration of 30 mM, the cells incubated for 20 minutes at 37°C, and enzyme activity determined as described below. COX-2 Assay
For the COX-2 assay, subconfluent HOSC are trypsinized and resuspended at 3 x 10" cells/mL in MEM- FBS containing 1 ng human IL-lb/mL, plated in 96-well tissue culture plates at a density of 3 x 104 cells per well, incubated on a shaker for 1 hour to evenly distribute cells, followed by an additional 2 hour static incubation to allow attachment. The media is then replaced with MEM containing 2% FBS (MEM-2%FBS) and 1 ng human IL-lb/mL, and the cells incubated for 18-22 hours. Following replacement of media with 190 mL MEM, 10 mL of test compound diluted in HBS is added to achieve the desired concentration and the cells incubated for 4 hours. The supernatants are removed and replaced with MEM containing 30 mM arachidonic acid, the cells incubated for 20 minutes at 37 °C, and enzyme activity determined as described below.
COX Activity Determined
After incubation with arachidonic acid, the reactions are stopped by the addition of 1 N HCl, followed by neutralization with 1 N NaOH and centrifugation to pellet cell debris. Cyclooxygenase enzyme activity in both HOSC and THP-1 cell supernatants is determined by measuring the concentration of PGE2 using a commercially available ELISA (Neogen #404110) . A standard curve of PGE2 is used for calibration, and commercially available COX-1 and COX-2 inhibitors are included as standard controls.
The following compounds exhibit activities in the Cyclooxygenase assay with IC50 values of 20 μM or less: 6 - ( 6 ' - amino - 1 ' - oxo-hexylamino) - 3 - (4 -pyridyl ) - 2 - ( 4 - fluoro phenyl) -7-aza-indole; and 6 - (1 ' -oxo- 2 ' S-N-methylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole. The following compounds exhibit activities in the Cyclooxygenase assay with IC50 values of 5 μM or less: 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' -D, L- aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole; 6- (methyl sulfonylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole; and 3 - (4-pyridyl) -2- (4-fluorophenyl) indole. This invention further relates to the use of a compound of this invention in the manufacture of a medicament for the prophylaxis and treatment, either acutely or chronically, of TNF-a mediated disease states. In addition, the compounds of this invention are useful in the manufacture of a medicament for treating disease states in which IL-1, IL-6 and/or IL-8 play a role. Also, the compounds of this invention are useful in the manufacture of a analgesic medicament and a medicament for treating pain disorders, such as hyperalgesia. The compounds of the present invention also are useful in the manufacture of a medicament to prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway.
This invention also relates to a pharmaceutical composition comprising a compound of this invention and a pharmaceutically acceptable carrier, and if desired other active ingredients. The compounds of this invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art.
All of the compounds of this invention are useful in the prophylaxis and treatment of TNF-a mediated disease states. The compounds are also useful in the prophylaxis and treatment of disease states in which IL- 1, IL-6, and IL-8 play a role. Preferably, the compounds of this invention are useful in the prophylaxis and treatment of rheumatoid arthritis; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; antiviral therapy including those viruses sensitive to TNF-a inhibition - HIV-1, HIV- 2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, and the herpes viruses including HSV-1, HSV-2, and herpes zoster; muscle degeneration; cachexia; Reiter's syndrome; type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; brain trauma; atherosclerosis; Alzheimer's discease; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever and mylagias due to infection.
In addition to inhibiting the production of TNF-a, compounds of this invention can also reduce levels of other cytokines including but not limited to IL-1, IL-6 or IL-8. Reducing elevated levels of these inflammatory cytokines to basal levels or below is favorable in controlling, slowing progression, or possibly alleviating many disease states.
The present invention provides a method of treating a disease state in which cytokine levels are elevated which comprises administering an effective amount of a compound of this invention. Compounds of this invention are of use in the prophylaxis and acute or chronic therapy of any disease state in a human, or other mammal, which is exacerbated by or mediated by elevated or unregulated IL-1, IL-6, IL-8 and/or TNF-a production by such mammal's cells, such as, but not limited to monocytes, macrophages, and glial cells. More preferably, this invention relates to a method of lowering the levels of TNF-a and/or IL-1 in a mammal in need thereof which comprises administering an effective dose of a compound of this invention or a pharmaceutical composition thereof. In addition, this invention relates to a method of lowering the levels of IL-6 and/or IL-8 in a mammal in need thereof which comprises administering an effective dose of a compound of this invention or a pharmaceutical composition thereof.
Accordingly, the compounds of this invention or a pharmaceutical composition thereof are useful in the treatment or prophylaxis of a number of disease states including rheumatoid arthritis; Pagets disease; osteophorosis ; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; pancreatic β cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; asthma; muscle degeneration; cachexia; Reiter's syndrome; type I and type II diabetes; bone resorption diseases; graft vs. host reaction; ischemia reperfusion injury; atherosclerosis; brain trauma; Alzheimer's disease; stroke; myocardial infarction; multiple sclerosis; cerebral malaria; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection. HIV-1,
HIV- 2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses (including HSV-1, HSV-2), and herpes zoster, all of which are sensitive to TNF-α and/or IL-1 inhibition or glucagon antagonism, will also be positively effected by the compounds and methods of the invention.
The compounds of the present invention also may possess analgesic properties and may be useful for the treatment of pain disorders, such as hyperalgesia due to excessive IL-1. The compounds of the present invention may also prevent the production of prostaglandins by inhibition of enzymes in the human arachidonic acid/prostaglandin pathway, including cyclooxygenase (WO 96/03387, incorporated herein by reference in its entirety) .
Because of their ability to lower TNF-α and IL-1 concentrations or inhibit glucagon binding to its receptor, the compounds of the invention are also useful research tools for studying the physiology associated with blocking these effects.
In another aspect, this invention comprises the use of a compound of the invention, or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment either acutely or chronically of a TNF-α, IL-lβ, IL-6, and/or IL-8 mediated disease state, including those described previously.
In still another aspect, this invention provides a pharmaceutical composition comprising an effective TNF- α, IL-lβ, IL-6, and/or IL-8 lowering amount and/or effective plasma glucose level lowering amount of a compound of the invention and a pharmaceutically acceptable carrier or diluent, and if desired other active ingredients. The compounds of the invention are administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds of the present invention required to arrest the progress or prevent tissue damage associated with the disease are readily ascertained by one of ordinary skill in the art using standard methods. -
For the treatment of TNF-α, IL-lβ, IL-6, and IL-8 mediated diseases and/or hyperglycemia, the compounds of the present invention may be administered orally, parentally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal , infusion techniques or intraperitoneally .
For the prophylaxis and treatment of disease states, the compounds of the present invention may be administered orally, parentally, or by inhalation spray, rectally, or topically in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneally.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
The dosage regimen for treating a disease state with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex and medical condition of the patient, the severity of the condition, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to 80 mg per kilogram of body weight per day, preferably from about 0.5 mg to 30 mg/kg, more preferably from about 1 mg to 15 mg/kg are useful for all methods of use disclosed herein. The pharmaceutically active compounds of this invention can be processed in accordance with convential methods of pharmacy to produce medicinal agents for administration to patients, mammals including humans. For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 250 mg, preferably from about 25 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors .
The compounds of this invention may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen wll be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.5 to about 30 mg/kg, and more preferably from about 1 mg to 15 mg/kg.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 , 3 -butanediol . Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides . In addition, fatty acids such as oleic acid find use in the preparation of injectables. Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug. A suitable topical dose of compounds of this invention is 0.1 mg to 150 mg administered one to four, preferably two or three times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation. Formulations suitable for topical administration include liquid or semi -liquid peparations suitable for penetration through the skin such as liniments, lotions, ointments, creams, or pastes and drops suitable for administration to the eye, ear, or nose.
For administration, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the compounds of this invention may be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, benzyl alcohol, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art. The pharmaceutical compositions may be made up in a solid form including granules, powders or suppositories or in a liquid form such as solutions, suspensions, or emulsions. The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings. Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.
Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or non- racemic mixtures thereof.
The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of this invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of this invention can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2 -hydroxy- ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2 -naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3 -phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen - containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl , and diamyl sulfates, long chain halides such as decyl , lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil -soluble or dispersible products are thereby obtained.
Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.
While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.
The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula
Figure imgf000173_0001
or a pharmacutically acceptable salt thereof, wherein
Xl is N, CH or CRi ; X2 is N, CH or CR2 ; X3 is N, CH or CR3 ; and X4 is N, CH or CR4 ; provided that at least one of ∑ι , X2 , X3 and X4 is N or CH, and that not more than two of Xi, X2 , X3 and X4 are N;
wherein Ri , R2 , R3 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri , R2 , R and R4 is 0-4;
wherein each Z is independently a
(1) bond;
(2) alkyl, alkenyl or alkynyl radical optionally substituted by (a) 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano or halo, and (b) 1-2 radicals of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl;
(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl ;
each Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo, cyano or nitro radical;
(3) -C(O)-R20, -C(0)-OR2ι, -C(0)-NR5R2ι or -C (NR5 ) -NR5R2ι radical ; (4) -OR21, -0-C(0)-R2ι, -O-C(O) -NR5R21 or -0-C (0) -NR22 - S(O)2-R20 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20, -S(0)2-NR5R2ι, -S(0)2- NR22-C(0) -R2i, -S(0)2-NR22-C(0) -OR20 or - S (0) 2 -NR22 -C (0) - NR5R21 radical; or (6) -NR5R21, -NR22-C(0) -R2i, -NR22-C(0) -OR20/ -NR22-C(0)- NR5R21, -NR22-C(NR5) -NR5R2ι, -NR22 - S (0) 2 - R20 or -NR22- S(0)2-NR5R2ι radical;
wherein each R5 is independently (1) hydrogen radicals;
(2) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano or halo; or (3) aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, heterocyclylalkyl , cycloalkyl or cycloalkylalkyl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
wherein each R20 is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -C0 R23, amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, N- (alkoxycarbonyl) -N- (alkyl) amino, aminocarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo or aralkoxy, aralkylthio, aralkylsulfonyl , cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkanoyl, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, cyano, halo, azido, alkyl or haloalkyl;
each R2ι is independently hydrogen radical or R2o;
each R22 s independently
(1) hydrogen radical;
(2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; or (3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; and
each R23 is independently hydrogen or alkyl, or aryl, heteroaryl, aralkyl or heteroaralkyl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl; and
RiO is a hydrogen, R30, -C(0)-R29, -C(0)-OR3o, -C(O)- NR31R32 -S(O)2" 30 or -S (0) 2"NR3ιR32 radical;
Ru and R12 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of
(1) R30;
(2) halo or cyano radicals; (3) -C(O)-R30, -C(0)-OR29, -C (0) -NR3iR32 or -C(NR3i)- NR3 R 2 radicals;
(4) -OR29, -0-C(0)-R2g, -0-C(0) -NR31R32 or -O-C (0) -NR33 - S(O)2"R30 radicals;
(5) -SR29, -S(O)-R30, -S(O)2-R30» -S(0)2-NR3ιR32, -S(0) - NR33-C(0) -R30, -S(0)2-NR33-C(0) -OR30 or - S (0) 2 -NR33 -C (0) -
NR31R32 radicals; or
(6) -NR3ιR32, -NR33-C(0) -R29, -NR33 -C (0) -OR30 - -NR33-C(0)- R31R32 -NR33-C(NR3i) -NR3]R32, -NR33 - S (0) 2 -R30 or -NR33-
S (0) 2"NR31R3 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Ru and R12 is 0-1;
wherein each R3o is independently (1) alkyl, alkenyl or alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, -C02R23/ hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo or aralkoxy, aralkyl thio, aralkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, alkylsulfinyl , alkylsulfonyl , cyano, halo, alkyl or haloalkyl;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, halo, alkyl or haloalkyl ;
each R29 is independently hydrogen radical or R30;
each R3ι and R32 are each independently
(1) hydrogen radicals;
(2) alkyl radical optionally substituted by an cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; or
(3) aryl, heteroaryl, heterocyclyl or cycloalkyl radical optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
wherein each R33 is independently (1) hydrogen radical; or (2) alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, alkylamino, dialkylamino, alkanoylamino, alkoxycarbonylamino, alkylsulfonylamino, hydroxy, alkoxy, alkylthio, cyano, alkyl or haloalkyl; and
provided that when each of Xi, X2 , X3 and X4 represent carbon atoms, then Ru is a substituted aryl radical and R12 is heteroaryl radical, or Rχι is a heteroaryl radical and R12 is a substituted aryl radical.
2. The compound of Claim 1 or a pharmaceutically acceptable salt thereof, wherein
Xi is N, CH or CRi; X2 is N, CH or CR2 ; X3 is N, CH or CR3 ; and X4 is N, CH or CR4 ; provided that at least one of Xi , X2 , X3 and X4 is N or CH, and that not more than two of Xi, X2/ X3 and X4 are N;
wherein Ri , R2 , R and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Ri , R2 , R3 and R4 is 0-4;
each Z is independently a
(1) bond;
(2) C1-C8 alkyl, C2-Cs alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Ci- C4 haloalkyl of 1-3 halo radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each Y is independently a (1) hydrogen radical, provided Z is other than a bond;
(2) halo, cyano or nitro radical;
(3) -C(O)-R20, -C(0)-OR2ι, -C(O) -NR5R21 or -C(NR5) -NR5R21 radical ;
(4) -OR21, -0-C(0)-R2ι, -O-C(O) -NR5R21 or -O-C (0) -NR22 " S(O)2-R20 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20. -S(0)2-NR5R2ι, -S(0)2- NR22-C(0) -R2i, -S(0)2-NR22-C(0) -OR20 or - S (0) 2 -NR2 -C (0) - NR5R21 radical; or
(6) - R5R21, -NR22-C(0) -R2i, -NR22-C(0) -OR20, -NR22-C(0)- NR5R21, -NR22-C(NR5) -NR5R21, -NR22-S (0) 2-R20 or -NR22"
S(0)2-NR5R21 radical;
each R5 is independently
(1) hydrogen radicals; (2) Ci-Cs alkyl, C2-C8 alkenyl or C2-Cs alkynyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di - (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano or halo; or (3) aryl, heteroaryl, aryl -C1-C4 -alkyl , heteroaryl -Ci - C4- alkyl, heterocyclyl, heterocyclyl -Ci -C4 -alkyl , C3-Cβ cycloalkyl or C3 -Cs -cycloalkyl -Ci -C4 -alkyl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (Ci -C4 -alkyl) amino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R2o s independently
(1) Ci-Cβ alkyl, C2-C8 alkenyl or C2-C8 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, N-((Cι-C4 alkoxy) carbonyl) -N- (C1-C4 alkyl) amino, aminocarbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo or aryl -Ci -C4- alkoxy, aryl - Cι-C -alkylthio, aryl -Ci -C -alkylsulfonyl , C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl)amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, C1-C5 alkanoyl, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, (C1-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di- (C1-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, Cι-C4 alkylsulfonylamino , (C1.-C4 alkoxy) carbonyl , hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, azido, C1-C4 alkyl or C1-C4 haloalkyl of 1- 3 halo radicals;
each R21 is independently hydrogen radical or R20;
each R22 is independently (1) hydrogen radical;
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulf inyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(3) heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R23 is independently hydrogen or C1-C4 alkyl, or aryl, heteroaryl, aryl -C1-C4 -alkyl or heteroaryl -Ci -C4 - alkyl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; Rio is a hydrogen, R30, -C(0)-R29, -C(O)-OR30/ -C(O)- NR3ιR32, -S(O)2-R30 or - S (0) 2 -NR31R32 radical;
Ru and Rχ2 are each independently an aryl or heteroaryl radical optionally substituted by 1-3 radicals of
(1) R30;
(2) halo or cyano radicals;
(3) -C(0)-R3o- -C(0)-OR29» -C(0) -NR3ιR32 or -C(NR3i)- NR31R32 radicals; (4) -OR29, -0-C(0)-R29, -O-C(O) -NR3ιR32 or -O-C (0) -NR33 -
S(0)2'R3o radicals;
(5) -SR29, -S(O)-R30, -S(O)2-R30» -S(0)2-NR3ιR32, "S(0)2-
NR33-C(0) -R30, -S (0)2-NR33-C(0) -OR30 or - S (0) 2 -NR33 -C (0) -
NR3ιR 2 radicals; or (6) -NR31R32, -NR33-C(0) -R29, -NR33 -C (0) -OR30 , -NR33-C(0)-
NR3iR32, -NR33-C(NR3ι) -NR31R32, - NR33 - S (0) 2 - R30 or - NR33 -
S (0) 2-NR31R32 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Ru and R12 is 0-1;
each R30 is independently
(1) C1-C4 alkyl, C2-C4 alkenyl or C2-C4 alkynyl radicals optionally substituted by 1-3 radicals of -NR31R31, - CO2R23 hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C1-C4 alkylsulf inyl , C1-C4 alkylsulfonyl , cyano, halo or aryl - Cχ-C4-alkoxy, aryl -Ci -C4 -alkylthio, aryl-Cι-C4- alkylsulfonyl , heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C -C4 alkylthio, C1-C4 alkylsulfinyl , C1-C4 alkylsulfonyl , cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C— C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, halo, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals;
each R29 is independently hydrogen radical or R3Q;
each R31 and R32 are each independently
(1) hydrogen radicals; (2) C1-C4 alkyl radical optionally substituted by an C3- Cδ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C8 cycloalkyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and
each R33 is independently
(1) hydrogen radical; or
(2) C1-C4 alkyl radical optionally substituted by a radical of heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cι-C4 alkyl) amino, C1-C5 alkanoylamino, (C1-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, cyano, C1-C4 alkyl or Cχ~ C4 haloalkyl of 1-3 halo radicals; and
wherein heterocyclyl is a radical of a monocyclic or bicyclic saturated heterocyclic ring system having 5-8 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally partially unsaturated or benzo- fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic or bicyclic aromatic heterocyclic ring system having 5-6 ring members per ring, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo -fused or saturated C3 -C4 -carbocyclic- fused.
3. The compound of Claim 2 or a pharmaceutically acceptable salt thereof, wherein
each Z is independently a
(1) bond;
(2) Ci-Cs alkyl, C2-C8 alkenyl or C2-C8 alkynyl radical optionally substituted by 1-3 radicals of amino, C1-C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, C -C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, C -C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or C -C4 haloalkyl of 1-3 halo radicals;
each R5 is independently
(1) hydrogen radicals;
(2) Cχ-C4 alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di - (Cχ-C4 -alkyl) amino, hydroxy, C -C4 alkoxy, C -C4 alkylthio or halo; or
(3) aryl, heteroaryl, aryl -Cx -C4 -alkyl , heteroaryl -Cx - C4-alkyl, heterocyclyl, heterocyclyl -Cx -C4 -alkyl , C3-Cβ cycloalkyl or C3 -Cs -cycloalkyl -Cx -C4 -alkyl radicals optionally substituted by 1 - 3 radicals of amino, Cχ-C4 alkylamino, di- (C -C4 -alkyl) amino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals;
each R2o is independently (1) Cχ-Cs alkyl, C2-C5 alkenyl or C2-C5 alkynyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (Cχ-C4 alkyDamino, aminocarbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy,
Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl , halo or aryl -Cχ-C4 -alkoxy, aryl-Cχ-C4- alkylthio, aryl -Cx -C4 -alkylsulfonyl , C3-C8 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, Cχ-Cs alkanoyl, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C alkylsulfonyl , cyano, halo, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals; (2) heterocyclyl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, C -C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals;
each R2χ is independently hydrogen radical or R20;
each R3o is independently
(1) Cχ-C4 alkyl radical optionally substituted by 1-3 radicals of (a) -NR31R31; (b) C -C4 alkoxy- carbonyl or phenoxycarbonyl or phenylmethoxycarbonyl optionally substituted by 1-3 radicals of amino, alkylamino, di - (Cx -C4 -alkyl) amino, Cχ-C5 alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl; or
(c) hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, or phenyl -Ci- C4-alkoxy, phenyl -Cx -C4 -alkylthio, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C haloalkyl of 1-3 halo radicals;
(2) Cχ-C haloalkyl of 1-3 halo radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R3o;
each R3χ is independently
(1) hydrogen radicals; or (2) Cχ-C4 alkyl radical optionally substituted by an phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, Cχ-C4 alkyl or trifluoromethyl radicals; and
each R32 is independently
(1) hydrogen radicals; (2) Cχ-C4 alkyl radical optionally substituted by an C3- Cβ cycloalkyl, aryl, heterocyclyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, Cχ-C4 alkyl or Cχ-C4 haloalkyl of 1-3 halo radicals; or (3) aryl, heteroaryl, heterocyclyl or C3-C6 cycloalkyl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, C1-C4 alkyl or C1-C4 haloalkyl of 1-3 halo radicals; and
each R33 is independently hydrogen or C -C4 alkyl radical .
4. The compound of Claim 3 or a pharmaceutically acceptable salt thereof, wherein
Rx , R2 , R3 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Rx , R2 , R3 and R4 is 0-3;
each Z is independently a (1) bond;
(2) Cχ-Cδ alkyl or C2-C8 alkenyl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, C -C4 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C4 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl radicals; or (4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, C1-C4 alkylsulfonylamino, hydroxy, C1-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, C1-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
each Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(0)-R2o, -C(0)-OR2χ, -C(0)-NR5R2χ or -C (NR5) -NR5R21 radical ; (4) -OR21, -0-C(0)-R21 or -O-C (0) -NR5R21 radical;
(5) -SR21, -S(O)-R20, -S(O)2-R20 or - S (0) 2 -NR5R21 radical; or
(6) -NR5R2χ, -NR22-C(0) -R21, -NR22-C(0) -OR20, -NR22-C(0)- NR5R χ, -NR22-C(NR5) -NR5R2χ, -NR22 - S (0) 2 - 20 or -NR22" S(0) -NR5R2χ radical;
each R5 is independently
(1) hydrogen radicals;
(2) Cχ-C4 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of amino, di-(Cχ-C4- alkyl) amino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or halo; or
(3) phenyl -Cx -C2 -alkyl , heteroaryl -Cx -C2 -alkyl , heterocyclyl -Cχ-C2 -alkyl or C3 -Cg -cycloalkyl -C -C2 - alkyl radicals optionally substituted by 1-3 radicals of amino, di - (C -C4 -alkyl) amino, hydroxy, Cχ-C4 alkoxy, Cχ~ C4 alkylthio, cyano, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1- 3 halo radicals;
each R2o is independently
(1) Cχ-Cs alkyl or C2-Cs alkenyl radicals optionally substituted by 1-3 radicals of -C02R23, amino, C -C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-C5 alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) - N-(Cχ-C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , C -C4 alkylsulfonyl , halo or aryl -Cx -C4 -alkoxy, aryl-Cχ-C4- alkylthio, aryl -Cx -C4 - lkylsulfonyl , C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, Cχ-Cs alkanoyl, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy,
Cχ-C4 alkoxy, Cχ-C alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1- 3 halo radicals;
each R2X is independently hydrogen radical or R2o;
each R22 is independently (1) hydrogen radical; or
(2) Cχ-C4 alkyl radical optionally substituted by a radical of phenyl or heteroaryl optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
each R23 is independently hydrogen or C -C4 alkyl, or phenyl, heteroaryl, phenyl -Cx -C2 -alkyl or heteroaryl ~Cχ - C2-alkyl optionally substituted by 1-3 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, C1-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
Rχo is a hydrogen, R30, -C(0)-R29, -C (0) -NR31R32 , -S(0)2- R3o or -S (0) 2"NR3χR32 radical;
Rxx and Rχ2 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (D R3o; (2) halo or cyano radicals;
(3) -C(O)-R30, -C(0)-OR29, -C(0) -NR3χR32 or -C(NR3χ)- NR3XR32 radicals; or
(4) -OR29, -SR29- -S(O)-R30, -S(O)2-R30/ -S(0)2-NR3ιR32, -NR31R32, -NR33-C (0) -R29 or -NR33-C (0) -OR30 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rx and Rχ2 is 0-1;
each R30 is independently (1) Cχ-C4 alkyl radical optionally substituted by
(a) amino, Cχ-C4 alkylamino or di - (Cx -C4 -alkyl) amino radicals; or
(b) hydroxy, Cχ-C4 alkoxy, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals; (2) Cχ-C2 haloalkyl of 1-3 halo radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals; each R29 is independently hydrogen radical or R3o;
each R3χ is independently hydrogen or Cχ-C4 alkyl radicals; and
each R32 is independently
(1) hydrogen radicals;
(2) Cχ-C4 alkyl radical optionally substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, C -C4 alkoxy, Cχ-C4 alkyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkyl or trifluoromethyl radicals; and
each R33 is independently hydrogen or methyl radical; and
wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo -fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-3 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo- fused or saturated C3 -C4 - carbocyclic- fused.
5. The compound of Claim 4 or a pharmaceutically acceptable salt thereof, wherein each Z is independently a
(1) bond;
(2) Cχ-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or heterocyclyl, aryl or heteroaryl optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C2 alkyDamino, Cχ-Cs alkanoylamino,
(Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals ;
(3) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio or Cχ-C4 alkyl radicals; or
(4) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, Cχ-Cs alkanoylamino, (C -C4 alkoxy) carbonylamino, hydroxy, Cχ~ C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently (1) hydrogen radical;
(2) Cχ-C4 alkyl radical optionally substituted by 1-3 radicals of amino, di - (C -C2 -alkyl) amino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio or halo; or
(3) phenyl -Cχ-C2- alkyl, heteroaryl -Cχ-C2 -alkyl , heterocyclyl -Cχ-C2- alkyl or C3 -Cg - cycloalkyl -Cχ-C2 -alkyl radicals optionally substituted by 1-3 radicals of amino, di- (Cχ-C2 -alkyl) amino, hydroxy, Cχ-C2 alkoxy, Cχ~ C2 alkylthio, methoxy, methylthio, cyano, Cχ-C4 alkyl or trifluoromethyl radicals;
each R22 is independently hydrogen or Cχ-C4 alkyl radical; each R23 is independently hydrogen or C1-C4 alkyl, or phenyl, heteroaryl, phenyl -Cx -C2 -alkyl or heteroaryl -Cx - C2 -alkyl optionally substituted by 1 - 3 radicals of amino, di-(Cχ-C alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
Rxx and Rχ2 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (D R3o;
(2) halo or cyano radicals;
(3) -C(O)-R30, -C(0)-OR2g, -C(0) -NR3χR32 or -C(NR3χ)- R3XR32 radicals; or
(4) -0R2 , -SR29, -S(O)-R30, -S(O)2-R30, -S(0)2- R3iR32, -NR31R32 or -NR33-C (0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rx and R1 is 0-1;
each R3o is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, acetamido, hydroxy, Cχ-C2 alkoxy, halo, C1-C4 alkyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, di-(Cχ-C alkyDamino, acetamido, hydroxy, Cχ-C2 alkoxy, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R3o; and
each R32 is independently (1) hydrogen radicals; (2) C1-C4 alkyl radical or Cχ-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, acetamido, hydroxy, Cχ-C2 alkoxy, Cχ-C4 alkyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, acetamido, hydroxy, Cχ-C2 alkoxy, Cχ-C4 alkyl or trifluoromethyl radicals; and
wherein heterocyclyl is a radical of a monocyclic saturated heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo- fused and optionally substituted by 1-2 oxo or thioxo radicals; aryl is a phenyl or naphthyl radical; and heteroaryl is radical of a monocyclic aromatic heterocyclic ring system having 5-6 ring members, wherein 1-2 ring members are oxygen, sulfur or nitrogen heteroatoms, which is optionally benzo -fused.
6. The compound of Claim 5 or a pharmaceutically acceptable salt thereof, wherein
each Z is independently a
(1) bond;
(2) Cχ-C4 alkyl or C2-C5 alkenyl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, C -C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of amino, di-(Cχ- C alkyl) amino, acetamido, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ> C4 alkyl or trifluoromethyl radicals; or
(3) aryl or heteroaryl radical optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, acetamido, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals ;
each Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20, -C(0)-OR2χ or -C(0)-NR5R21 radical;
(4) -0R21, -SR2χ, -S(O)-R20, -S(O)2-R20 θr - S (0) 2 -NR5R2χ radical; or
(5) -NR5R21, -NR22-C(0) -R2χ, -NR22-C(0) -OR20, -NR22-C(0)- NR5R2χ, -NR22-S(O)2-R20 or -NR22 - S (0) 2 -NR5R21 radical;
each R5 is independently (1) hydrogen radical;
(2) Cχ-C4 alkyl radical optionally substituted by 1-3 halo radicals; or
(3) phenyl -Cχ-C - alkyl or heteroaryl -Cx -C2 -alkyl , radicals optionally substituted by 1-3 radicals of amino, dimethylamino, hydroxy, methoxy, methylthio, methyl or trifluoromethyl radicals;
each R2o is independently
(1) Cχ-C8 alkyl or C2-C5 alkenyl radicals optionally substituted by 1-3 radicals of -C02R 3, amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) - N- (C -C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl, halo or aryl -Cx -C4 -alkoxy, aryl-Cχ-C4- alkylthio, aryl -C -C4 -alkylsulfonyl , C3-C cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, Cχ-Cs alkanoyl, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or Cχ-C2 haloalkyl of 1-3 halo radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C4 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, C -C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, di-(Cχ-C4 alkyDamino, acetamido, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2X is independently hydrogen radical or R20?
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2 -alkyl or heteroaryl -Cx -C2 -alkyl optionally substituted by 1-3 radicals of amino, di-(Cχ-C2 alkyDamino, acetamido, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ~
C4 alkyl or trifluoromethyl radicals;
Rxx and Rχ2 are each independently an aryl or heteroaryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -0R2 , -SR29, -S(O)-R30, -S(0)2-R3o, " S (0)2'NR31R32, -NR31R 2 or -NR33 -C (0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and Rχ2 is 0-1;
each R3o is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
each R29 is independently hydrogen radical or R3rj;
each R31 is independently hydrogen, methyl or ethyl radicals; and
each R32 is independently (1) hydrogen radicals;
(2) Cχ-C4 alkyl radical or Cχ-C2 alkyl radical substituted by phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals; or
(3) phenyl or heteroaryl radical optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
7. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xi is N; X2 is CH or CR2 ; X3 is CH or CR3 ; and X is CH or CR ;
wherein R2 , R3 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 , R3 and R is 0-3.
8. The compound of Claim 7 or a pharmaceutically acceptable salt thereof, wherein
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-OR2χ, -C (0) -NR5R2χ , - S(O)2"R20 or -S (0) 2-NR5R χ radicals; and
R2 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 , R3 and R4 is 0-3.
9. The compound of Claim 8 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X2 is CR2 ; X3 is CH or CR3 ; and X4 is CH; and
wherein R2 is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 is 0-3;
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals; Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of
(D R30;
(2) halo or cyano radicals; or (3) -C(0) -NR31R32, -OR29, -SR29, -NR31R32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -OR29, -SR29- -S(O)-R30, -S(O)2-R30» " S (0) 2-NR XR32, - R3 R3 or -NR33 - C (0) - R 9 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and Rχ2 is 0-1.
10. The compound of Claim 9 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C4 alkyl radical;
each R20 is independently
(1) Cχ-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, C -C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (C - C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, C -C4 alkylsulfinyl , C -C4 alkylsulfonyl , halo or C3-C6 cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, C -C4 alkylthio or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Ci- C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R2o;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2 -alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
Rχθ is a hydrogen, R30, -C(0)-R2g or -C (0) -NR31R 2 radical;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals;
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals ;
R3o is independently (1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; (2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
R3χ is independently hydrogen, methyl or ethyl radicals; and
R32 is independently (1) hydrogen or Cχ-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
11. The compound of Claim 10 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a (1) bond; or (2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20, -C(0)-OR2χ or -C(0)-NR5R2χ radical;
(4) -OR2χ, -SR2χ, -S(O)-R20/ -S(O) "R20 or - S (0) 2 -NR5R21 radical; or
(5) -NR5R2χ, -NR22-C(0) -R2χ, -NR2 - S (0) 2 "R20 or -NR22- S(0)2-NR5R2χ radical;
R5 is a hydrogen radical;
each R20 is independently
(1) Cx-Cς alkyl radicals optionally substituted by 1-3 radicals of -Cθ2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R o;
each R22 is independently hydrogen or methyl radical; each R23 is independently hydrogen or Cχ-C4 alkyl radicals ;
Rχo is a hydrogen or methyl radical;
R is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and
Rχ is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
12. The compound of Claim 11 or a pharmaceutically acceptable salt thereof, wherein
R2 is independently Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 is 0-3;
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido or N,N- dimethylamido radicals; and
Y is independently a
(1) halo radical;
(2) -C(O)-R20 or -C(0)-NR5R21 radical;
(3) -OR χ, -SR2 or -S(0)-R2o radical; or (4) -NR5R21, -NR22-C(0) -R2χ, -NR22 " S (0) 2 -R20 or -NR22' S(0) -NR5R21 radical.
13. The compound of Claim 12 or a pharmaceutically acceptable salt thereof, wherein
R3 is halo or trifluoromethyl radicals;
Y is independently a halo, - R5R21, -NR 2 -C (0) -R21 or - NR22-S(O)2-R20 radical;
each R20 s independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -CO2R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or Cs-C cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by t- butoxycarbonyl ; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, halo, azido, methyl or trifluoromethyl radicals;
each R2X is independently hydrogen radical or R20;
Rxx is a 4-pyridyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and
Rχ2 is an unsubstituted phenyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfonyl , methyl or trifluoromethyl radicals .
14. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X2 is CH or CR2 ; X3 is CH or CR3 ; and X4 is N;
wherein R2 and R3 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R3 is 0-3.
15. The compound of Claim 14 or a pharmaceutically acceptable salt thereof, wherein
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20/ -C(0)-OR2ι, -C (0) -NR5R2χ , S(0)2-R2Q or -S (0) 2-NR5R2X radicals;
R2 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R3 is 0-3;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of
(D R30; (2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -OR29, -SR29, -NR3χR32 or -NR33-C(0)- R2g radicals; and Rχ2 is an aryl radical optionally substituted by 1-2 radicals of (D R30; (2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -OR29, - SR29 , -S(O)-R30, -S(O)2-R30, - S (0) 2-NR3χR32, -NR31R32 or -NR33 -C (0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and R12 is 0-1.
16. The compound of Claim 15 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X is CR2 ; X3 is CH or CR3 ; and X4 is N; and
wherein R2 is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 is 0-3;
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
Z is independently a (1) bond; or (2) C -C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, 1 - C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals; each R5 is independently hydrogen or Cχ-C4 alkyl radical ;
each R2o is independently (1) Cχ-Cδ alkyl radicals optionally substituted by 1-3 radicals of -C02R 3, amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (Cx - C4 alkyDamino, aminocarbonylamino, hydroxy, C -C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl , halo or C3-C cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (C -C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Ci- C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R χ is independently hydrogen radical or R2o;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2- alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, C -C2 alkylthio, cyano, halo, C -C4 alkyl or trifluoromethyl radicals;
Rχo is a hydrogen, R30, -C(0)-R29 or -C (0) -NR3χR32 radical ;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals ;
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals;
R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R32 is independently
(1) hydrogen or C -C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
17. The compound of Claim 16 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20 -C(0)-OR2χ or -C(0)-NR5R2χ radical; (4) -0R2χ, -SR2χ, -S(O)-R20, -S(0)2-R20 θr - S (0) 2 -NR5R2χ radical; or (5) -NR5R2χ, -NR2 -C(0) -R2χ, -NR22 - S (0) 2 - R20 or -NR22- S(0) -NR5R21 radical;
R5 is a hydrogen radical;
each R2o is independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -C02R 3, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or Cs-Cg cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R2o;
each R is independently hydrogen or methyl radical;
each R23 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical;
Rxx is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; Rχ is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
18. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X2 is CH or CR2 ; X3 is N; and X4 is CH or CR ;
wherein R2 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R4 is 0-3.
19. The compound of Claim 18 or a pharmaceutically acceptable salt thereof, wherein
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-OR2χ, -C (0) -NR5R21 , S(O)2-R20 or -S (0) 2-NR5R2χ radicals;
R2 is -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R4 is 0-3; Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of
(1) R30;
(2) halo or cyano radicals; or (3) -C(O) -NR31R32, -OR29, -SR29, -NR3χR32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of (1) R30;
(2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -OR29, -SR29, -S(0)-R3o, "S(O)2-R30, - S (0) 2-NR31R32, -NR3XR32 or -NR33 -C (0) - R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and R 2 is 0-1.
20. The compound of Claim 19 or a pharmaceutically acceptable salt thereof, wherein
X is N; X is CR2; X3 is N; and X is CH or CR ;
wherein R2 is -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 is 0-3;
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
Z is independently a (1) bond; or (2) C -C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C4 alkyl radical;
each R20 is independently
(1) Cχ-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (C - C4 alkyl) amino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, C -C4 alkylsulfinyl , C -C4 alkylsulfonyl , halo or C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (C -C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, C -C4 alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (C -C4 alkoxy) carbonyl , hydroxy, Cχ~
C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2X is independently hydrogen radical or R20
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2 -alkyl optionally substituted by 1-2 radicals of hydroxy, C -C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
Rχo is a hydrogen, R30, -C(0)-R29 or -C (0) -NR31R32 radical;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals;
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals;
R30 is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
R2g is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R 2 is independently
(1) hydrogen or Cχ-C4 alkyl radical; or (2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
21. The compound of Claim 20 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a (1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20/ -C(0)-OR2χ or -C(0)-NR5R2χ radical;
(4) -OR2χ, -SR21, -S(O)-R20, -S(O)2-R20 or - S (0) 2 -NR5R2χ radical; or
(5) -NR5R2χ, -NR22-C(0) -R21, -NR22-S(O)2-R20 or -NR2 " S(0)2-NR5R2χ radical;
R5 is a hydrogen radical;
each R20 is independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl, halo or Cs-C cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals; (2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;
each R23 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical;
Rxx is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and
Rχ2 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
22. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X2 is N; X3 is CH or CR3 ; and X4 is CH or CR ;
wherein R3 and R4 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R is 0 - 3.
23. The compound of Claim 22 or a pharmaceutically acceptable salt thereof, wherein
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20, -C(0)-OR2χ, -C (0) -NR5R2χ , - S(0)2-R2o or -S (0)2-NR5R2χ radicals;
R3 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each
-Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R3 and R4 is 0 - 3 ;
Rx is a heteroaryl radical optionally substituted by 1- 2 radicals of
(1) R30;
(2) halo or cyano radicals; or
(3) -C(O) -NR31R32, -OR29, -SR29, -NR31R32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of
(1) R30; (2) halo or cyano radicals; or
(3) -C(0) -NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30. "
S (0) - R3χR32, -NR3XR32 or -NR33-C(0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rx and Rχ2 is 0-1.
24. The compound of Claim 23 or a pharmaceutically acceptable salt thereof, wherein
Xx is N; X2 is N; X3 is CR3 ; and X is CH or CR4 ;
wherein R3 is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R3 is 0-3;
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C4 alkyl radical;
each R20 is independently (1) Cχ-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N- ( (Cχ-C4 alkoxy) carbonyl) -N- (Cχ~ C4 alkyl) amino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl , halo or C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1 - 2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~
C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R2o;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2 -alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
Rχo is a hydrogen, R3o, -C(0)-R2g or -C (0) -NR31R3 radical ;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals;
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl, methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals;
R3o is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
R 9 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R32 is independently
(1) hydrogen or Cχ-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
25. The compound of Claim 24 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) C -C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20, -C(0)-OR2χ or -C(0)-NR5R21 radical; (4) -OR2χ, -SR2χ, -S(O)-R20, -S(0)2-R20 or - S (0) 2 -NR5R2χ radical; or (5) -NR5R2χ, -NR22-C(0) -R21, -NR22 - S (0) 2 - R2o or -NR22" S(0)2-NR5R2χ radical;
R5 is a hydrogen radical;
each R20 is independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -CO2R23- amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or Cs-C cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2X is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;
each R23 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical;
Rxx is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; Rχ2 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
26. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH or CRx; X2 is CH or CR2 ; X3 is N; and X4 is N;
wherein Rx and R2 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Rx and R2 is 0-3.
27. The compound of Claim 26 or a pharmaceutically acceptable salt thereof, wherein
Rx is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(O)-R20/ -C(0)-OR2χ, -C (0) -NR5R2X , -S(O)2"R20 or -S (0) 2-NR5R2X radicals;
R is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Rx and R2 is 0 - 3 ;
Rxx is a heteroaryl radical optionally substituted by 1 2 radicals of ( D R30 ;
(2) halo or cyano radicals; or
(3) -C(0) -NR31R32, -OR29, -SR29, "NR3χR32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of (D R30;
(2) halo or cyano radicals; or (3) -C(O) -NR3χR32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, - S (0) 2-NR31R3 , -NR31R32 or -NR33 -C (0) -R2g radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and Rχ is 0-1.
28. The compound of Claim 27 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH or CRx ; X2 is CR2 ; X3 is N; and X4 is N;
wherein Rx is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
R2 is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 is 0-3;
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C4 alkyl radical ;
each R2o is independently
(1) Cχ-Cs alkyl radicals optionally substituted by 1-3 radicals of -C0 R23, amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyl) amino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (Cx - C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl , halo or C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R o;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2- alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals; Rχθ is a hydrogen, R30, -C(0)-R29 or -C (0) -NR31R32 radical ;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals ;
R12 is an aryl radical optionally substituted by 1 - 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals ;
R2g is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R3 is independently
(1) hydrogen or Cχ-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
29. The compound of Claim 28 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a (1) hydrogen radical, provided Z is other than a bond; (2) halo radical;
(3) -C(O)-R20, -C(0)-OR21 or -C(0)-NR5R21 radical;
(4) -0R21, -SR2χ, -S(O)-R20, - S (O) 2 -R20 or - S (0) 2 -NR5R21 radical; or (5) -NR5R2χ, -NR22-C(0) -R2χ, -NR22 " S (0) 2 -R20 or -NR22- S(0)2-NR5R2χ radical;
R5 is a hydrogen radical;
each R20 is independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -CO2R23- amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl, halo or C5-C6 cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1 - 2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2 is independently hydrogen radical or R20''
each R22 is independently hydrogen or methyl radical;
each R23 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical; R x is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and
Rχ2 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
30. The compound of Claim 6 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH or CRx; X2 is CH or CR2 ; X3 is CH or CR3 ; and X4 is CH or CR4; provided that at least one of Xx, X2 , X3 and X4 is CH;
wherein Rx , R2 , R3 and R4 are each independently -Z-Y, provided that (1) R2 and R4 are not both substituted or unsubstituted amino radicals; (2) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (3) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in Rx , R2, R3 and R4 is 0-3.
31. The compound of Claim 30 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH; X2 is CH; X3 is CH or CR3 ; and X4 is CH or CR ;
wherein R3 and R4 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R4 is 0 - 3.
32. The compound of Claim 31 or a pharmaceutically acceptable salt thereof, wherein
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-OR2χ, -C (0) -NRsR2χ , - S(O)2-R20 or -S (0) 2-NR5R2χ radicals;
wherein R3 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R3 and R4 is 0-3;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of (D R30;
(2) halo or cyano radicals; or
(3) -C(0) -NR31R32, -OR29, -SR29, -NR3χR32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of
(D R3o;
(2) halo or cyano radicals; or (3) -C(O) -NR31R32, -OR29, -SR29, -S(O)-R30, -S(O)2-R30, - S (0) 2" R3 R32, -NR3 R32 or -NR33-C (0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of Rxx and Rχ2 is 0-1.
33. The compound of Claim 32 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH; X2 is CH; X3 is CR3 ; and X is CH or CR4 ;
wherein R3 is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R3 is 0-3;
R4 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C2 alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1 - 2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C4 alkyl radical ;
each R20 is independently (1) Cχ-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N- ( (Cχ-C4 alkoxy) carbonyl) -N- (Cχ~ C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulfinyl , Cχ-C4 alkylsulfonyl, halo or C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, C - C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or
(3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~
C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2 is independently hydrogen radical or R20;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -C -C2 -alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
Rχθ is a hydrogen, R30, -C(0)-R29 or -C (0) -NR31R32 radical;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals;
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl, aminocarbonyl, methyl or trifluoromethyl radicals;
R30 is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
(2) trifluoromethyl radical; or (3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals ;
R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R32 is independently
(1) hydrogen or Cχ-C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
34. The compound of Claim 33 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) C -C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(O)-R20/ -C(0)-0R2χ or -C(0)-NR5R2χ radical; (4) -OR2χ, -SR2χ, -S(O)-R20, -S(O)2-R20 θr - S (0) 2 -NR5R21 radical; or (5) -NR5R2χ, -NR2 -C(0) -R2χ, - NR22 - S (0) 2 " R20 or -NR22" S(0)2-NR5R2ι radical;
R5 is a hydrogen radical;
each R20 s independently
(1) Cχ-Cg alkyl radicals optionally substituted by 1-3 radicals of -Cθ2R23 amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or Cs-C cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R20;
each R22 is independently hydrogen or methyl radical;
each R 3 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical;
Rxx is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and Rχ2 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
35. The compound of Claim 30 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH; X2 is CH or CR2 ; X3 is CH or CR3 ; and X is CH;
wherein R2 and R3 are each independently -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0- 3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R3 is 0 - 3.
36. The compound of Claim 35 or a pharmaceutically acceptable salt thereof, wherein
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, -C(0)-R2o, -C(0)-0R2χ, -C (0) -NR5R2X , - S(O)2"R20 or -S (O) 2-NR5R2X radicals;
R2 is -Z-Y, provided that (1) the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in each -Z-Y is 0-3; and (2) the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R2 and R3 is 0-3;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of (D R30;
(2) halo or cyano radicals; or
(3) -C(0) -NR31R32, -OR29, -SR29, -NR31R32 or -NR33-C(0)- R29 radicals; and
Rχ2 is an aryl radical optionally substituted by 1-2 radicals of
(D R3o;
(2) halo or cyano radicals; or (3) -C(0) -NR3χR32, -0R29/ -SR29, -S(0)-R3o# -S(O)2-R30, " S (0) 2- R3XR32, -NR31R32 or -NR33 -C (0) -R29 radicals; provided that the total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals substituted on each of R x and Rχ2 is 0-1.
37. The compound of Claim 36 or a pharmaceutically acceptable salt thereof, wherein
Xx is CH; X2 is CR2; X is CH or CR3 ; and X4 is CH; and
wherein R is -Z-Y, provided that the combined total number of aryl, heteroaryl, cycloalkyl and heterocyclyl radicals in R is 0-3;
R3 is halo, trifluoromethyl, phenyl, methyl, hydroxymethyl, hydroxyethyl, dimethylamino, methoxy, trifluoromethoxy, acetyl, methoxycarbonyl, ethoxycarbonyl, amido, N, N-dimethylamido, methylsulfonyl or aminosulfonyl radicals;
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, di-(Cχ-C alkyDamino, (Cχ-C4 alkoxy) carbonylamino, hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, halo, or aryl or heteroaryl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
each R5 is independently hydrogen or Cχ-C alkyl radical;
each R20 is independently
(1) Cχ-C8 alkyl radicals optionally substituted by 1-3 radicals of -CO2R23 amino, Cχ-C4 alkylamino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, N-((Cχ-C4 alkoxy) carbonyl) -N- (Cx - C4 alkyDamino, aminocarbonylamino, hydroxy, Cχ-C4 alkoxy, Cχ-C4 alkylthio, Cχ-C4 alkylsulf inyl , Cχ-C4 alkylsulfonyl , halo or C3-Cg cycloalkyl, heterocyclyl, aryl or heteroaryl radicals optionally substituted by 1- 2 radicals of amino, di-(Cχ-C4 alkyDamino, Cχ-Cs alkanoylamino, (Cχ-C4 alkoxy) carbonylamino, Cχ-C4 alkylsulfonylamino, (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, C -C4 alkoxy, Cχ-C4 alkylthio or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of (Cχ-C4 alkoxy) carbonyl , hydroxy, Cχ~ C4 alkoxy, Cχ-C4 alkylthio, cyano, halo, azido, Cχ-C4 alkyl or trifluoromethyl radicals;
each R2χ is independently hydrogen radical or R20;
each R23 is independently hydrogen or Cχ-C4 alkyl, or phenyl -Cχ-C2 -alkyl optionally substituted by 1-2 radicals of hydroxy, Cχ-C2 alkoxy, Cχ-C2 alkylthio, cyano, halo, Cχ-C4 alkyl or trifluoromethyl radicals; Rχo is a hydrogen, R30, -C(0)-R2g or -C (0) -NR31R32 radical ;
Rxx is a heteroaryl radical optionally substituted by 1- 2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals ;
Rχ is an aryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals ;
R3o is independently
(1) Cχ-C4 alkyl radical optionally substituted by a phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
(2) trifluoromethyl radical; or
(3) aryl or heteroaryl radicals optionally substituted by 1-3 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals;
R29 is an aryl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, methoxy, methyl or trifluoromethyl radicals; and
R32 is independently
(1) hydrogen or C -C4 alkyl radical; or
(2) phenyl or heteroaryl radical optionally substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, methoxy, methyl or trifluoromethyl radicals.
38. The compound of Claim 37 or a pharmaceutically acceptable salt thereof, wherein
Z is independently a
(1) bond; or
(2) Cχ-C4 alkyl radical optionally substituted by 1-2 radicals of amino, t-butoxycarbonylamino, dimethylamino, hydroxy, methoxy, methylthio or halo radicals;
Y is independently a
(1) hydrogen radical, provided Z is other than a bond;
(2) halo radical;
(3) -C(0)-R2o, -C(0)-0R2χ or -C(0)-NR5R2χ radical; (4) -OR21, -SR2χ, -S(O)-R20, -S(O)2-R20 or - S (0) 2 -NR5R2χ radical; or
(5) -NR5R2χ, -NR2 -C(0) -R2χ, -NR22 - S (0) 2 -R20 or -NR22- S(0)2-NR5R21 radical;
R5 is a hydrogen radical;
each R2o is independently
(1) Cχ-C6 alkyl radicals optionally substituted by 1-3 radicals of -C02R23, amino, methylamino, dimethylamino, t-butoxycarbonylamino, N- ( (t-butoxy) carbonyl) -N- (methyl) amino, aminocarbonylamino, hydroxy, butoxy, methoxy, butylthio, methylthio, methylsulfinyl , methylsulfonyl , halo or Cs-Cg cycloalkyl, heterocyclyl, phenyl or heteroaryl radicals optionally substituted by 1-2 radicals of amino, dimethylamino, acetamino, hydroxy, methoxy, methylthio, halo, methyl or trifluoromethyl radicals;
(2) heterocyclyl radical optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, or Cχ-C4 alkyl; or (3) aryl or heteroaryl radicals optionally substituted by 1-2 radicals of t-butoxycarbonyl, hydroxy, methoxy, methylthio, cyano, halo, azido, methyl or trifluoromethyl radicals;
each R χ is independently hydrogen radical or R2o;
each R22 is independently hydrogen or methyl radical;
each R23 is independently hydrogen or Cχ-C4 alkyl radicals;
Rχo is a hydrogen or methyl radical;
Rxx is a 4-pyridyl, 4 -quinolinyl , 4-imidazolyl or 4- pyrimidinyl radical optionally substituted by a radical of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methyl or trifluoromethyl radicals; and
Rχ2 is an unsubstituted phenyl or naphthyl radical or a phenyl radical substituted by 1-2 radicals of amino, dimethylamino, acetamido, hydroxy, halo, cyano, methoxy, methylthio, methylsulfinyl , methylsulfonyl , aminocarbonyl, methyl or trifluoromethyl radicals.
39. The compound of Claim 1 which is:
3 - (4 -pyridyl) -2- (4 -fluorophenyl) indole;
3 - (4 - fluorophenyl) -2 - (4 -pyridyl) indole;
6 -amino- 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6-amino-3- (4-fluorophenyl) -2- (4-pyridyl) -7-aza-indole;
6 - (4 ' - t-butoxycarbonylamino- 1 ' -oxo-butylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (4 ' -amino- 1 ' -oxo-butylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole;
6 - ( 5 ' - ureido- 1 ' - oxo- 2 ' - 1 - butoxycarbonylaminopentylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6 - (5 ' -ureido- 1 ' -oxo- 2 ' -aminopentylamino) - 3 - (4 -pyridyl) -
2- (4-fluorophenyl) -7-aza-indole;
6 - (6 ' - t-butoxycarbonylamino- 1 ' -oxo- 2 ' - t-butoxycarbonyl aminohexylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (6 ' -amino- 1 ' -oxo-2 ' -aminohexylamino) -3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7-aza-indole;
6 - (5 ' -t-butoxycarbonylamino- 1 ' -oxo-2 ' - t-butoxycarbonyl aminopentylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza- indole; 6 - (5 ' -amino- 1 ' -oxo-2 ' -aminopentylamino) - 3 - (4 -pyridyl) - 2 - (4-fluorophenyl) -7-aza-indole;
6 - (3 ' - (4 - iodophenyl) - 1 ' -oxo- 2 ' - 1 -butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ' - (4 - iodophenyl) - 1 ' -oxo-2 ' -aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (3 ' -methyl - 1 ' -oxo- 2 ' - t-butoxycarbonylaminobutylamino) - 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (3 ' -methyl - 1 ' -oxo-2 ' -aminobutylamino) - 3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7-aza-indole;
6- (4 ' , 4 ' - dimethyl -1 ' -oxo-2 ' - t-butoxycarbonylamino pentylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (4 ' , 4 ' -dimethyl- 1 ' -oxo-2 ' -aminopentylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (5 ' - t-butoxycarbonylamino- 1 ' -oxo-pentylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (5 ' -amino- 1 ' -oxo-pentylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole;
6- (6 ' - 1 -butoxycarbonylamino- 1 ' -oxo-hexylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (6 ' -amino- 1 ' -oxo -hexylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7 -aza- indole; 6 - (3 ' -cyclohexyl - 1 ' -oxo-2 ' - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ' -cyclohexyl - 1 ' -oxo-2 ' -aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (4 ' - 1 -butoxycarbonyl - 1 ' -oxo-2 ' - t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6 - (4 ' -carboxy- 1 ' -oxo-2 ' -aminobutylamino) -3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole;
6 - (3 ' -0- 1 -butoxy- 1 ' -oxo-2 ' - t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6 - (3 ' -hydroxy- 1 ' -oxo- 2 ' -aminobutylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole;
6 - ( 3 ' -phenyl - 1 ' - oxo- 2 ' - 1 - butoxycarbonylaminopropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (3 ' - henyl -1 ' -oxo-2 ' -D, L- aminopropylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (3 ' - (4 - 1 -butoxyphenyl) - 1 ' -oxo-2 ' -t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6 - (3 ' - (4 -hydroxyphenyl ) - 1 ' -oxo- 2 ' - aminopropy1amino) - 3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (3 ' - t -butoxycarbonylamino - 1 ' - oxo -propylamino) - 3 - (4 pyridyl ) - 2 - ( 4 - f luorophenyl ) - 7 - aza - indole ; 6 - (3 ' -amino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole;
6 - (2 ' - 1 -butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (2 ' - amino -1 ' -oxo-ethylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole;
6- (methylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6 - (1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) - 7-aza-indole;
6- (2 ' - (5 -chlorothienyl) sulfonylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole;
6- (phenylsulfonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (2 ' -N-phthaloyl -1 ' -oxo-ethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (3 ' -N-phthaloyl- 1 ' -oxo-propylamino) -3 - (4-pyridyl) -2- (4 - fluorophenyl) -7-aza-indole;
3- (4-pyridyl) -2- (4-fluorophenyl) -4 , 7 -diaza- indole;
6- (2 ' -N- t-butoxycarbonyl -L-prolylamino) -3 - (4-pyridyl) -2 (4-fluorophenyl) -7-aza-indole;
6- (2 ' -L-prolylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7 aza-indole; 6 - (2S ' -dimethylamino- 1 ' -oxo-propylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole;
6 - (2 ' -dimethylamino- 1 ' -oxo-ethylamino) - 3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7-aza-indole;
6 - (2 ' -N-methyl - t-butoxycarbonylamino- 1 ' -oxo-ethylamino) - 3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (2 ' -N-methyl -amino- 1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4-fluorophenyl) -7-aza-indole;
6 - (4 ' -N- t-butoxycarbonylisonipecotylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (4 ' - isonipecotylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -7-aza-indole;
6- (4 ' -methylsulfoxo- 1 ' -oxo-2 ' S- t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (4 ' -methylsulfoxo- 1 ' -oxo-2 ' S- aminobutylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (3 ' - ( 3 -pyridyl ) - 1 ' - oxo- 2 ' S - 1 -butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ■ - (3 -pyridyl) - 1 ' -oxo-2 ' S- aminopropylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (N,N-Di- t-butoxycarbonyl-L-histidinylamino) -3- (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (L-histidinylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) 7 -aza- indole; 6- (N- t-butoxycarbonyl -3 (S) l',2',3',4' -tetrahydro-3' - isoquinolinyloxo-amino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6-(3(S) l',2',3',4'- tetrahydro- 3 ' - isoquinolmyloxoamino) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole;
6- (2 ' -phenyl - 1 ' -oxo-2 'R-N- t-butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (2 ' -phenyl - 1 ' -oxo- 2 ' R-aminoethylamino) - 3 - (4 -pyridyl) - 2- (4-fluorophenyl) -7-aza-indole;
6- (2 ' -phenyl- 1 ' -oxo-2 ' S-N- t-butoxycarbonylaminoethyl amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (2 ' -phenyl -1 ' -oxo-2 ' S-aminoethylamino) -3 - (4-pyridyl) - 2- (4-fluorophenyl) -7-aza-indole;
6- (2 ' -phenyl- 1 ' -oxo-2 ' R-N- t-butoxycarbonyl -N- methylaminoethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole;
6- (2 ' -phenyl -1 ' -oxo-2 ' R-N-methylaminoethylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo-2 ' S- t-butoxycarbonylaminopropylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo-2 ' S- aminopropylamino) -3 - (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (3 ' -phenyl - 1 ' -oxo-2 ' - (L) -t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole; 6 - (3 ' -phenyl - 1 ' -oxo- 2 ' - (L) -aminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo-2 ' S- t-butoxycarbonyl -N- methylaminopropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6 - (1 ' -oxo- 2 ' S-N-methylaminopropylamino) - 3 - (4 -pyridyl ) - 2 - (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo-2 ' S- t-butoxycarbonyl -N-methyl -4 -methyl -2 - aminopentyl- amino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza- indole;
6 - (1 ' -oxo-2 ' S -N-methyl - 4 -methyl -2 -aminopentylamino) - 3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo-2 ' R- t-butoxycarbonylaminopropylamino) - 3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (1 ' -oxo- 2 ' R- aminopropylamino) - 3 - (4 -pyridyl) - 2 - (4 - fluorophenyl) -7-aza-indole;
6 - (3 ' - (2 - thienyl) - 1 ' -oxo-2 ' - (L) - t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ■ - (2 -thienyl) -1 ' -oxo-2 ' - (L) -aminopropylamino) -3 - (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (3 ' - (4 -azidophenyl) -1 ' -oxo-2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ' - (4 -azidophenyl) -1 ' -oxo-2 ' S- aminopropylamino) -3 - (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole; 6 - (3 ' - (3 -benzothienyl) - 1 ' -oxo- 2 ' S- t-butoxycarbonylamino propylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ' - (3 -benzothienyl) - 1 ' -oxo-2 ' S- aminopropylamino) -3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6- (4 ' -phenyl - 1 ' -oxo-2 ' - (L) -t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6 - (4 ' -phenyl - 1 ' -oxo-2 ' - (L) -aminobutylamino) -3 - (4 - pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (4 ' -phenyl- 1 ' -oxo-2 ' - (D) -t-butoxycarbonylamino butylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (4 ' -phenyl -1 ' -oxo-2 ' - (D) -aminobutylamino) -3 - (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole;
6 - (2 ' - amino- 1 ' - oxo - ethylamino) - 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl) - 1 - isobutoxycarbonyl -7 -aza- indole;
6- (phenylmethylammo) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole;
6- (diethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3' -phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (2' (R,S) -phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole; 6- (2' (R,S) -ethylhexylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6 -Amino- 5 -chloro- 3 - (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6 -Amino - 5 - fluoro- 3 - (4 -pyridyl ) - 2 - (4 - fluorophenyl ) -7-aza- indole;
6 -Amino - 5 -bromo - 3 - (4 -pyridyl ) - 2 - (4-fluorophenyl ) -7-aza - indole;
6- (di- isoamylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7- aza- indole;
6- (2' ,2' -dimethylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (isoamylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (2' -ethylbutylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) - 7 -aza- indole;
6- (2' - thienylmethylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (3' , 3' di-phenylpropylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6- (ethylamino) -3- (4-pyridyl) -2- (4-fluorophenyl) -7-aza- indole;
6- (3 ' -phenyl -1 ' -oxo-2 ' - (R, S) -methylpropylamino) -3- (4- pyridyl) -2- (4-fluorophenyl) -7-aza-indole; 6- (2 ' - amino -1 ' -oxo-ethylamino) -3 - (4 -pyridyl) -2 - (4 - fluorophenyl) -1 -methyl -7 -aza-indole;
6- (3 ' , 3 ' -dimethyl- 1 ' -oxo-butylamino) -3- (4 -pyridyl) -2- (4 - fluorophenyl) -7-aza-indole;
6- (ethoxycarbonylamino) -3- (4-pyridyl) -2- (4- fluorophenyl) -7-aza-indole;
6 - (2 ' S- amino- 1 ' -oxo-propylamino) -3 - (4-pyridyl) - 2 - (4 - fluorophenyl) - 1 -methyl -7 -aza-indole;
6- (2 ' S- amino- 1 ' -oxo-propylamino) -3 - (4-pyridyl) -2 - (4 - fluorophenyl) - 1 - isobutyl -7 -aza- indole; or
6- (2 ' S- amino- 1 ' -oxo-propylamino) -3 - (4-pyridyl) -2 - (4 fluorophenyl) - 1 -cyclohexylmethyl -7-aza- indole.
40. A pharmaceutical composition comprising a compound of Claims 1 to 39 and a pharmaceutically acceptable carrier.
41. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a compound of Claims 1 to 39.
42. A method of prophylaxis or treatment of inflammation comprising administering an effective amount of a composition of Claim 40.
43. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever or myalgias due to infection, or infections of HIV-1, HIV- 2, HIV-3, cytomegalovirus, influenza, adenovirus, herpes viruses or herpes zoster in a mammal comprising administering an effective amount of a compound of Claims 1-39.
44. A method of prophylaxis or treatment of rheumatoid arthritis, Pagets disease, osteophorosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever or myalgias due to infection, or infections of HIV-1, HIV- 2, HIV-3, cytomegalovirus, influenza, adenovirus, herpes viruses or herpes zoster in a mammal comprising administering an effective amount of a composition of Claim 40.
45. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a compound of Claims 1-39.
46. A method of lowering plasma concentrations of either or both TNF-a and IL-1 comprising administering an effective amount of a composition of Claim 40.
47. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a compound of Claims 1-39.
48. A method of lowering plasma concentrations of either or both IL-6 and IL-8 comprising administering an effective amount of a composition of Claim 40.
49. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a compound according to claims 1 to 39 to produce a glucagon antagonist effect.
50. A method of prophylaxis or treatment of diabetes disease in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 40 to produce a glucagon antagonist effect .
51. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a compound according to claims 1 to 39.
52. A method of prophylaxis or treatment of a pain disorder in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 40.
53. A method of decreasing prostaglandins production in a mammal comprising administering an effective amount of a compound according to claims 1 to 39.
54. A method of decreasing prostaglandins production in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 40.
55. A method of decreasing cyclooxygenase enzyme activity in a mammal comprising administering an effective amount of a compound according to claims 1 to 39.
56. The method of claim 55 wherein the cyclooxygenase enzyme is COX-2.
57. A method of decreasing cyclooxygenase enzyme activity in a mammal comprising administering an effective amount of a pharmaceutical composition according to claim 40.
58. The method of claim 57 wherein the cyclooxygenase enzyme is COX-2.
PCT/US1997/021344 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents WO1998022457A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA002271767A CA2271767A1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
IL12992897A IL129928A0 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
DE69728688T DE69728688T2 (en) 1996-11-19 1997-11-18 ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLE AS AN ANTI-FLAMMING AGENT
IL15525897A IL155258A0 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
AU52659/98A AU734841B2 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
AT97947617T ATE264318T1 (en) 1996-11-19 1997-11-18 ARYL AND HETEROARYL SUBSTITUTED CONDENSED PYRROLES AS ANTI-INFLAMMATORY AGENTS
JP52391498A JP2001506980A (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
EP97947617A EP0948495B1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
DK97947617T DK0948495T3 (en) 1996-11-19 1997-11-18 Aryl- and heteroaryl-substituted condensed pyrrole as anti-inflammatory agents
SI9730639T SI0948495T1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US09/269,600 US6180643B1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
HU9903330A HUP9903330A2 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole derivatives, as antiinflammatory agents containing the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3120796P 1996-11-19 1996-11-19
US60/031,207 1996-11-19

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/269,600 A-371-Of-International US6180643B1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US09/644,102 Division US6440973B1 (en) 1996-11-19 2000-08-23 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents

Publications (2)

Publication Number Publication Date
WO1998022457A1 true WO1998022457A1 (en) 1998-05-28
WO1998022457A9 WO1998022457A9 (en) 1998-08-20

Family

ID=21858180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021344 WO1998022457A1 (en) 1996-11-19 1997-11-18 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents

Country Status (15)

Country Link
US (3) US6180643B1 (en)
EP (1) EP0948495B1 (en)
JP (1) JP2001506980A (en)
KR (1) KR20000057137A (en)
CN (1) CN1246856A (en)
AT (1) ATE264318T1 (en)
AU (1) AU734841B2 (en)
CA (1) CA2271767A1 (en)
DE (1) DE69728688T2 (en)
DK (1) DK0948495T3 (en)
ES (1) ES2215242T3 (en)
HU (1) HUP9903330A2 (en)
IL (1) IL129928A0 (en)
PT (1) PT948495E (en)
WO (1) WO1998022457A1 (en)

Cited By (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020624A1 (en) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Bicyclic kinase inhibitors
EP1121360A1 (en) * 1998-10-13 2001-08-08 SmithKline Beecham Corporation Il-8 receptor antagonists
WO2001047922A3 (en) * 1999-12-24 2002-01-17 Aventis Pharma Ltd Azaindoles
JP2002527510A (en) * 1998-10-16 2002-08-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted thiadiazole sulfonamides as interleukin-1-β inhibitors
US6440993B1 (en) 1999-10-12 2002-08-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
JP2003519144A (en) * 1999-12-24 2003-06-17 アベンティス・フアーマ・リミテッド Azaindore
WO2003051884A1 (en) * 2001-12-18 2003-06-26 Takeda Chemical Industries, Ltd. Fused indole compound, process for producing the same, and use
US6686374B1 (en) * 1999-08-12 2004-02-03 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2004016610A1 (en) * 2002-08-14 2004-02-26 Astrazeneca Ab Substituted pyrrolopyridines
US6730683B2 (en) 1997-12-19 2004-05-04 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
WO2004087704A1 (en) * 2003-03-31 2004-10-14 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6897207B2 (en) 2001-06-21 2005-05-24 Aventis Pharmaceuticals Inc. Azaindoles
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US7342029B2 (en) 1999-10-26 2008-03-11 Sanofi-Aventis Deutschland Gmbh Substituted indoles
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
US7973069B2 (en) 2004-07-14 2011-07-05 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
US8383624B2 (en) 2009-07-15 2013-02-26 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US8658649B2 (en) 2006-09-11 2014-02-25 Sanofi Kinase inhibitor
FR3001219A1 (en) * 2013-01-22 2014-07-25 Centre Nat Rech Scient KINASE INHIBITORS
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
CN102206216B (en) * 2005-06-22 2014-11-12 普莱希科公司 Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors
US9000028B2 (en) 2007-08-17 2015-04-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
RU2593369C2 (en) * 2009-12-14 2016-08-10 Ф.Хоффманн-Ля Рош Аг Azaindoles as glucokinase activators
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2020002611A1 (en) 2018-06-28 2020-01-02 Phenex-Fxr Gmbh Novel lxr modulators with bicyclic core moiety
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10981908B2 (en) 2017-02-01 2021-04-20 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AHR) modulator compounds
US11376241B2 (en) 2017-02-01 2022-07-05 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AhR) modulator compounds
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
DE60024480T2 (en) * 1999-10-27 2006-07-27 Novartis Ag THIAZOL AND IMIDAZO [4,5-B] PYRIDINE COMPOUNDS AND THEIR USE AS PHARMACEUTICALS
AU2001232556A1 (en) * 2000-02-11 2001-08-20 Astrazeneca Ab Pyrimidine compounds and their use as modulators of chemokine receptor activity
CA2412462A1 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030144219A1 (en) 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
AR039241A1 (en) * 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
TW200615268A (en) * 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
CA2637933C (en) * 2006-01-24 2013-03-12 Eli Lilly And Company Indole sulfonamide modulators of progesterone receptors
DE102006012617A1 (en) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
US20100197657A1 (en) * 2007-09-25 2010-08-05 Chang Ronald K 2-aryl or heteroaryl indole derivatives
DE102008052943A1 (en) * 2008-10-23 2010-04-29 Merck Patent Gmbh azaindole derivatives
WO2011053697A1 (en) * 2009-10-30 2011-05-05 Genzyme Corporation 2-aminoindole compounds and methods for the treatment of malaria
MX337548B (en) 2010-04-16 2016-03-10 Ac Immune Sa Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins.
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
US9321756B2 (en) 2011-03-22 2016-04-26 Amgen Inc. Azole compounds as PIM inhibitors
MX346043B (en) 2012-01-06 2017-03-03 Novus Int Inc Sulfoxide-based surfactants.
EP2812313A4 (en) 2012-02-09 2015-09-30 Novus Int Inc Functionalized polymer compositions
ES2703051T3 (en) 2012-07-12 2019-03-06 Novus Int Inc Compositions of matrix and layer for the protection of bioactive agents
WO2016040570A2 (en) 2014-09-12 2016-03-17 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10227551B2 (en) 2015-11-12 2019-03-12 Novus International, Inc. Sulfur-containing compounds as solvents
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429874A (en) * 1966-12-22 1969-02-25 Schering Corp 1-polyhalogenoalkyl-2-oxo-1,3-dihydro-2h-1,4-benzodiazepines
FR1587692A (en) * 1967-09-01 1970-03-27
US3565912A (en) * 1969-01-27 1971-02-23 Upjohn Co 5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
WO1995006040A1 (en) * 1993-08-25 1995-03-02 Yamanouchi Pharmaceutical Co. Ltd. Benzodiazepine compounds useful as antagonists of cck or of gastrine
EP0682027A1 (en) * 1994-05-03 1995-11-15 Ciba-Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative action

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3420838A (en) 1965-12-20 1969-01-07 Upjohn Co 2,3-bis(p-(omega-aminoalkoxy)phenyl)-indoles
DE1795061A1 (en) 1968-08-05 1972-02-24 Rhein Pharma Arzneimittel Gmbh Process for the preparation of 3-pyridyl (4) indoles
US3551567A (en) 1968-08-07 1970-12-29 American Cyanamid Co Compositions containing indolylpyridinium salts and method of use
US3654308A (en) 1969-01-27 1972-04-04 Upjohn Co 2 3-bis(p-methoxyphenyl)-indole-5-carboxylic acid derivatives
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
DE2909779A1 (en) 1979-03-13 1980-09-18 Thomae Gmbh Dr K NEW INDOLDER DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS
US4794114A (en) 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
KR920702621A (en) 1989-06-13 1992-10-06 스튜어트 알. 슈터 Inhibition of Interleukin-1 or Tumor Factor Factor Production by Monocytes and / or Macrophages
AU5921890A (en) 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
CA2098177A1 (en) 1990-12-13 1992-06-13 Jerry L. Adams Csaids
JPH06503349A (en) 1990-12-13 1994-04-14 スミスクライン・ビーチャム・コーポレイション New CSAIDS
WO1992012154A1 (en) 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
GB9121727D0 (en) 1991-10-14 1991-11-27 Ici Plc Heterocyclic compounds
MX9300141A (en) 1992-01-13 1994-07-29 Smithkline Beecham Corp NOVEL IMIDAZOLE COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
FR2687402B1 (en) 1992-02-14 1995-06-30 Lipha NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
ATE197051T1 (en) 1992-04-03 2000-11-15 Upjohn Co PHARMACEUTICALLY ACTIVE BICYCLIC HETEROCYCLIC AMINE
DE69214633T2 (en) 1992-06-19 1997-05-22 Agfa Gevaert Nv Thermally transferable fluorescent compounds
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JP3119758B2 (en) 1993-02-24 2000-12-25 日清製粉株式会社 7-Azaindole derivative and antiulcer drug containing the same as active ingredient
JP3465827B2 (en) 1993-02-24 2003-11-10 株式会社日清製粉グループ本社 Azaindole derivative and anti-ulcer drug containing the same as active ingredient
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
MX9705296A (en) 1995-01-12 1997-10-31 Smithkline Beecham Corp Novel compounds.
US6140332A (en) 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
WO1997016442A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
JPH1035267A (en) * 1996-07-22 1998-02-10 Denso Corp Vehicle roof-mounted cooler
WO1998047899A1 (en) 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
JP3579350B2 (en) * 1997-10-20 2004-10-20 エフ．ホフマン−ラ ロシュ アーゲー Bicyclic kinase inhibitor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429874A (en) * 1966-12-22 1969-02-25 Schering Corp 1-polyhalogenoalkyl-2-oxo-1,3-dihydro-2h-1,4-benzodiazepines
FR1587692A (en) * 1967-09-01 1970-03-27
US3565912A (en) * 1969-01-27 1971-02-23 Upjohn Co 5-lower-alkanoyl-2,3-bis(p-methoxyphenyl)indoles
WO1995006040A1 (en) * 1993-08-25 1995-03-02 Yamanouchi Pharmaceutical Co. Ltd. Benzodiazepine compounds useful as antagonists of cck or of gastrine
EP0682027A1 (en) * 1994-05-03 1995-11-15 Ciba-Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative action

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
A. FÜRSTNER ET AL.: ""Site selective" formation of low-valent titanium reagents: an "instant" procedure for the reductive coupling of oxo amides to indoles", JOURNAL OF ORGANIC CHEMISTRY., vol. 59, no. 18, 1994, EASTON US, pages 5215 - 5229, XP002059625 *
A. MYASHITA ET AL.: "Synthesis of fused pyrimidinones by reaction of aminoarenecarboxamide with esters; preparation of pyrrolo[2,3-d]thieno[2,3-d]-, isoxazolo[5,4-d]-, and 1,2,3-triazolo[4,5-d]pyrimidinones, and quinazolones", HETEROCYCLES., vol. 42, no. 2, 1996, AMSTERDAM NL, pages 691 - 699, XP002059624 *
A.H. KELLY ET AL.: "Diazaindenes (Azaindoles). Part II. Thermal indolisation of 3- and 4-pyridylhydrazones", JOURNAL OF THE CHEMICAL SOCIETY., 1970, LETCHWORTH GB, pages 303 - 307, XP002059637 *
B.A.J. CLARK ET AL.: "Formation of certain substituted 5h-pyrrolo[2,3-b]pyrazines by thermal cyclisation of pyrazinylhydrazones and a route to 5h-pyrazino[2,3-b]indole", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., 1976, LETCHWORTH GB, pages 1361 - 63, XP002059634 *
C.R. HARDY ET AL: "Ring opening or rearrangement versus N-oxidation in the action of peracids upon pyrrolo[2,3-b]pyridines", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., 1980, LETCHWORTH GB, pages 506 - 511, XP002059631 *
CHEMICAL ABSTRACTS, vol. 112, no. 15, 1990, Columbus, Ohio, US; abstract no. 138989s, A. MENDEL ET AL.: "Some derivatives of benzoin" page 716; XP002059640 *
CHEMICAL ABSTRACTS, vol. 96, no. 17, 1982, Columbus, Ohio, US; abstract no. 142648y, T.V. STUPNIKOVA ET AL.: "Anhydro bases of 2-phenyl-3-pyridylindoles" page 738; XP002059641 *
D.C. BLACK ET AL.: "Synthesis of 2-(7-indolyl)-benzimidazoles via 7-formylindoles", SYNTHESIS., 1986, STUTTGART DE, pages 474 - 476, XP002059628 *
H. BIERE ET AL.: "Ein einfacher Zugang zum Pyrrolo[1,2-c]pyrimidin- und Pyrrolo[3,2-c]pyridin-System", LIEBIGS ANNALEN DER CHEMIE., 1987, WEINHEIM DE, pages 491 - 494, XP002059627 *
H. DEUBEL ET AL.: "Der Verlauf der Pyridylierung von Indolen und Pyrrolinonen mit Pyridin und Benzoylchlorid", CHEMISCHE BERICHTE., vol. 104, 1971, WEINHEIM DE, pages 705 - 716, XP002059636 *
H. FENNER ET AL.: "9-Deazapurine aus Pyrimido[4,5-b][1,4]thiazinen", ARCHIV DER PHARMAZIE., vol. 311, 1978, WEINHEIM DE, pages 153 - 161, XP002059632 *
H. PICHLER ET AL.: "Synthese von 7-unsubstituierten 7H-Pyrrolo[2,3-d]pyrimidinen", LIEBIGS ANNALEN DER CHEMIE., no. 9, 1986, WEINHEIM DE, pages 1485 - 1505, XP002059629 *
H.J. ROTH ET AL.: "Synthese von Pyrrolo[2,3-d]pyrimidinen", ARCHIV DER PHARMAZIE., vol. 308, 1975, WEINHEIM DE, pages 252 - 258, XP002059633 *
K.C.C. BANCROFT ET AL.: "Application of the Bischler reaction to the preparations of some pyrrolopyridines and the novel dipyrrolopyridine system", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., 1974, LETCHWORTH GB, pages 1852 - 1858, XP002059635 *
K.G. DAVE ET AL.: "Reaction of nitriles under acidic conditions. Part I. A general method of synthesis of condensed pyrimidines", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 17, 1980, PROVO US, pages 1497 - 1500, XP002059630 *
M. COLONNA ET AL.: "Analogie e sintesi enica", GAZZETA CHIMICA ITALIANA, vol. XCVI, 1966, ROMA, pages 1410 - 1422, XP002059639 *
M.G. PUROHIT ET AL.: "Synthesis of biheterocycles containing indole nucleus", INDIAN JOURNAL OF CHEMISTRY, SECT.B, vol. 32B, 1993, NEW DELHI, pages 257 - 261, XP002059626 *
R. HERBERT ET AL.: "Syntheses and properties of 1H-pyrrolo[2,3-b]pyridines", JOURNAL OF THE CHEMICAL SOCIETY., 1969, LETCHWORTH GB, pages 1505 - 1514, XP002059638 *
RES. DISCL., vol. 303, 1989, pages 504 - 511 *
UKR. KHIM. ZH (RUSS. ED.), vol. 48, no. 1, 1982, pages 76 - 9 *

Cited By (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020624A1 (en) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Bicyclic kinase inhibitors
US6316464B1 (en) 1997-10-20 2001-11-13 Syntex (U.S.A.) Llc P38 MAP kinase inhibitors
US6479507B2 (en) 1997-10-20 2002-11-12 Syntex (U.S.A.) Llc p38 MAP kinase inhibitors
US6730683B2 (en) 1997-12-19 2004-05-04 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1121360A1 (en) * 1998-10-13 2001-08-08 SmithKline Beecham Corporation Il-8 receptor antagonists
EP1121360A4 (en) * 1998-10-13 2002-01-23 Smithkline Beecham Corp Il-8 receptor antagonists
JP2002527510A (en) * 1998-10-16 2002-08-27 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted thiadiazole sulfonamides as interleukin-1-β inhibitors
JP4733270B2 (en) * 1998-10-16 2011-07-27 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Substituted thiadiazole sulfonamides as interleukin-1-beta inhibitors
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6861417B2 (en) 1998-11-04 2005-03-01 Smithkline Beecham Corporation Pyridin-4-YL or pyrimidin-4-YL substituted pyrazines
US7268127B2 (en) 1999-08-12 2007-09-11 Nps Allelix Corp Azaindoles having serotonin receptor affinity
US6686374B1 (en) * 1999-08-12 2004-02-03 Nps Allelix Corp. Azaindoles having serotonin receptor affinity
US6440993B1 (en) 1999-10-12 2002-08-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US7342029B2 (en) 1999-10-26 2008-03-11 Sanofi-Aventis Deutschland Gmbh Substituted indoles
HRP20020357B1 (en) * 1999-10-26 2010-10-31 Sanofi-Aventis Deutschland Gmbh SUBSTITUTED INDOLES FOR MODULATING NFkB ACTIVITY
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US6982270B1 (en) 1999-11-23 2006-01-03 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003519144A (en) * 1999-12-24 2003-06-17 アベンティス・フアーマ・リミテッド Azaindore
US7227020B2 (en) 1999-12-24 2007-06-05 Aventis Pharma Limited Azaindoles
US6770643B2 (en) 1999-12-24 2004-08-03 Aventis Pharma Limited Azaindoles
HRP20020547B1 (en) * 1999-12-24 2011-06-30 Aventis Pharma Limited Azaindoles
CZ301751B6 (en) * 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyclic pyrrole derivative, pharmaceutical composition in which the derivative is comprised, the composition for use in therapy and use of the derivative when preparing a medicament
JP4871474B2 (en) * 1999-12-24 2012-02-08 アベンティス・フアーマ・リミテッド Azaindole
AP1587A (en) * 1999-12-24 2006-03-02 Aventis Pharma Ltd Azaindoles.
JP2012031181A (en) * 1999-12-24 2012-02-16 Aventis Pharma Ltd Azaindole
EP1990343A3 (en) * 1999-12-24 2008-12-10 Aventis Pharma Limited Azaindoles
CZ301750B6 (en) * 1999-12-24 2010-06-09 Aventis Pharma Limited Bicyclic pyrrole derivative, its use in the preparation of a medicament, pharmaceutical composition in which the derivative is comprised and for use in therapy
KR100755622B1 (en) * 1999-12-24 2007-09-04 아벤티스 파마 리미티드 Azaindoles
EP1990343A2 (en) 1999-12-24 2008-11-12 Aventis Pharma Limited Azaindoles
KR100910488B1 (en) * 1999-12-24 2009-08-04 아벤티스 파마 리미티드 Azaindoles
CN100379734C (en) * 1999-12-24 2008-04-09 阿文蒂斯药物有限公司 Azaindoles
WO2001047922A3 (en) * 1999-12-24 2002-01-17 Aventis Pharma Ltd Azaindoles
AP1917A (en) * 1999-12-24 2008-11-12 Aventis Pharma Ltd Azaindoles
US7943616B2 (en) 2001-06-21 2011-05-17 Aventis Pharmaceuticals Inc. Azaindoles for inhibiting aurora2 and other kinases
US6897207B2 (en) 2001-06-21 2005-05-24 Aventis Pharmaceuticals Inc. Azaindoles
WO2003051884A1 (en) * 2001-12-18 2003-06-26 Takeda Chemical Industries, Ltd. Fused indole compound, process for producing the same, and use
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US8106050B2 (en) 2002-08-09 2012-01-31 Centre National De La Recherche Scientifique (C.N.R.S.) Derivatives of pyrrolo-pyrazines having a kinase inhibitory activity and their biological applications
WO2004016614A3 (en) * 2002-08-09 2004-05-06 Centre Nat Rech Scient Pyrrolopyrazines as kinase inhibitors
WO2004016614A2 (en) * 2002-08-09 2004-02-26 Centre National De La Recherche Scientifique (C.N.R.S.) Pyrrolopyrazines as kinase inhibitors
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2004016610A1 (en) * 2002-08-14 2004-02-26 Astrazeneca Ab Substituted pyrrolopyridines
WO2004016609A1 (en) * 2002-08-14 2004-02-26 Astrazeneca Ab Substituted pyrrolopyridines
US7384955B2 (en) 2003-03-31 2008-06-10 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2004087704A1 (en) * 2003-03-31 2004-10-14 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7973069B2 (en) 2004-07-14 2011-07-05 Ptc Therapeutics, Inc. Methods for treating hepatitis C
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EP2878297A1 (en) 2004-12-24 2015-06-03 Boehringer Ingelheim International GmbH Medicaments for the treatment or prevention of fibrotic diseases
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
CN102206216B (en) * 2005-06-22 2014-11-12 普莱希科公司 Pyrrolo[2,3-B] pyridine derivatives as protein kinase inhibitors
US7696229B2 (en) 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
US8658649B2 (en) 2006-09-11 2014-02-25 Sanofi Kinase inhibitor
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10426760B2 (en) 2007-07-17 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9000028B2 (en) 2007-08-17 2015-04-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
WO2010124793A1 (en) 2009-04-27 2010-11-04 Bayer Cropscience Ag Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
EP2245936A1 (en) 2009-04-27 2010-11-03 Bayer CropScience AG Use of 4-aza indole derivatives for the reduction of mycotoxin contamination
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US8383624B2 (en) 2009-07-15 2013-02-26 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2593369C2 (en) * 2009-12-14 2016-08-10 Ф.Хоффманн-Ля Рош Аг Azaindoles as glucokinase activators
US9512111B2 (en) 2010-11-08 2016-12-06 Lycera Corporation N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
US10377768B2 (en) 2012-05-08 2019-08-13 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9657033B2 (en) 2012-05-08 2017-05-23 Lycera Corporation Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease
US10208061B2 (en) 2012-05-08 2019-02-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9802958B2 (en) 2012-05-08 2017-10-31 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
FR3001219A1 (en) * 2013-01-22 2014-07-25 Centre Nat Rech Scient KINASE INHIBITORS
US10745364B2 (en) 2013-12-20 2020-08-18 Lycera Corporation Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
US10221146B2 (en) 2013-12-20 2019-03-05 Lycera Corporation Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
US10189777B2 (en) 2014-05-05 2019-01-29 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
US10364237B2 (en) 2014-05-05 2019-07-30 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10442798B2 (en) 2014-05-05 2019-10-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US11059796B2 (en) 2015-06-11 2021-07-13 The Regents Of The University Of Michigan Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
US10689369B2 (en) 2015-10-27 2020-06-23 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10584121B2 (en) 2015-10-27 2020-03-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof
US10287272B2 (en) 2015-10-27 2019-05-14 Merck Sharp & Dohme Corp. Substituted indazole compounds as RORgammaT inhibitors and uses thereof
US10981908B2 (en) 2017-02-01 2021-04-20 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AHR) modulator compounds
US11376241B2 (en) 2017-02-01 2022-07-05 Phenex Pharmaceuticals Ag Aryl hydrocarbon receptor (AhR) modulator compounds
WO2020002611A1 (en) 2018-06-28 2020-01-02 Phenex-Fxr Gmbh Novel lxr modulators with bicyclic core moiety
US11618747B2 (en) 2018-06-28 2023-04-04 Orsobio, Inc. LXR modulators with bicyclic core moiety
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Also Published As

Publication number Publication date
DE69728688T2 (en) 2004-08-19
EP0948495A1 (en) 1999-10-13
ATE264318T1 (en) 2004-04-15
CA2271767A1 (en) 1998-05-28
AU734841B2 (en) 2001-06-21
JP2001506980A (en) 2001-05-29
US6180643B1 (en) 2001-01-30
DK0948495T3 (en) 2004-06-01
ES2215242T3 (en) 2004-10-01
US6605634B2 (en) 2003-08-12
EP0948495B1 (en) 2004-04-14
KR20000057137A (en) 2000-09-15
US6440973B1 (en) 2002-08-27
HUP9903330A2 (en) 2000-03-28
CN1246856A (en) 2000-03-08
AU5265998A (en) 1998-06-10
DE69728688D1 (en) 2004-05-19
IL129928A0 (en) 2000-02-29
US20030096819A1 (en) 2003-05-22
PT948495E (en) 2004-08-31

Similar Documents

Publication Publication Date Title
EP0948495B1 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO1998022457A9 (en) Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6458813B1 (en) Substituted pyridine compounds and methods of use
US6420385B1 (en) Substituted pyrimidinone and pyridone compounds and methods of use
EP1448564B1 (en) Substituted indolizine-like compounds and methods of use
EP1042293B1 (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
AU735901C (en) Substituted pyrimidinone and pyridone compounds and methods of use
US6174901B1 (en) Substituted pyridine and pyridazine compounds and methods of use
US6410729B1 (en) Substituted pyrimidine compounds and methods of use
WO1998024782A2 (en) Substituted pyrimidine compounds and their use
AU733877C (en) Substituted pyrimidine compounds and their use
WO2005019202A1 (en) Substituted pyrimdinone derivatives and methods of use
MXPA99004590A (en) Mixes comprising polyurethane termoplast
EP1314731A2 (en) Substituted pyrimidine compounds and their use
MXPA00006070A (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97181372.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 141, DESCRIPTION, REPLACED BY A NEW PAGE 141

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 52659/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2271767

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1997947617

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004598

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 523914

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997004405

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09269600

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997947617

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997004405

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 52659/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 155258

Country of ref document: IL

WWR Wipo information: refused in national office

Ref document number: 1019997004405

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997947617

Country of ref document: EP